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General introduction 
The skin is the largest organ of the body and it plays an important role in the regulation 
of body temperature, the defence against pathogens, and the prevention from dehydration. 
Morphologically, the skin can be divided in a dermal and an epidermal layer, positioned on 
top of a subcutaneous fat layer (Fig. 1). 
 
Figure 1. Schematic representation of the human skin. Three different layers are visible: The epidermis (top), dermis 
(middle) and subcutaneous fat layer (bottom part). Blood and lymph vessels are present throughout the dermis and 
appendages like a hair follicle, sebaceous and sweat gland are indicated. Reprinted from: 
http://commons.wikimedia.org/wiki/File:HumanSkinDiagram.jpg.  
 
The dermis consists of soft connective tissue containing fibroblasts as the major cell 
type. It contains functional structures like hair follicles, sweat glands, sebaceous glands, 
blood and lymph vessels. The dermal extracellular matrix consists mainly of type I collagen 
providing the skin its structural strength, elastic fibres providing elasticity, and long, un-
branched polysaccharides called glycosaminoglycans, which provide water-binding capacity 
and play an important role in the binding and modulation of growth factors and other effector 
molecules [1]. The top of the dermis has a wave-like pattern consisting of dermal papillae.  
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The epidermis consists of a cell-dense layer of mainly keratinocytes, and these cells 
produce a basement membrane containing type IV collagen. The basal cells continuously 
divide and undergo differentiation when moving upwards, thereby outlining the different 
layers of the epidermis. The top layer, the stratum corneum, consists of dead keratinocytes 
filled with a highly crosslinked network of structural proteins like keratins that form a physical 
barrier. 
 
When the skin is damaged, its functions and architecture have to be restored as quickly 
as possible. Evolutionary, the fastest way to close large full-thickness wounds and burns is 
by contraction, but this often results in scarring [2]. Scar tissue may differ from normal skin 
by an aberrant colour, increased thickness, irregular surface area and poor functional quality 
and this can have functional, cosmetic, and psychological consequences [3]. A novel ap-
proach in the reduction of contraction and its negative consequences may be found in the 
use of tissue engineering/regenerative medicine. 
 
Tissue engineering has been defined as an interdisciplinary field that applies the prin-
ciples of engineering and the life sciences toward the development of biological substitutes 
that restore, maintain, or improve tissue function [4]. Different approaches can be used, 
mostly requiring a natural or synthetic scaffold, often in combination with cells. Our approach 
is to construct molecularly-defined acellular scaffolds based on natural type I collagen [5,6]. 
By using natural components, the original extracellular matrix can be mimicked as closely as 
possible. Biological effector molecules can be incorporated to attract cells from the sur-
rounding tissue to infiltrate the scaffold and to stimulate regeneration of the original tissue. 
Highly-purified constituents are used to facilitate the investigation of the effect of each indi-
vidual component on the wound healing process. From a commercial point of view, acellular 
constructs are preferred, since cellular constructs require additional handling and storage 
conditions. In addition, the use of cells from the patient will require time, knowledge, and 
equipment for cell isolation, expansion and/or scaffold seeding. 
Growth factors are potent biological signalling molecules that regulate cellular processes 
like growth, proliferation, and differentiation. Binding of growth factor to specific receptors on 
the cell membrane of target cells leads to activation of a signalling pathway and finally re-
sults in regulation of gene expression. Growth factors play an important role during devel-
opment, tissue homeostasis and repair. Therefore, specific growth factors can be incorpo-
rated in tissue-engineered constructs to guide the cellular regeneration process. Members of 
the fibroblast growth factor (FGF) family are involved in angiogenesis, wound healing and 
embryonic development [7], and members of the vascular endothelial growth factor (VEGF) 
family are involved more specifically in the process of angiogenesis. Like most FGFs, FGF2 
(also known as basic FGF) has an effect on a large variety of different cell types and can 
bind to isoforms of all four FGF tyrosine kinase receptor types (FGFR1-4) [8]. FGF7 (also 
known as keratinocyte growth factor, KGF) is a special member of the FGF family and acts 
only on epithelial cells and specifically binds FGFR2b. Members of the VEGF family (VEGF 
A-VEGFE, and placental growth factor (PIGF)) also signal through tyrosine kinase receptors 
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[9]. VEGFA, the best studied VEGF, exists in five isoforms which all bind to VEGFR-1 (Flt-1) 
and VEGFR-2 (KDR/Flk-1) homo- and heterodimers, and the isoform that we used (VEGF-
A165) also binds receptors neurophilin 1 and 2. Receptor signalling of most FGFs and most 
VEGFA isoforms is dependent on simultaneous binding to glycosaminoglycans like heparin 
and heparan sulfate. We have previously demonstrated that incorporation of heparin, FGF2 
and VEGF stimulates blood vessel formation and maturation in an acellular skin construct in 
vivo [10], and since FGF7 can stimulate keratinocytes this can be incorporated in the epi-
dermal part of a construct to guide re-epithelialisation. 
A wide range of tissue-engineered skin constructs has been reviewed by others [11-17]. 
However, despite the multitude of constructs that have already been developed, perfect skin 
regeneration without complications is for large wounds still science fiction.   
Aims and outline of this thesis 
This thesis focuses on the development and evaluation of tissue-engineered collagen-
based scaffolds for skin regeneration.  
Chapter 2 starts with an overview of methods that are currently used in the clinic for the 
assessment of scar tissue. Subsequently, methods are reviewed that have been used for 
the evaluation of tissue-engineered skin constructs in animal models. A large variation in 
evaluation methods between different reports was noticed, and therefore recommendations 
are given for a more uniform evaluation to enable a more systematic comparison between 
different studies. 
 
The next chapters deal with different steps in the development of a novel tissue-
engineered skin construct.  
Glycosaminoglycans like heparin can be incorporated in such a construct, but the pres-
ence of the insoluble biomaterial may interfere with the analysis of the exact amount and/or 
activity of bound glycosaminoglycan. In chapter 3, seven different methods are compared 
that can be used for the determination of scaffold-bound heparin. The (dis)advantages of 
these methods are discussed and the hexosamine assay is recommended for the determi-
nation of the absolute amount of bound heparin.  
Chapter 4 describes the development a biomaterial array for the in vitro evaluation of the 
proliferation and differentiation of keratinocytes on collagen membranes that can be used as 
the epidermal component of a construct. An array of 48 different membranes was prepared 
and only a few membranes stimulated keratinocyte proliferation. This type of pre-screening 
facilitates the selection of the proper modifications for a specific application and may reduce 
the number of animals required for further in vivo evaluation studies.  
Growth factors are potent biological effector molecules that may also be incorporated in 
tissue-engineered skin constructs. Regenerating skin requires a vascular network for nou-
rishment of infiltrating cells and removal of waste products, but formation of this network is 
often a slow process. Vascular endothelial growth factor can stimulate the formation of new 
blood vessels, and the production and purification of this molecule is described in chapter 5.   
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Based on a rational design, a double-layered collagen-based construct containing elas-
tin, glycosaminoglycans and growth factors was constructed. Chapter 6 describes the pro-
duction, implantation and evaluation of this molecularly-defined, acellular skin construct in a 
rat full-thickness wound model. Compared with a commercially available construct (Integra) 
and an untreated wound, the double-layered construct showed more cellular influx, less 
contraction, and an increased formation of blood vessels at early time points, and more 
newly-formed elastic fibres at a later time point. This indicates that the skin regeneration 
process can be guided by providing the appropriate extracellular microenvironment. 
 
The last chapters describe novel evaluation tools and techniques to construct innovative 
scaffolds.  
In chapter 7, gene expression microarrays are presented as a fast and unbiased tool for 
the in vivo evaluation of tissue-engineered constructs. Gene expression levels were com-
pared between regenerating wounds treated with or without the double-layered skin con-
struct of chapter 6. Lists of up- and downregulated genes were analysed for associated 
biological processes using gene ontology (GO) terms. The presence/absence of identified 
processes was confirmed by immunohistochemical staining, demonstrating the power of 
microarrays as a novel evaluation tool. 
Finally, chapter 8, shows the feasibility to produce a microstructured collagen mem-
brane that mimics the 3D-architecture of the dermal papillae. Keratinocytes cultured on 
these membranes were morphologically different and microarray analysis showed that 
genes involved in proliferation and migration were upregulated when compared to keratino-
cytes on flat membranes. These microstructured membranes have therefore potential to be 
used as an epidermal component to stimulate re-epithelialisation and rete ridge formation in 
an innovative tissue-engineered skin construct. 
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Abstract 
Cutaneous wounding often leads to contraction and scarring, which may result in a range 
of functional, cosmetic and psychological complications. Tissue-engineered skin substitutes 
are being developed to enhance restoration of the skin and improve the quality of wound 
healing. The aim of this review is to provide researchers in the field of tissue engineering an 
overview of the methods that are currently used to clinically evaluate skin wound healing, 
and methods that are used to evaluate tissue engineered constructs in animal models.  
Clinically, the quality of wound healing is assessed by non-invasive subjective scar as-
sessment scales and objective techniques to measure individual scar features. Alternatively, 
invasive technologies are used.  
In animal models, most tissue-engineered skin constructs studied are at least evaluated 
macroscopically and by using conventional histology (H&E staining). Planimetry and immu-
nohistochemistry are also often applied. An overview of antibodies used is provided. In addi-
tion, some studies used methods to assess gene expression levels and mRNA location, 
transillumination for blood vessel visualisation, in situ/in vivo imaging, electron microscopy, 
mechanical strength assessment, animal behaviour analysis and microbiological sampling.  
A more systematic evaluation of tissue-engineered skin constructs in animal models is 
recommended to enhance the comparison of different constructs, thereby accelerating the 
trajectory to application in human patients. This would be further enhanced by the em-
bracement of more clinically relevant objective evaluation methods. In addition, fundamental 
knowledge on construct-mediated wound healing may be increased by new developments in 
e.g. gene expression analysis and non-invasive imaging. 
  
An overview of methods for the in vivo evaluation of tissue-engineered skin constructs 
 
15 
Introduction 
Cutaneous wound healing is a complex process, often resulting in contraction and scar 
tissue formation [1]. Scars may lead to an array of functional, cosmetic and psychological 
implications, and often differ from normal skin by an aberrant colour, increased thickness, 
irregular surface area and a poor functional quality. Each individual scar feature is important 
and contributes to the final form and cosmetic acceptability of a scar [2].  
Tissue-engineered skin substitutes are being developed to enhance restoration of the 
skin and improve the quality of wound healing. Different approaches exist to reach this goal, 
including commercially available constructs, and these have been reviewed extensively [3-
10]. Typical approaches use a natural or synthetic scaffold, often in combination with cells. 
Prior to possible application to humans, constructs are first evaluated in cell culture systems 
and in animal models.  
As will be apparent, a large variability exists in the read-out methods used to evaluate 
the performance of these constructs in animal models. This variability, combined with the 
lack of standard protocols, severely hampers the systematic comparison of different stud-
ies/constructs. 
This review will first provide an overview of standard methods that are currently used in 
the clinic to evaluate wound healing in patients (without tissue-engineered constructs). Sec-
ond, methods are listed that are currently used to evaluate the performance of tissue-
engineered constructs in animal models, and the strengths and limitations of these methods 
will be discussed. Finally, recommendations are presented to introduce standardisation in 
the evaluation of tissue-engineered skin constructs in vivo which will allow a more system-
atic comparison between studies.  
Evaluation methods for wound healing in patients 
Methods that are currently used for the clinical evaluation of wound healing in patients 
can be divided in non-invasive and invasive. The non-invasive methods can be further sub-
divided into subjective (mainly questionnaires) and objective evaluation methods that assess 
specific scar features. 
Non-invasive evaluation methods 
Subjective methods 
Subjective non-invasive measurement tools predominantly include the scar assessment 
scales that have been developed to give an easy and quick impression of a scar. They are 
filled out by an observer (O) and sometimes by the patient (P) as well. In the past decades, 
several attempts have been made to create an appropriate scale and their origin is mostly 
found in the assessment of burn scars. A chronologic overview of the different scar assess-
ment scales is given in Table 1. 
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Table 1. Overview of subjective scar assessment scales. 
Scale name Scar type 
evaluated 
Asses-
sor 
Reference 
Cosmetic Disfigurement 
Scale 
Burns O Smith 1988 [11] 
Vancouver Scar Scale (VSS) Burns O Sullivan 1990 [12] 
VSS with additional tool Burns O Baryza 1995 [13] 
Seattle Scale Burns O Yeong 1997 [14] 
Manchester Scar Scale  Surgical, hypertro-
phic and keloids 
O Beausang 1998 [15] 
Hamilton Scale Burns O Crowe 1998 [16] 
Modified VSS Burns and surgical O Nedelec 2000 [17] 
Patient and Observer Scar 
Assessment Scale (POSAS) 
Burns O, P Draaijers 2004 [18] 
Matching Assessment of 
Scars and Photographs 
Burns O Masters 2005 [19] 
Modified POSAS  Burns and surgical O, P Van de Kar 2005 [20] 
Stony Brook Scale Surgical O Singer 2007 [21] 
O=observer, P=patient 
Objective methods 
Table 2 lists objective evaluation techniques that are currently used in the clinic and for 
patient studies for the assessment of specific scar features. Each scar feature with its con-
comitant measurement tools is described separately below. 
1. Colour 
Scar colour can be determined by measuring the wavelengths of reflected light. Based 
on this principle, two different methods can be distinguished: tristimulus reflectance col-
orimetry and narrow-band spectrophotometry. In tristimulus reflectance colorimetry any color 
is described by three values: L*, the lightness (relative brightness of the color); a*, the 
amount of green or red (redness); and b*, the amount of yellow or blue (pigmentation). Ex-
amples of tristimulus devices are the Labscan XE (Hunter Associates Inc., Texas, USA) and 
the Minolta Chromameter CR-221-R and CR-300 (Minolta Camera Co., Ltd., Osaka, Japan). 
For narrow-band spectrophotometry, redness and pigmentation is measured in the form of 
erythema and melanin. This method is based on the differences in light absorption of red 
and green by haemoglobin and melanin [22-24]. The DermaSpectrometer (Cortex Technol-
ogy, Hadsund, Denmark) and the Mexameter (Courage and Khazaka, Cologne, Germany) 
are examples of narrow-band spectrophotometers.  
2. Thickness 
When measuring thickness of a scar it is important to distinguish clinical thickness from 
histological thickness. Clinically, thickness is usually measured by comparing the height of 
the scar with the normal surrounding skin, whereas the histological thickness may differ 
because of bulky connective tissue occupying deeper skin layers, especially in immature 
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scars. Ultrasound measurement devices such as the Tissue Ultrasound Palpation System 
(TUPS) (Biomedical Ultrasonic Solutions, Hong Kong) and the Dermascan C (Fig. 1, Cortex 
Technology, Denmark) are devices frequently used for measuring thickness of normal and 
scarred skin [25-28]. In addition, the Vivid 900 (Konica-Minolta, Milton Keynes, United King-
dom), a laser scanning technique for volume measurements, can be used for this purpose 
[29]. 
 
 
 
Figure 1. A non-invasive method for the objective evaluation of cutaneous thickness (circled, in mm) using the Der-
mascan C. An echogenic profile (line) generated by dedicated software can be used to select the set points for thick-
ness calculation, in this case the stratum corneum peak (first peak) and the peak just inside the subcutaneous fat 
(second peak). Reprinted from Nedelec B et al. Quantitative measurement of hypertrophic scar: interrater reliability and 
concurrent validity. J Burn Care Res 29, 501. Copyright (2008), with permission from Wolters Kluwer Health [28]. 
3. Relief 
Surface irregularities, also referred to as relief, can be measured by various measure-
ment tools. Relief measurement tools should be subdivided in devices which measure small 
irregularities of normal skin and devices which are more suitable to measure larger irregu-
larities of scars. Devices like the Skin-Visiometer (Courage and Khazaka electronic, Co-
logne, Germany) for transparency profilometry [30] and the Dermatop system (Breuckmann, 
Meersburg, Germany) for interference fringe profilometry (interferometry) [31] are able to 
precisely measure skin microrelief, which can be relevant for the evaluation of therapies for 
dermatological diseases or the cosmetic industry. Devices that could be more useful for 
quantifying macrorelief of scars are the TKC 300 Hommeltester (Hommelwerke, Villingen-
Schwenningen, Germany) for mechanical profilometry [32], digital image analysis for optical 
profilometry [33], laser profilometry [34] and Phaseshift Rapid In vivo Measurement Of the 
Skin (PRIMOS, GF Messtechnik, Berlin, Germany) [35]. Of all profilometry methods men-
tioned, PRIMOS is the only validated technique that can directly measure relief and does not 
require an intermediate silicone replicate of the skin. 
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4. Mechanical properties 
The most important mechanical characteristics to distinguish normal skin from scar tis-
sue are tensile strength, ultimate extension, and stress-strain curves that describe the visco-
elastic properties of the tissue [36]. Tools that measure these mechanical qualities are 
based on different types of load on the skin: suction, pressure, torsion, and tension.  
The Cutometer® Skin Elasticity Meter [37-41] (Courage and Khazaka Electronic GmbH, 
Cologne, Germany) is a visco-elasticity measurement tool which works by suction on the 
skin or scar. Similarly, the DermaLab® [42] (Cortex Technology, Hadsund, Denmark), which 
has replaced the Dermaflex® [43-46], measures the stress that is required to achieve an 
elevation of the skin of 1.5 mm. The Cicatrometer (University of California, San Diego, USA) 
[47], Pneumatonometer (Medtronic Solan, Jacksonville, USA) [48], Tissue Tonometer (Flin-
ders University Biomedical Engineering Department, Adelaide, Australia) [49], and Durome-
ter (Rex Gauge Company Inc., Glenview, USA) [50-55] are all tonometers. Tonometry is a 
measurement method which works by exerting pressure on the scar, and was used to quan-
tify firmness and flexibility of skin and scars. The Dermal Torque Meter (Dia-stron, Andover, 
United Kingdom) is a measurement tool that assesses visco-elasticity via torsional force 
onto the skin [56-58]. This device has also been used on patients with burn scars treated 
with a tissue-engineered skin construct [59]. Finally, the Elastometer (Washington Univer-
sity, St. Louis, USA) [60] and the Extensometer (University of Hong Kong, Hong Kong, 
China) [61] work by measuring skin deformation after tension is exerted in the horizontal 
plane of the skin, but these measurement tools are not commercially available anymore. 
5. Planimetry 
One of the most simple methods to evaluate wound healing and the size of a scar is by 
measuring the length and width with a ruler and, if applicable, its depth by insertion of e.g. a 
sterile cotton swab in the deepest part of the wound. To determine the wound or scar sur-
face area different measurement methods are available. Scar or wound margins can be 
traced on e.g. Transparent Acetate Wound Perimeter Sheets (Labelon Projection Transpar-
encies, Braintree, United Kingdom) [62-66]. A cut-out of this trace can be used in the Weigh-
ing Method (Transparency Film, Scotch 3M, St Paul, USA, and Gram-atic® Balance, Metler 
Instrument Corporation, Highstown, USA) [62]. In Computer Assisted Planimetry digitised 
sheets are analysed [67-70].  
In Photogrammetry, a camera is positioned on a standardised distance from the area of 
interest and the area can be calculated using a calibrated grid [71]. The Measurement of 
Area and Volume Instrument System (MAVIS) uses coloured stripes to generate a three-
dimensional image of the wound area [72]. Stereophotogrammetry is Photogrammetry, 
which is extended by the use of two cameras to generate a more detailed three-dimensional 
reconstruction of the area of interest [73]. 
An overview of methods for the in vivo evaluation of tissue-engineered skin constructs 
 
19 
6. Epidermal barrier 
The epidermal barrier function of skin has several characteristics that can be assessed.  
However, most devices that have been developed for this purpose require further clinimetric 
evaluation to determine its reliability. Stratum corneum/surface hydration can be measured 
using techniques like confocal Raman spectroscopy [74] and devices like a nova dermal 
phase meter (Nova Technology Corporation, Gloucester, MA, USA) [75], and corneometer 
(Courage and Khazaka Electronic GmbH) [76]. Trans-epidermal water loss (TEWL) can be 
assessed using e.g. a VapoMeter (Delfin Technologies Ltd, Kuopio,Finland) [77], a Der-
maLab (Cortex Technologies, Hadsund, Denmark) [77] or Cyberderm evaporimeter (Broom-
all, PA, USA) [75,76]. Other aspects like the epidermal pH and percutaneous penetration of 
different substances may also be subject of investigation. 
 
Invasive evaluation methods 
Ample research has been performed to unravel the wound healing process on the mo-
lecular and cellular level, in order to find clues for the prevention of scar formation. Growth 
factors and cytokines, for example, play an important role in the precisely orchestrated proc-
ess of wound healing [1]. A derailed inflammatory reaction leads to excessive scarring, al-
though the exact mechanism is unknown [87]. Scarring is characterized by the deposition of 
excessive extracellular matrix components, contraction and altered extracellular matrix re-
modelling. Cells involved in these processes, like (myo)fibroblasts [88], and proteins like 
matrix metalloproteinases [89] have therefore received much attention. This section dis-
cusses the invasive methods that are often required to study the presence and location of 
specific proteins and cells. 
To explore the effects of a specific treatment in time or to identify the sequential events 
during wound healing on the cellular and molecular level, tissue specimens at different time 
points in the healing process are required. Since this puts a heavy burden on patients, these 
methods are mainly confined to animal experiments. When performed in human studies, 
sampling is mostly limited to the scenario when a scar has to be surgically corrected. Sam-
ples obtained by invasive methods are generally analysed using molecular or histological 
techniques. Usually, this analysis is performed directly, but cells may also be isolated from 
the samples and cultured first to answer specific research questions. 
Molecular biological methods 
On the molecular level, mRNA and protein expression are the main subjects of investiga-
tion. 
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Table 2. Overview of objective scar assessment tools. 
Scar  
Feature 
Technique name Tested on Reference 
Colour 
Minolta CR-300 and CR-221-R Normal skin,  
Burn scars 
Van den Kerckhove 2001 
[78], Draaijers 2004 [79] 
Labscan XE Normal skin 
Burn scars 
Li-Tsang 2003 [80] 
DermaSpectrometer Burn scars Draaijers 2004 [79] 
Mexameter Normal skin 
Hypertrophic burn 
scars 
Nedelec 2008 [26] 
Thickness 
Tissue Ultrasound Palpation 
System (TUPS) 
Surgical and burn 
scars 
Lau 2005 [81] 
Vivid 900 (volume) Keloids (surgical 
scars) 
Taylor 2007 [29] 
Dermascan C Hypertrophic burn 
scars 
Nedelec 2008 [28] 
Relief 
Optical Profilometry Normal skin Corcuff 1982 [33] 
Mechanical Profilometry Normal skin Kautzky 1995 [32] 
Laser Profilometry Normal skin Saur 1991 [34] 
Transparency Profilometry Metal plates, Normal 
skin 
De Paepe 2000 [30] 
Interferometry Normal skin Lagarde 2001 [31] 
Phaseshift Rapid In vivo  
Measurement Of the Skin 
(PRIMOS) 
Normal skin 
Burn scars 
Bloemen 2010 [35] 
Mechanical 
properties 
Tonometry Sclerodermal skin 
Normal skin 
Burn scars 
Spann 1996 [48], Lye 
2006 [49], Corica 2006 
[82], Merkel 2008 [53] 
Dermal Torque meter Burn scars 
 
Murray 1997 [83] 
Boyce 2000 [59] 
Cutometer Normal skin 
(Hypertrophic) burn 
scars 
Draaijers 2004 [38], Nede-
lec 2008 [26] 
Dermaflex, Dermalab Normal skin Pedersen 2003 [42] 
Planimetry 
Weighing method Wounds Bohannon 1983 [62] 
Stereophotogrammetry  Wounds Johnson 1996 [69] 
Photogrammetry (including 
MAVIS) 
Normal skin (artificial 
drawings) 
Wounds 
Van Zuijlen 2004 [84], 
Plassmann 1998 [72] 
Computer Assisted Planimetry 
(Visitrak and Videometry) 
Wounds Gethin 2006 [85], Wunder-
lich 2000 [86] 
Transparent Acetate Wound 
Perimeter Tracing 
Normal skin (artificial 
drawings) 
Van Zuijlen 2004 [84] 
Epidermal 
barrier 
Surface hydration: Raman 
spectroscopy, Dermal Phase 
Meter, Corneometer 
Normal skin Caspers 2001 [74], Vis-
scher 2001 [75] Eberlein-
König 2000 [76] 
Trans-epidermal water loss 
(TEWL): Vapometer, Derma-
lab, Evaporimeter 
Normal skin, artificial 
skin 
Cohen 2009 [77], Eber-
lein-König 2000 [76] , 
Visscher 2001 [75] 
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1. mRNA expression 
The mRNA expression levels of relevant proteins are usually evaluated by two common 
techniques: microarrays and real time quantitative Reversed Transcription PCR (real-time 
qRT-PCR). With microarrays, differences in genes expression can be determined between 
samples. Depending on the method used, the expression profile of the total genome can be 
studied. Greco et al. used this technique to compare skin gene expression levels between 
patients with burn wounds with normal skin samples [90], and Nassiri et al. investigated 
keloids with arrays specific for genes involved in apoptosis and cytokine signalling [91]. 
Microarrays are seen as an exploratory method to study differentially expressed genes in 
different RNA populations. In addition, qRT-PCR is often performed to confirm the differ-
ences detected with microarrays [92]. Since, in this method, the expression levels of target 
genes are expressed relative to reference genes, a validation of these reference genes is 
important. However, it is often not examined whether the expression level of the reference 
gene is also influenced by the treatment or different conditions of the tissues under investi-
gation. In addition, while in the microarray field it is widely acknowledged that the mRNA 
populations to be studied should be of indisputable quality, in qRT-PCR research this is less 
well recognized and proper quality control experiments are not always performed [93].  
RT-qPCR was used to determine gene expression levels in keloids [91,94]. Discrimina-
tion between collagen subtypes is often difficult to establish at the protein level because of 
the lack of specific antibodies. Therefore, changes in collagen synthesis are often assessed 
by qRT-PCR. Excessive extracellular matrix deposition is not only caused by increased 
synthesis but also by decreased breakdown due to reduced matrix metalloproteinase activ-
ity. The latter may be caused by decreased synthesis and activation of the proteins and 
increased inhibitors of the enzymes. Van der Slot et al. analysed wound-derived fibroblasts 
for collagen and collagen modifying enzymes with qRT-PCR [95].  
Next to the identification of differentially expressed genes with the above mentioned 
methods, mRNA expression can also be localised using in situ hybridization techniques. 
Toksoy et al. used this technique to visualise the spatiotemporal expression of the 
chemokine CXCL12 during human wound healing [96].  
2. Protein expression 
Although analysis of mRNA expression can provide valuable information, it is the result-
ing protein that plays a role in the wound healing process. Since many factors are involved 
in translation, it is important to confirm the differences found at the mRNA level at the (ac-
tive) protein level.  
Different assays can be used to assess protein expression. One of these methods is 
SDS-PAGE, e.g. used to assess collagen production of fibroblasts isolated from scar tissue 
[97]. In combination with Western blotting, this technique can also be used to differentiate 
e.g. between inactive and active (phosphorylated) proteins [98]. Enzyme-Linked Immuno 
Sorbent Assay (ELISA) is frequently used to study the role of cytokines and growth factors in 
wound healing. Schrementi et al. used ELISA to compare the levels of TGF-β in oral and 
dermal wounds [99].  
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To analyse the activity of proteolytic enzymes, specific ELISAs were developed as well 
as the less specific Azocoll assay, or zymography [100]. The Azocoll assay measures azo 
dye release of impregnated collagen and Zymography is an electrophoretic method in which 
a substrate (gelatin or casein) is incorporated and can be cleaved in a polyacrylamide gel 
[101-103]. For several proteases such as cathepsins, trypsin and plasmin, more specific 
chromogenic synthetic peptide substrates were developed [104], which allows a colorimetric 
measurement of the specific proteolytic activity.  
To study the localisation of enzymatic degradation by matrix metalloproteinases in the 
tissue in situ zymography can be used [105-107]. In this technique cryo-sections are cov-
ered with a substrate which is subsequently cleaved by the protease and visualised. The 
development of substrates labelled with both a fluorescent label and a quencher which 
quenches the fluorescent dye in the uncleaved substrate greatly enhanced this technique. At 
the location of proteolytic activity the substrate is cleaved and the fluorescence becomes 
apparent. This and various other techniques to study proteolytic activity of various enzymes 
in situ are reviewed by Frederics et al. [108]. 
Cellular viability 
The hypertrophic nature of a scar can be assessed by investigation of the balance be-
tween cell proliferative capacity and apoptosis of e.g. cells isolated from scar tissue. Tech-
niques include a DNA fragmentation assay using agarose gel electrophoresis, propidium 
iodide staining for apoptotic cells, and an MTT assay for cell viability [109]. 
Histopathology and immunohistochemistry 
Standard histochemical staining techniques (like haematoxylin-eosin (H&E) staining) on 
tissue sections can be used to evaluate tissue cellularity, cell morphology, and architectural 
aspects such as thickness of the epidermis or dermis and orientation of the collagen bun-
dles. Immunohistochemical techniques can visualise the presence and location of specific 
cell types and proteins. This technique was used to visualise epidermal components in hy-
pertrophic scars [110], angiogenesis in surgical wounds [111], and components of the im-
mune system after thermal injury [112].  
One of the most pronounced differences between normal skin and scar tissue is the ar-
chitecture of the collagen fibres. These differences are already apparent on the standard 
H&E-stained sections. With the picrosirius red staining individual collagen fibres can be 
visualised with polarised light. In scar tissue fibre thickness differs from normal skin and 
fibres are oriented more parallel to each other [113]. Images of these sections can be used 
for Fourier analysis to quantify collagen bundle orientation and collagen “bundle packing” 
[114,115]. The Fourier transformation calculates the structure organization in two-
dimensional images. The Fourier zeroth order maximum can be used for calculating the 
orientation of collagen bundles and has been widely applied to determine the orientation of 
structures in diseased skin and scars [113,115-120]. Secondly, the Fourier first order maxi-
mum allows the estimation of the “bundle packing”, which is the distance between the cen-
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tres of the collagen bundles. This morphometric method has also been applied in several 
studies[113,120,121]. 
Evaluation methods for tissue-engineered skin constructs in animal 
models 
Tissue-engineered skin constructs are being developed with the goal to improve wound 
healing. Most constructs are first evaluated in vitro to assess e.g. their biocompatibility and 
capacity to induce cell proliferation and/or differentiation. Based on these results, some 
constructs are further evaluated in vivo. For this review, a literature study was performed to 
list methods that have been used to evaluate tissue-engineered skin constructs (i.e. a natu-
ral or synthetic scaffold with or without cells) in full-thickness skin wounds in animal models 
(summarised in Table 3). Pubmed was searched for original research papers primarily 
based on the following search terms: “skin wound scaffold”, “biomaterial vivo skin wound”, 
“tissue engineering skin wound vivo”, and “substitute full-thickness wound”. Studies describ-
ing an animal full-thickness wound model in combination with a tissue-engineered skin con-
struct in English were included. Tissue engineering is a highly dynamic field, combining 
various fields of scientific research, and using a variety of materials and cell sources. There-
fore, the authors acknowledge the possibility of not being completely comprehensive, and 
apologise beforehand when a particular study is missing. 
As will be apparent, not all clinical methods as described in section 2 are used to evalu-
ate constructs in animal models. One reason is that animal models are more suitable for 
invasive evaluation methods. However, this does not explain the remarkable underrepresen-
tation of non-invasive (clinical) measurement methods, the latter is very well possible without 
omission of the first. Another striking observation is that different types of animal models are 
being used, ranging from rat and mouse to pig. This may have major impact on the transla-
tion of results to the human situation, since wounds in rodents heal primarily by contraction, 
while pig skin is more comparable to human skin and heals by the formation of granulation 
tissue. In addition, a large variation in animal strains was noticed and also the size and loca-
tion of wounds varied between studies (outside the scope of this review and therefore not 
further discussed in detail). Various wound models have been reviewed by others [122-125]. 
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Table 3. Overview of studies describing the evaluation of tissue-engineered skin constructs in animal 
models, including the animal species, type of construct, and evaluation methods, sorted on publication 
year. 
 
A=Macroscopic evaluation, B=Planimetry, C=Histology, D=Immunohistochemistry (see Table 4), 
E=Gene expression, F=Transillumination, G=In vivo imaging, H=Electron microscopy, I=Mechanical 
properties, J=Epidermal barrier 
Reference Species Construct A B C D E F G H I J 
Lammers 2010 [126] Rat Collagen-GAG + GFs           
Matsumoto 2010 [127] Rat Hyaluronic acid-collagen -/+ human 
FBs 
          
Steinstraesser 2010 
[128] 
Pig Collagen           
Kurpinski 2010 [129] Rat PLLA -/+ GAG           
Wang 2010 [130] Rat Collagen-GAG + rat FBs           
Klingenberg 2009 [131] Mouse Collagen-GAG + human FBs & KCs           
Egana 2009 [132] Mouse Collagen-GAG + pancre-
atic/submandibular gland SCs 
          
Egana 2009 [133] Mouse Collagen-GAG + human MSCs           
Scherer 2009 [134] Mouse poly-N-acetyl-glucosamine vs. cellu-
lose 
          
Kim 2009 [135] Mouse PLLA -/+ human EPCs           
Li 2009 [136] Rat Polyurethane + PDGF           
Okabayashi 2009 [137] Pig Hydroxyapatite-silk fibroin gel           
Masuda 2009 [138] Mouse Peptide-conjugated chitosan + 
human KCs 
          
Xiao 2009 [139] Mouse Porcine DED + porcine vs. human 
KCs 
          
Salem 2009 [140] Mouse Collagen-elastin + pancreatic SCs           
Bao 2008 [141] Rabbit Agar-collagen           
Altman 2009 [142] Mouse Silk fibroin-chitosan + ASCs           
Breen 2009 [143] Rabbit Fibrin -/+ beta-galactosidase expres-
sion vector 
          
Yang 2009 [144] Mouse Human amniotic membrane + human 
FBs & KCs 
          
Baynosa 2009 [145] Rat Collagen           
Windsor 2009 [146] Mouse Collagen + human FBs & KCs           
Zhang 2009 [147] Mouse Porcine DED + human FBs           
Schneider 2009 [148] Rat Collagen-elastin or collagen-GAG           
Wang 2008 [149] Mouse Collagen           
Kalyanaraman 2008 
[150] 
Mouse Collagen-GAG + human FBs & KCs           
Bannasch 2008 [151] Pig Fibrin + porcine KCs -/+ DED           
Bannasch 2008 [152] Mouse & 
Pig 
Mouse: DED + human KCs; Pig: 
Fibrin + porcine FBs -/+ DED 
          
Powell 2008 [153] Mouse Collagen + human FBs & KCs           
Garcia 2008 [154] Rat Collagen           
Nillesen 2007 [155] Rat Collagen-GAG + GFs           
Falanga 2007 [156] Mouse Fibrin + murine BMCSs           
Myers 2007 [157] Pig GAG + porcine KCs           
Tanihara 2008 [158] Rabbit Collagen           
Ma 2007 [159] Pig Collagen-chitosan           
Perng 2008 [160] Mouse Gelatin-acrylamide + human BMSCs           
Breen 2008 [161] Rabbit Fibrin -/+ eNOS expressing vector           
Richters 2008 [162] Pig Human DED           
Lee 2007 [163] Mouse GAG, PEG-PLGA-PEG + murine 
HSCs, MDSCs or MSCs 
          
Waldeck 2007 [164] Rat PEGylated-RGD gelatin & KGF-1           
Lin 2006 [165] Rat Collagen -/+ PDGF           
Ng 2006 [166] Rat Collagen-GAG or PLGA -/+ human 
FBs & KCs 
          
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Table 3 (continued) 
 
Reference Species Construct A B C D E F G H I J 
Lee 2005 [167] Mouse Gelatin -/+ human FBs           
Zweers 2005 [168] Mouse Collagen + human FBs & KCs           
Druecke 2004 [169] Pig Collagen(-GAG) or PEGT/PBT           
Gu 2004 [170] Rabbit Collagen -/+ transfected PDGF           
Price 2004 [171] Pig GAG -/+ porcine FBs -/+ porcine KCs           
Llames 2004 [172] Mouse Plasma + human FBs & KCs           
Middelkoop 2004 [124] Pig Biological and synthetic scaffolds -/+ 
porcine FBs 
          
Wang 2004 [173] Mouse PEGT/PBT -/+ human FBs           
Breitbart 2003 [174] Mouse PGA -/+ murine FBs -/+ transfected 
PDGF 
          
Lee 2003 [175] Mouse Gelatin-B-glucan  -/+ human FBs & 
KCs 
          
Grant 2002 [176] Pig Collagen-GAG + fibrin & porcine KCs           
Lamme 2002 [177] Pig Collagen-elastin hydrosylate + 
porcine FBs 
          
Breitbart 2001 [178] Rabbit PGA -/+ rabbit FBs -/+ transfected 
VEGF/PDGF 
          
Pandit 2000 [179] Rabbit Fibrin -/+ FGF-1           
Lamme 2000 [180] Pig Collagen-elastin hydrosylate -/+ 
porcine FBs 
          
Gorodetsky 1999 [181] Pig Fibrin -/+ human FBs -/+ PDGF           
Breitbart 1999 [182] Rat PGA -/+ rat FBs -/+ transfected 
PDGF 
          
Pandit 1999 [183] Rabbit Collagen-/+ TGFβ           
Supp 1999 [184] Mouse Collagen-GAG + human FBs & KCs           
Pandit 1998 [185] Rabbit Collagen -/+ FGF-1           
Fauza 1998 [186] Sheep PGA -/+ sheep FBs & KCs           
Pandit 1998 [187] Rabbit Fibrin + PEG beads           
Pandit 1998 [188] Rabbit Fibrin-PEG beads + FGF-1           
Lamme 1998 [189] Pig Collagen-elastin hydrosylate + 
porcine FBs 
          
Orgill 1998 [190] Pig Collagen-GAG           
Compton 1998 [191] Pig Collagen-GAG + porcine KCs           
Butler 1998 [192] Pig Collagen-GAG + porcine KCs           
Lamme 1996 [193] Pig Collagen-elastin hydrosylate           
Boyce 1996 [194]  Mouse Collagen-GAG + human FBs & KCs           
De Vries 1995 [195] Pig Collagen-elastin hydrolysate -/+ FBs 
or stromal cells 
          
Hafemann 1994 [196] Rat Collagen + rat KCs -/+ fibrin           
Hansbrough 1993 
[197] 
Mouse Polyglactin + human FBs & KCs           
De Vries 1993 [198] Pig Collagen, polyglactin or PEU           
Yannas 1989 [199] Guinea 
pig 
Collagen-GAG -/+ guinea pig FBs & 
KCs 
          
Doillon 1984 [200] Guinea 
pig 
Collagen -/+ fibronectin           
Bell 1981 [201] Rat Collagen + rat FBs           
Yannas 1981 [202] Guinea 
pig 
Collagen-GAG -/+ KCs           
Chardack 1962 [203] Pig Polyvinyl alcohol    
 
       
 
ASCs=adipose-derived SCs, BMSCs=Bone marrow-derived SCs, DED=de-epidermised dermis, EPCs=endothelial 
progenitor cells, FBs=fibroblasts, FGF=fibroblast growth factor, GAG=glycosaminoglycan, GF=growth factor, 
HSCs=hematopoetic SCs, KCs=keratinocytes, KGF=keratinocyte growth factor, MDSCs=muscle-derived SCs, 
MSCs=mesenchymal stromal/SCs, PBT=polybuthylene therephthalate, PDGF=platelet-derived growth factor,  
PEG=polyethylene glycol, PEGT=polyethylene oxide therephthalathe, PEU=polyether urethane, PGA=poly glycolic 
acid, PLGA=poly(lactic-co-glycolic acid), PLLA=poly-L-lactide acid, RGD=arginine-glycine-aspartic acid, SCs=stem 
cells, TGF=transforming growth factor, VEGF=vascular endothelial growth factor 
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Macroscopic evaluation 
Most of the studies reviewed describe macroscopic aspects of the healing wounds and 
approximately half of the studies show macroscopic pictures. However, the description is 
often limited to one or two sentences, predominantly mentioning the take rate of the con-
struct, colour (pigmentation, vascularisation), signs of granulation tissue or epithelialisation 
and the absence of signs of infection/inflammation or necrosis. Bannasch et al. provided a 
relatively detailed description of the appearance of the healing wounds in time, and specified 
different areas with e.g. granulation tissue and neo-epithelium [151]. Llames et al. men-
tioned the presence of fine wrinkles and hyperkeratosis, characteristic for the regenerated 
human skin in their mouse model, and stated that the regenerated skin was easy to lift and 
move [172], and Hansbrough et al. also mentioned graft surface smoothness during the 
regeneration process [197]. Druecke et al. mentioned in their macroscopic evaluation the 
presence of epidermal flakes/scales, white opaque granules representing hyperkeratinisa-
tion. In addition, they used a scale that was also used in other studies to systematically 
score for wound colour, surface smoothness, and wound suppleness/stiffness 
[169,177,180,198].  
Taken together, most studies provide a macroscopic but unsystematic description of 
wounds. To improve the comparison between studies, we recommend the use of a standard 
checklist: a subjective scar assessment tool could be used for this purpose, as described in 
Table 1. Since an animal „patient‟ cannot evaluate its own wounds, scoring can only be 
performed by the observer. Therefore, the observer part (OSAS) of the clinically emerging 
POSAS would be suitable, containing a 1-10 scale to score for scar vascularity, pigmenta-
tion, thickness, relief, pliability, and surface area [204]. 
Macroscopic analysis was also used to evaluate wound contraction and reepithelialisa-
tion subjectively, but in most cases these were further analysed by planimetry. 
Planimetry to measure wound contraction and/or reepithelialisation 
Analogous to the clinical evaluation of wound healing, approximately half of the animal 
studies mentioned wound contraction. However, it is not always stated what was measured 
exactly (e.g. how wound margins were defined), which makes it unclear whether wound 
healing (closure) by re-epithelialisation or real contraction is reported. Also the exact method 
used to measure contraction is not always completely clear [164,166]. A calliper can be 
used to manually measure wound area [163], but most studies make use of photographs to 
analyse wound contraction. Occasionally, it is stated that a ruler was included in the photo-
graph [142,147], but in other cases it is not clear how corrections for photographing distance 
were made. Other studies used transparent papers to trace the wounds edges 
[153,154,169]. In some cases, the software used to calculate the wound area is specified 
[134,137,142,146,147,150]. However, differences in software is probably causing the least 
variation. Most studies do not correct for growth of the animals during the study by e.g. the 
use of reference spots on the unaffected skin. In pig, this has been achieved by determina-
tion of a tattooed wound outline with respect to a larger tattooed grid, unaffected by contrac-
tion (Fig. 2) [124,162,177,180,198]. As long as corrections for animal growth and e.g. photo-
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graphing distance and wound surface convex are made, the method employed for area 
calculation is of less importance when contraction has to be compared between different 
studies. 
 
 
 
Figure 2. Tattoo method to monitor contraction in a porcine wound model. Before operation, a grid with defined dimen-
sions was drawn on the pigs flank. At day 0, a treatment (collagen-heparin scaffold in this example) was applied. 
Contraction was monitored with pictures and to correct for the growth of the animal during the experiment, wound area 
(inner lines) was calculated as a percentage of the large, unaffected square (outer lines). Tattoo ink is highlighted with 
black dots for clarity at day 0 and 55. 
 
Comparable methods were used to determine reepithelialisation [134,148], e.g. by trac-
ing the epidermal edges on transparent papers as described in Price et al. [205]. However, 
these macroscopic methods can only be applied on wounds lacking a crust that covers the 
newly-forming epithelium. Since the reepithelialisation rate is dependent on the total wound 
area, it is important to correct for contraction when this rate is calculated.  
 Histological evaluation with conventional staining techniques 
Depending on the structures of interest that have to be visualised, different histological 
staining methods can be used. However, the most important issues for a reliable histological 
evaluation are correct sampling and processing of these samples. Since in most cases the 
skin regeneration process moves from the wound edges to the centre, comparable sampling 
positions are important when comparing different wounds.  
Almost all studies reviewed used H&E staining to evaluate different aspects of the wound 
healing process (Fig. 3A). These aspects include the presence and thickness of granulation 
tissue, degradation of the biomaterial, extracellular matrix arrangement, vascularisation, 
(extent of) reepithelialisation or epithelial gap, epithelial thickness and differentiation, and the 
presence of normal skin structures like rete ridges, papillary plexus and appendages. H&E 
staining is also extremely useful in the identification and localisation of different cell types 
involved in the wound healing process, like macrophages, granulocytes (polymorphonuclear 
leukocytes), lymphocytes, (foreign body multinuclear) giant cells, and fibroblasts. 
Alternative dyes were used to further distinguish between different tissue/biomaterial 
components. Richters et al. used an Elastic-van Gieson (EVG, also named Verhoeff-Van 
Gieson) staining to visualise elastic fibres and collagen [162]. Bannasch et al. used an Elas-
tic-van Gieson staining to show Alloderm degradation (containing elastin fibres) and 
Trichrome-Goldner staining to analyse dermal collagen structures and epithelial morphology 
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[151,152]. Li et al. used Mallory‟s trichrome staining to distinguish scaffold polymer (white), 
tissue (red), and collagen deposition (green) [136], and Myers et al. used it to visualise col-
lagen organisation and blood vessels, but also the general appearance of the dermis and 
epidermis [157]. Several studies used Masson‟s Trichrome staining to visualise scaffold 
remnants and to present a more general histological picture (inflammatory cells, blood ves-
sels) [143,153,154,161,167,170,179,181,187]. Lamme et al. used Herovici picropolychrome 
staining to distinguish scaffold collagen (highly crosslinked, red/purple) from newly-formed 
collagen (blue) [189]. After four weeks, also the newly-formed collagen started to stain 
red/purple. 
Polarised light microscopy on Sirius red-stained sections was used to analyse the or-
ganisation and orientation of collagen fibres in the wound bed, and provide clear details on 
the working mechanism of this technique [154,161]. Comparable methods including phase 
contrast (PH) microscopy were used on H&E-stained sections to assess collagen fibre matu-
ration and/or orientation [169,177,180,198] and Lee et al. used it to localise collagen and 
subsequently measured the staining intensity to quantify collagen deposition [163]. Windsor 
et al. used orcein to stain (scaffold) collagen and a periodic acid-Schiff (glycogen) staining to 
visualise basement membrane formation (Fig. 3B&C) [146]. Alternatively, collagen orienta-
tion can be assessed without staining by small-angle light scattering measurements, which 
is also based on scattering of polarised light and was used by Yannas et al. [199]. 
 Quantification of histological data has been technically challenging for a long time and 
was therefore hardly performed in studies. Lamme et al. used a semi-quantitative 1-5 scale 
to score for inflammation severity [177]. Other studies quantified the total area of granulation 
tissue [178] or the area of remaining polymer and newly-formed tissue [136] on images of 
tissue sections. Baynosa et al. simply counted blood vessels in tissue sections [145]. Pandit 
et al. used the IBAS image processing system (formerly sold by Kontron, Eching/München, 
Germany) to quantify contraction, epithelialisation, volume fractions of different cell types 
and blood vessels on H&E-stained sections [179,183,185,187,188]. This is also possible by 
using pixel intensities to quantify tissue and fibroblast ingrowth [200], which can be per-
formed using freely-available software like ImageJ (http://rsbweb.nih.gov/ij/). 
In conclusion, histological evaluation is generally used, but not systematically. Since 
most studies use H&E staining, we would recommend to introduce a standard checklist 
identifying the presence or absence of key players in wound healing, like keratinocytes, 
fibroblasts, macrophages, giant cells, and blood vessels. Currently, it often remains unclear 
whether cell types that are not mentioned, were studies at all. In addition, it would be worth-
while to quantify the area occupied by certain cells/structures, or total number of cells, but 
this remains technically challenging. 
3.4 Protein expression levels and location 
Protein expression is also an important read-out parameter in the evaluation of tissue-
engineered constructs in animal models. Specific protein expression was analysed in most 
studies by use of immunohistochemistry (Table 4, Figs. 4 and 5). This method provides 
information on the specific location of the proteins assessed. Often one or more antibodies 
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were used to visualise proliferation and differentiation of the epidermis, components of the 
dermal-epidermal basement membrane and/or blood vessels, proteins specific for dermal 
structures and cells, and general markers for cell migration and differentiation.  
 
 
 
Figure 3. Examples of histological methods to evaluate wound healing, 14 days after grafting of a collagen-based 
construct containing human fibroblasts and keratinocytes on mice. (A) Epidermal architecture and dermal cellularity 
were evaluated with H&E staining. (B) An orcein staining was performed to visualise construct collagen. (C) A periodic 
acid-Schiff staining for glycogen visualises basement membrane formation (arrowheads). Bar is 100 µm. Copyright 
(2009) Wiley. Used with permission from Windsor ML et al. A novel model of wound healing in the SCID mouse using a 
cultured human skin substitute. Australas.J Dermatol 50, 29 [146]. 
 
 
 
Figure 4. Immunohistological staining for type IV collagen on (A) a collagen-based construct, 7 days after implantation, 
visualising the basement membrane of blood vessels. (B) In normal rat skin less blood vessels are present, and mainly 
the basement membranes of appendages like hair follicles and sebaceous glands are visualised. Bar is 100 µm. 
Reprinted from Biomaterials, 31, Lammers et al., High density gene expression microarrays and gene ontology analy-
sis for identifying processes in implanted tissue engineering constructs, 8299, Copyright (2010), with permission from 
Elsevier [126]. 
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Table 4 shows that many studies have used immunohistochemistry as a read-out pa-
rameter. However, there has been a huge variation in target antigens used to study epider-
mal and dermal components, basement membranes and blood vessels. To facilitate inter-
study comparison, it is recommended to choose a standard panel of antibodies covering the 
most important structural aspects of skin. We suggest a panel of e.g. keratin 14 (basal 
keratinocytes), involucrin (cornified envelope keratinocytes), α-smooth muscle actin (myofi-
broblasts and mature blood vessels), type IV collagen (blood vessel and epidermal base-
ment membrane), and CD31 (blood vessel endothelium).  
As for conventional histology, quantification would be valuable, but was not often per-
formed on immunohistologically stained sections. Lamme et al. used Leica Qwin image 
analysis software (Wetzlar, Germany) to quantify positively stained area [180] and Breen et 
al. used histological pictures and a grid to quantify cell numbers and the number of intersec-
tions with a cycloid line to quantify positively-stained blood vessels [143,161]. 
When human cells were transplanted to a (immunedeficient) mouse model, survival and 
location of the human cells were often determined by staining for human-specific HLA 
[131,133,139,146,150,152,153,166,173,184]. In other studies, cells were labelled before 
transplantation with PKH26 red fluorescent cell linker, green fluorescent protein (GFP), β-
galactosidase, or DiI cell label, and the label was used to visualise these cells after explanta-
tion [130,135,142,143,147,156,163,189]. In addition, protein production after co-implantation 
of a gene expression vector was determined for e.g. platelet-derived growth factor (PDGF), 
vascular endothelial growth factor (VEGF), or endothelial nitric oxide synthase (eNOS) 
[161,170,174,178,182].   
The presence and relative levels of proteins in a tissue sample can also be assessed by 
alternative methods. Perng et al. used SDS-PAGE followed by Western blotting to analyse 
the changes in protein expression levels in time after transplantation of human bone mar-
row-derived stem cells in a mouse wound model. They investigated the transformation in 
expression from the human bone marrow stem cells markers CD13 and CD105 to the 
epithelial cells specific E-cadherin and pancytokeratin [160]. Lamme et al. pre-labelled fibro-
blasts with PKH-26 before implantation and later used flow cytometry on a wound-derived 
single cell suspension to identify the presence of this label in different cell populations [189]. 
Gene expression levels and mRNA location 
Construct-assisted wound healing in animal models can also be analysed by monitoring 
changes on the gene expression level. Scherer et al. used RT-qPCR to analyse the RNA 
expression levels in explanted mouse skin of the pro-angiogenic vasculature endothelial 
growth factor, the urokinase plasminogen activator receptor involved in cell migration, the 
inflammatory cytokine interleukin 1β, and matrix metalloproteinases 3 and 9 involved in 
extracellular matrix remodelling [134]. Other studies used real-time RT-PCR to determine 
gene expression levels of transplanted cells to assess the viability and contribution of these 
cells to the wound healing process. For example, expression of human vs. mouse house-
keeping genes was analysed after transplantation of human cells in a mouse model [135], or 
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Y-chromosome specific gene expression after transplantation of male cells in female 
wounds [171].  
 
 
Table 4. Overview of immunohistochemical staining used to evaluate tissue-engineered skin constructs 
in vivo. 
(continued on next page) 
 
 
 
 Antigen  Tissue/cells Reference(s) 
E
p
id
e
rm
a
l 
P63  Migrating keratinocytes [134] 
(Pan)cytokeratin Keratinocytes [146,166,191] 
Keratin 6 Hyperproliferative keratinocytes [171,176] 
Keratin 5  Basal keratinocytes [172] 
Keratin 14 Basal keratinocytes [140,163,176,191] 
Keratin 15 Basal keratinocytes [131] 
Keratin 1 Suprabasal keratinocytes [138,191,195] 
Keratin 10 Suprabasal keratinocytes [140,168,172] 
Keratin 2  Cornified envelope keratinocytes [131] 
Involucrin Cornified envelope keratinocytes [138,172,191,197] 
Loricrin  Cornified envelope keratinocytes [131,172] 
Fillaggrin Granular keratinocytes [140] 
Α6β4 integrin Attaching keratinocytes [190,191] 
Blood group antigens Maturating epidermis [146] 
HLA-DR Langerhans cells [146] 
Cartilage intermediate layer protein Epidermis [131] 
Osteoglycin Epidermis [131] 
 
D
e
rm
a
l 
α-smooth muscle actin (α-SMA) Myofibroblasts & mature blood 
vessels 
[138,142,152,155,162,163,173
,177,180,195] 
Type I collagen  (Newly-formed) dermis [128,166] 
Type III collagen  (Newly-formed) dermis [128,154] 
Elastin Elastic fibres [155,168,180,193] 
Fibrillin-1 Microfibrils (elastic fibre formation) [168] 
Fibronectin  Wounded dermis [138,193] 
Periostin Dermis [131] 
Tenascin-C  Wounded dermis/DEJ [138,168] 
Tenascin-X Extracellular matrix [168] 
Vimentin  Fibroblasts [127,146,168,169,189,195] 
Heat-shock protein 47 (hsp47)  Fibroblasts [142] 
F4/80  Macrophages [163] 
CD68 Monocytes/macrophages [129] 
„monocytes/macrophages‟ Monocytes/macrophages [169,195] 
CD8 alpha Immune cells [126] 
B
M
 
Chondroitin sulfate Dermis & basement membrane [193] 
Type VII collagen  Basement membrane [151,152,171,190,191] 
B
V
 
Type IV collagen  Blood vessels & basement mem-
brane 
[126,139,151-153,155,196] 
Laminin  Blood vessels & basement mem-
brane 
[128,139,166,172,190,191,193
,197,198] 
 
CD31 Blood vessels [129,135,148,153,161] 
Factor VIII Blood vessels/endothelial cells [159,191] 
PECAM-1 Blood vessels [134,163] 
Von Willebrand factor (vWF) Blood vessels [142,169,173,189,193,195] 
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Table 4 (continued) 
 
BM=basement membrane; BV=blood vessel, DEJ=dermal-epidermal junction 
 
 
 
 
Figure 5. Immunohistological staining for keratin 15 (A-D, red) plus loricrin (A and C, green) and keratin 2 (B and D, 
green) 56 days after implantation of a cultured human skin construct on athymic mice (A and B), and in normal human 
skin (C and D). Adapted by permission from Macmillan Publishers Ltd: J. Invest Dermatol., Klingenberg et al., Engi-
neered Human Skin Substitutes Undergo Large-Scale Genomic Reprogramming and Normal Skin-Like Maturation 
after Transplantation to Athymic Mice, copyright (2009) [131]. 
 
A relatively novel approach is the use of gene expression microarrays. With this tech-
nique, experimental changes in gene expression levels of virtually all known genes can be 
assessed in a single experiment. Subsequent analysis can be performed on the level of 
individual genes, but the use of gene clusters also enables the identification of changes in 
e.g. biological processes. Klingenberg et al. used gene expression microarrays to evaluate 
changes in the gene expression profile of human cells in a cultured skin substitute after 
grafting onto mouse full-thickness wounds [131]. They followed up on the expression of 
 Antigen  Tissue/cells Reference(s) 
O
th
e
r 
Desmin Muscle cells [126] 
Phospho-MAPK Migrating cells [134] 
Ki67 
 
Proliferating cells 
 
[134,138,169,170,191] 
TUNEL Apoptotic cells [126] 
 
‘L
a
b
e
ls
’ 
Endothelial nitric oxide synthase In situ transfected cells [161] 
Platelet-derived growth factor  In situ transfected cells [170,174,178,182] 
Vascular endothelial growth factor In situ transfected cells [178] 
Human HLA Transplanted cell „label‟ [131,133,139,146,150,152,153,166,173,184] 
β-galactosidase Transplanted cell label [143,163] 
DiI cell label Transplanted cell label [135] 
Green fluorescent protein Transplanted cell label [142,156] 
PKH26 red fluorescent cell linker Transplanted cell label [130,147,189] 
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individual genes that had previously not been associated with skin development, and vali-
dated the presence of the proteins in their skin construct. In addition, clusters of genes with 
comparable expression patterns were analysed for their role in skin development. Lammers 
et al. used microarrays to analyse changes in biological processes that occurred in a colla-
gen-based acellular skin construct after implantation in a rat full-thickness wound model 
(Fig. 6) [126]. By using a freely-available web-based tool, gene ontology terms for biological 
processes which are up- and downregulated in the construct versus normal skin were identi-
fied. Subsequently, these altered processes were validated (immuno)histochemically. Cur-
rent limitations of this approach include the poor annotation of e.g. the rat genome, and the 
lack of tissue engineering specific gene ontology terms. However, the fast developments in 
this field hold promises for the future. 
The location of gene expression can be visualised using in situ hybridisation. Although 
elegant in theory, this method proves to be rather specialistic in practice. It was used in only 
one of the reviewed studies to visualise transfected cells expressing human platelet-derived 
growth factor B after application to a rabbit wound model [170]. 
 
 
 
Figure 6. Schematic overview of the complete procedure for the identification of biological processes occuring in vivo 
in constructs used for tissue engineering using high-density gene expression microarrays, as proposed by Lammers et 
al. [126]. In short, mRNA was isolated from tissue samples and processed for hybridisation on rat exon arrays. The 
amount of hybridised RNA, reflecting the amount of specific mRNA‟s, was compared between groups, resulting in lists 
with up- and downregulated genes. Lists were uploaded in the free online DAVID functional annotation tool and the 
enrichment in biological process gene ontology (GO) terms was analysed. The minimal time required for each step is 
indicated on the right. Picture of microarray is courtesy of Affymetrix. Reprinted from Biomaterials, 31, Lammers et al., 
High density gene expression microarrays and gene ontology analysis for identifying processes in implanted tissue 
engineering constructs, 8299, Copyright (2010), with permission from Elsevier [126]. 
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Transillumination for visualisation of vascularisation 
Several studies used the transillumination method developed by Egana et al. to visualise 
blood vessels in explanted nude mice skin (Fig. 7) [132,133,140,206]. Removed skin was 
placed over a transilluminator and digital pictures were taken to calculate vessel area and 
length in a semi-automated way. Altman et al. used a comparable method, but did not quan-
tify the vasculature [142]. However, this method may be challenging in animals with hairs, or 
models like rat and pig with a thicker skin. 
 
 
 
Figure 7.Transillumination technique to visualise and quantify blood vessels. Excised skin was placed over a transillu-
minator and a picture was taken, coverted to a greyscale (A), and inverted (B). This picture was converted to a 
black/white image (C) that was used for further quantification. (D) A close-up of the delineate area in (C) shows that 
even small blood vessels were segmented. Bar is 5 mm. Reprinted with kind permission from Springer Sci-
ence+Business Media: Langenbecks Arch.Surg., Ex vivo method to visualize and quantify vascular networks in native 
and tissue engineered skin, 394(2):349-56, 2008. Egana et al. Fig. 3 [206]. 
In situ/in vivo imaging 
Wang et al. compared Optical Coherence Tomography (OCT) with conventional H&E 
staining as a read-out tool for scaffold-assisted wound healing in mice [149] (Fig. 8). OCT 
uses the reflectance of an optical signal to create an image of the tissue assessed, without 
tissue pre-treatment. Mice were sacrificed at different time points, the regenerating wounds 
were imaged with OCT and then explanted and processed for H&E staining. Images to a 
maximum depth of 0.5 mm were obtained, thereby reaching the upper part of the subcuta-
neous fat layer. Removal of the highly backscattering epidermis increased the maximal 
imaging depth to 1.5 mm. It was possible to distinguish the epidermis, dermis, and subcuta-
neous fat in normal skin. During wound healing, reepithelialisation, areas of inflammatory 
cells and blisters could be visualised, as well as an implanted collagen scaffold and its deg-
radation. Furthermore, the wound size determined in a lateral and vertical direction corre-
lated highly with histology. Although these developments are promising, the resolution of 
obtained images is still low when compared to histology. Therefore, we would in this stage 
recommend the use of conventional histological methods to assess (epi)dermal characteris-
tics. 
Other studies used in vivo imaging to track the survival and distribution of fluorescently-
labelled cells in vivo [135,160]. This is an elegant method, but it is dependent on fluorescent 
labelling and therefore difficult to apply to other cells/tissues. 
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Figure 8. Images obtained by optical coherence tomography (A) and conventional histology (B) three days after 
implantation of a collagen construct in a mouse full-thickness wound. E=epidermis, D=dermis, Ad=adipose tissue, 
M=muscle layer, CI=collagen implant, G=granular tissue, Bl=blisters. Reprinted with permission from Wang Z, et al. 
Assessment of dermal wound repair after collagen implantation with optical coherence tomography. TISSUE ENGI-
NEERING, Part C, 2008, published by Mary Ann Liebert, Inc, New Rochelle, NY [149]. 
Electron microscopy 
Although scanning electron microscopy is often used to characterise scaffolds before 
implantation, this technique is less useful as a read-out parameter. Transmission electron 
microscopy (TEM), on the other hand, was used by for a detailed examination of individual 
epidermal components and dermal elastic fibre, collagen, and fibroblast morphology 
[168,199]. Other studies used this technique to focus on newly-formed basement membrane 
components [190,196] and Lamme et al. used it to distinguish newly-synthesised collagen 
from scaffold collagen and identified myofibroblasts by visualisation of stress fibres in fibro-
blasts [193]. 
Because with TEM usually only small samples can be assessed, it is most suitable to 
answer specific research questions at a detailed level and is less appropriate in general 
wound evaluation. 
Mechanical properties 
Tissue strength is closely related to its functional performance and therefore it is remark-
able that this important aspect of regenerated skin is often not assessed. Yannas et al. de-
termined the „peeling force‟ of their construct after transplantation, but the method used for 
this determination was not stated [202]. Pandit et al. tested the mechanical strength (ulti-
mate tensile strength, stiffness, and failure strength) of explanted regenerating skin in time 
after treatment of rabbit wounds with a collagen scaffold with and without FGF-1 or TGF-β, 
and untreated wounds [179,183,185]. They used an Instron tester to evaluate 1x4 cm skin 
strips in uniaxial tension and calculated the ultimate tensile strength, modulus of elasticity, 
and strain-to-failure. Valuable information can thus be obtained, but the relatively large sam-
ples that are required may be a limiting factor.  
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Epidermal barrier 
One of the important functions of skin is its barrier function. It is therefore striking that 
this function was not often assessed directly. Only few studies used a NOVA dermal phase 
meter to measure skin surface electrical capacitance to assess hydration and thereby barrier 
function after implantation of a tissue-engineered skin construct on athymic mice [184,194]. 
Microbiological sampling 
Bacterial infection may influence the wound healing process [207] and is therefore an 
important aspect to monitor. Most studies did this by scoring signs of infection macro- or 
microscopically. For a more objective assessment of bacterial load, De Vries et al. took 
microbiological samples of wounds [198]. Quantitative microbiology of tissue samples is the 
only reliable method to prove tissue infection with respect to contamination or colonisation. 
Therefore, when facilities and expertise are available, this may be a helpful tool to obtain 
additional information on the condition of different wounds. 
Recommendations and future outlook 
A large number of tissue-engineered skin constructs has been developed and evaluated 
in vivo. Although many studies report promising results, so far only few constructs have 
entered the clinic. This discrepancy may in part be caused by the large variation in read-out 
methods used, and lack of standardisation thereof, severely hampering the systematic com-
parison of different studies/constructs. This variation can already be explained by the large 
number of different wound models used, ranging from wounds on the back of (immune-
deficient) mice, rat and pigs to ear wounds in rabbits. Interstudy comparison is further ham-
pered by the differences in description of macro- and microscopic observations and (when 
applicable) the large variation in antibodies used for immunohistological evaluation. We 
therefore propose the use of at least four standard evaluation methods (Table 5), viz: an 
observer scar assessment scale (OSAS), planimetry, H&E staining, and antibody staining 
for five key proteins in cutaneous wound healing. Using these parameters, it would be pos-
sible to calculate one over-all score for the in vivo performance of a tissue-engineered skin 
construct in an animal model. However, the importance of each single aspect may vary 
between studies and the reliability and validity of such a scoring system will require further 
investigation. 
In addition, the lack of use of most of the non-invasive clinical methods (section 2) as 
read-out method for tissue-engineered skin constructs (section 3) is striking. Except for the 
measurement of wound area (planimetry), few studies describe a systematic registration of 
scar colour, thickness, relief, and elasticity. Most of the clinical methods listed do not inter-
fere with subsequent invasive methods, and may therefore provide valuable additional in-
formation. Most of the methods were developed for, and validated on human skin, and this 
may be a reason for the lack of use in animal models, since the animal skin is different and 
will therefore require additional validation.  
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Table 5. Proposed standard assessment methods to evaluate wound healing in animal models after 
treatment with tissue-engineered skin constructs. 
 
Level Evaluation method Scar feature 
Macroscopic 
 
 
Observer scar assessment 
scale (OSAS) 
Vascularity, pigmentation, thickness, 
relief, and pliability 
Planimetry (direct tracing or 
on photographs) 
Contraction 
Microscopic H&E staining  
 
 
Amount of keratinocytes, fibroblasts, 
macrophages, giant cells, and blood 
vessels 
Antibody staining for keratin 
14, involucrin, α-smooth 
muscle actin, type IV colla-
gen, and CD31 
Keratinocyte differentiation, presence of 
myofibroblasts and (mature) blood ves-
sels 
 
Another important aspect in using read-out methods is the fundamental difference be-
tween point measurements and field measurements. In general, the statistical variation is 
higher between point measurements (like colour measurement using a chromameter or 
mexameter, or skin pH measurement with an electrode) than between field measurements 
(like photography or scanning optical coherence tomography). Therefore, when using tech-
niques that generate point measurements, a sound sampling plan is required to create data 
sets that will allow the detection of statistical differences. 
Organisations like the international society for biophysics and imaging of the skin (ISBS, 
http://www.i-s-b-s.org/) play an important role in the development and standardisation of 
non-invasive methods for the assessment of skin conditions. International organisations are 
also working on the standardisation of skin tissue engineering. The ASTM International 
(previously known as the American society for testing and materials, http://www.astm.org/) 
and the international organization for standardization (ISO, http://www.iso.org/iso/home.htm) 
have developed valuable standards for the classification of therapeutic skin substitutes 
(ASTM F2311), characterisation and testing of biomaterial scaffolds used in tissue-
engineered medical products (TEMPs, ASTM F2150), and testing for irritation and skin sen-
sitisation of medical devices (ISO 10993-10:2010). However, to our knowledge, these do not 
include standards for the in vivo evaluation of tissue-engineered skin constructs. 
Behavioural observations like scratching are of great importance since adverse effects 
like itching or pain are difficult to assess in animals (manuscript in preparation [208]). It is 
therefore recommended to closely monitor animal behaviour and report all relevant observa-
tions. Standardised methods for this evaluation are not yet available to our knowledge, but 
devices like the microAct (Neuroscience, Tokyo, Japan), that objectively measure scratching 
in mice, may be useful [209]. When possible, it is also recommended to assess gene ex-
pression. In our opinion, gene expression microarrays may provide valuable additional in-
formation on the wound healing process. With the rapid developments in the field of genom-
ics, this technique may be replaced soon by more advanced methods like RNA-sequencing 
[210]. On the protein profiling level a technique such as mass-spectrometry opens new op-
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portunities [211]. Also the dynamic field of imaging is rapidly developing and new techniques 
may be soon applicable in the field of tissue-engineering, including second harmonic imag-
ing [212] to visualise e.g. collagen and elastic fibres in ex vivo skin, and multiphoton tomo-
graphy [213] to visualise skin layers in vivo based on autofluorescence of e.g. keratinocytes, 
collagen and elastin.   
In conclusion, a more systematic evaluation of tissue-engineered skin constructs in ani-
mal models would greatly enhance the comparison between different constructs and thereby 
accelerate the trajectory to application in human patients. This would be further enhanced by 
the embracement of clinically relevant evaluation methods. In addition, fundamental knowl-
edge on construct-assisted wound healing may benefit by new developments in e.g gene 
expression analysis and non-invasive imaging. 
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Abstract 
Glycosaminoglycans, like heparin, are frequently incorporated in biomaterials because of 
their capacity to bind and store growth factors and because of their hydrating properties. 
Heparin is also often used in biomaterials for its anticoagulant activity. Analysis of biomateri-
al-bound heparin is challenging because most assays are based on heparin in solution. In 
this study, seven different methods were probed to analyse heparin covalently attached to 
collagen scaffolds. For each method the basic mechanism and the advantages and disad-
vantages are given. Analysis by a factor Xa assay and the Farndale assay clearly indicated 
that the amount of immobilised heparin cannot be determined correctly when the scaffold is 
intact. Scaffolds had to be proteolytically digested or acid treated in order to obtain reliable 
measurements. Methods used to quantify the amount of bound heparin included a hexosa-
mine assay, an uronic acid assay, a Farndale assay, agarose gel electrophoresis, and im-
muno dot blot analysis. Location and semi-quantification of heparin was accomplished by 
immunofluorescence. Although all assays had their advantages and disadvantages, the 
hexosamine assay turned out to be the most robust, and is recommended as the preferred 
assay to quantify the amount of heparin bound to scaffolds. It is applicable to all scaffolds 
that are acid hydrolysable. This study may allow researchers in the field to select the most 
appropriate method to analyse glycosaminoglycans in biomaterials. 
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Introduction 
Glycosaminoglycans are long, negatively charged, unbranched polysaccharides, consist-
ing of repeating disaccharide units. Being present at the cell surface and in the extracellular 
matrix, they play an important role in the binding and modulation of growth factors and other 
effector molecules, and endow tissues with water-binding capacity [1]. Consequently, glyco-
saminoglycans are often incorporated in tissue-engineered constructs that are designed to 
mimic the natural extracellular matrix [2,3].  
In tissue engineering, heparin is the most employed glycosaminoglycan for a number of 
reasons. It is well known for its anticoagulant activity and therefore used in vascular grafts to 
prevent thrombus formation [4]. Heparin is relatively cheap because it is prepared in large 
quantities. Immobilised heparin can be used to non-covalently bind growth factors, thus 
avoiding the risk of loss of growth factor activity which may occur when they are covalently 
bound to biomaterials [5].  
Heparin consists of highly sulfated disaccharide units (Fig. 1). In intestinal mucosa, a 
common source of commercially available heparin, about 75% of the disaccharides consist 
of a 2-O-sulfated iduronic acid residue and a 6-O-sulfated, N-sulfated glucosamine residue 
[6]. 
 
Figure 1. Frequently occurring disaccharide present in heparin from the intestinal mucosa, and consisting of a 2-O-
sulfated iduronic acid (left) and a 6-O-sulfated, N-sulfated glucosamine residue (right) [6]. 
 
When immobilizing heparin to a biomaterial it is important to quantify the amount 
present. The analysis of heparin covalently bound to a solid substrate like a collagen scaf-
fold, may pose a number of challenges because heparin is generally assayed in solution, 
and the presence of the insoluble biomaterial may interfere.  
In this study, seven different methods were used to analyse the amount and location of 
collagen scaffold-bound heparin. Of each method, the mode of action is briefly reviewed and 
the advantages and disadvantages are given to enable researchers to select the most ap-
propriate method to analyse heparin in (collagen-based) biomaterials. 
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Materials and methods 
Materials 
Insoluble type I collagen was purified from bovine Achilles tendon using extractions with 
aqueous acetic acid, NaCl and urea, and acetone as described [7]. Heparin sodium from 
porcine mucosa (187.4 units/mg) with an average molecular weight of 15 kDa (10-20 kDa), 
was purchased from Diosynth (Oss, The Netherlands).  
Preparation of (heparinised) collagen scaffolds 
Scaffolds were prepared in 24-well plates (Greiner Bio-One) by freezing 800 μl of a 0.8% 
type I collagen suspension in 0.25 M acetic acid per well at -20°C and subsequent lyophili-
sation [8].  
To covalently couple heparin, scaffolds were wetted in 50 mM 2-morpholinoethane sul-
phonic acid buffer (MES, pH 5.0) containing 40% ethanol, and preincubated for 30 min in 
400 μl of a heparin solution (0-4%) in MES buffer. Scaffolds were chemically crosslinked for 
4 h by adding 400 μl 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC)/N-hydroxy-
succinimide (NHS) in MES buffer, the final concentrations being 33 and 6 mM respectively, 
followed by washings with 0.1 M Na2HPO4, 1 M NaCl, 2 M NaCl and demineralised water 
[9]. The final contents of heparin in the crosslinking solution were 0, 0.05, 0.1, 0.2, 0.3, 0.4, 
0.5, 0.75, 1 and 2%. 
To ensure representative sampling, pie part-shaped pieces from the round scaffolds 
were assayed, unless stated otherwise. 
Determination of amine group content 
The amine group content of the scaffolds was estimated spectrophotometrically by using 
2,4,6-trinitrobenzene sulfonic acid (TNBS) [10,11]. To calculate the amount of amine groups 
per mg of collagen scaffold, a correction was applied for the amount of bound heparin, using 
a hexosamine assay (see below).  
Papain digestion of scaffolds 
To digest collagen scaffolds, 1 mg was incubated in 2.5 U papain (Sigma-Aldrich, St. 
Louis, MO, USA) in 1 ml digestion buffer (50 mM NaPO4, 2 mM cysteine, 2 mM EDTA, pH 
6.5) for 16 h at 65°C. 
To evaluate for the presence of large (undigested) protein fragments, 70 µl 100% trichlo-
roacetic acid (TCA) per 400 µl sample was added and incubated on ice for 30 min, centri-
fuged at 10,000 g for 20 min at 4ºC. No pellet was observed, indicating that the papain 
treatment was sufficient to digest the collagen scaffolds to soluble protein fragments.  
Seven methods used for the determination of heparin in scaffolds 
Table 1 provides an overview of different aspects of the seven methods used for the de-
termination of heparin in scaffolds. 
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Table 1. Overview of the mechanism, sensitivity, assay time, sample pre-treatment, and 
(dis)advantages of seven methods used to evaluate the amount of heparin in collagen scaffolds. *o/n = 
overnight. 
 
Method 
Mode of action  
(see also text) 
Sensi-
tivity 
As-
say 
time 
Sample 
pre-
treatment 
Prime 
advan-
tages 
Limitations 
Factor Xa 
assay 
Antithrombin III activa-
tion => Factor Xa inacti-
vation => less hydrolysis 
of chromogenic sub-
strate (less colour) 
MilliU 
(ng) 
30 
min 
None or 
papain 
digestion 
Functional 
assay 
(coagula-
tion)  
 
Detection of 
only antico-
agulant hepa-
rin 
Farndale 
assay 
Multiple sulphate groups 
+ dimethylmethylene 
blue => change in ab-
sorption maximum 
(metachromasia) (= 
colour change) 
µg 2 
days  
(2x 
o/n*) 
Papain 
digestion 
Specific 
for poly-
sulfated 
molecules 
Many steps 
required, 
enzymatic 
digestion 
Hexosa-
mine 
assay 
Glucosamine + acety-
lacetone ->  pyrroles. 
Pyrroles + p-
dimethylamino-
benzaldehyde => colour 
µg 3 
days  
(3x 
o/n) 
Acid 
hydrolysis 
Robust 
method 
Long proce-
dure 
Uronic 
acid 
assay 
Acid hydrolysis of uronic 
acid => carboxylated 
furans + m-
hydroxybiphenyl => 
colour 
µg 2 
hrs 
Acid 
hydrolysis 
Fast assay Collagen 
interference , 
hazardous 
chemicals (hot 
80% H2SO4)  
Agarose 
gel elec-
tro-
phoresis 
Differential migration of 
GAGs in the presence of  
divalent cations contain-
ing buffer (backbone 
dependent) => silver 
staining 
ng 1 
day  
(1x 
o/n) 
Papain 
digestion 
Discrimi-
nation of 
GAG 
classes 
Enzymatic 
digestion, 
limited number 
of samples per 
gel 
Immuno-
dot blot 
Binding of GAG-protein 
fragment to membrane 
=> anti-GAG antibody 
binding => visualisation 
ng  
 
1 
day  
(1x 
o/n) 
Papain 
digestion 
Direct 
visual 
result, 
simple 
equipment 
Standards for 
quantification 
not readily 
available, 
many steps 
required, 
enzymatic 
digestion 
Immuno-
fluores-
cence 
assay 
Anti-GAG antibody 
binding to cryosections 
=> visualisation 
n.a. 1 
day  
(1x 
o/n) 
Freezing, 
sectioning 
Topologi-
cal data 
Semi-
quantitative 
Factor Xa assay  
This method is based on the conformational change of the serine proteinase inhibitor an-
tithrombin III by heparin, resulting in factor Xa inhibition [12,13]. The capacity of scaffold-
bound heparin to delay the blood coagulation cascade was assessed using a Coatest Hepa-
rin (Chromogenix, Milan, Italy) according to the manufacturer‟s protocol [14]. Scaffolds (0.5-
1.5 mg) were incubated in 50 µl normal human plasma enriched with 2.5 mU antithrombin III 
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in 50 mM Tris (pH 8.4) for 5 min at 37ºC to allow antithrombin III to bind to heparin and un-
dergo a conformational change. Heparin standards (0-100 ng) were used as controls. Then, 
25 µl factor Xa was added, mixed, and incubated for 30 s at 37ºC to allow activated antith-
rombin III to inactivate factor Xa. A 50 µl aliquot of a 1 mM chromogenic substrate (S-2222 
(Bz-IIe-Glu-(g-OR)-Gly-Arg-pNA·HCl)) was added, mixed, and incubated for 10 min at 37ºC, 
allowing the remaining active factor Xa to hydrolyse the substrate, thereby releasing chro-
mophore p-nitroaniline (pNA). The reaction was stopped by the addition of 100 µl 20% acetic 
acid and absorbance was measured at 405 nm.  
Alternatively, a factor Xa assay was performed on papain digested samples (see papain 
digestion section) in the presence of 25 µM antipain (Sigma-Aldrich) to prevent papain from 
digesting antithrombin III and factor Xa. 
Farndale assay  
This method is based on a shift in the maximum absorbance wavelength of the dye 1,9-
dimethylmethylene blue after binding to multiple sulphate groups (metachromasia) [15]. Dry 
scaffold pieces were incubated in Farndale reagent (43 µM dimethylmethylene blue contain-
ing 40 mM glycine and 41 mM NaCl adjusted to pH 3.0 with 2 M HCl) and incubated at room 
temperature.  
Alternatively, papain digested scaffold preparation after TCA precipitation was used (see 
papain digestion section). Glycosaminoglycans present in the supernatant (bound to small 
protein fragments) were analysed by precipitation with 2 ml ice cold ethanol, overnight incu-
bation at -20ºC, and centrifugation at 17,000 g for 20 min at 4 ºC. The precipitate was dis-
solved in 100 µl MilliQ and 10 µl was used for analysis. Heparin standards (0-5 µg) were 
included and 1 ml Farndale reagent was added to the samples and the standards. The ab-
sorbance of dimethylmethylene blue after binding with the sulphate groups in heparin was 
measured at 525 nm [16].  
Hexosamine assay 
This method is based on the colourimetric determination of hexosamines, like glucosa-
mine [17,18]. Scaffolds (0.5-4 mg dry weight) and heparin standards (0-500 µg) were hydro-
lysed with 500 µl 6 M HCl at 105ºC for 6 h under nitrogen gas in sealed glass tubes. HCl 
and water were removed by drying the hydrolysed samples in a vacuum-desiccator in the 
presence of NaOH pellets. Samples were dissolved in 1.25 ml MilliQ, and to 1 ml sample 1 
ml 4% acetylacetone in 1.25 M Na2CO3 was added and incubated at 95ºC for 1 h to convert 
the glucosamines to pyrroles. Then, 5 ml 95% ethanol was added, followed by 1 ml Ehrlich 
reagent containing 2.66% p-dimethylamino-benzaldehyde in 3 M HCl and 47.5% ethanol to 
condense pyrroles to a coloured product. The absorbance was measured spectrophotometr-
ically at 527 nm. 
Uronic acid assay 
This method is based on the conversion of uronic acids to a coloured product [19]. First, 
scaffolds (0.5-3 mg) were hydrolysed in 1 ml hot 83% H2SO4 containing 120 mM sodium 
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tetraborate in a 48-well plate in a water bath at 80ºC for 45 min. Heparin standards (0-150 
µg) were used as controls. Uronic acids (both iduronic acid and the less frequently present 
glucuronic acid) were transformed to a coloured product by the addition of 200 µl 0.2% m-
hydroxybiphenyl in 78.4% H2SO4 at room temperature for 15 min, and measured at 450 nm.  
Agarose gel electrophoresis  
This method is based on backbone-dependent separation of glycosaminoglycans in an 
agarose gel and subsequent staining with the cationic dye azure A and silver as described 
by Van De Lest et al. [20]. Papain-digested scaffold preparation (see papain digestion sec-
tion) was diluted 5x in MilliQ water and 1 µl was loaded on 1% agarose gels. To enable 
quantification, heparin standards of 5, 10, 20 and 40 ng were included. Electrophoresis was 
performed in 50 mM barium acetate buffer (pH 5.0) at 60 V for 50 min. Gels were subse-
quently fixed and prestained in 0.1% (w/v) azure A in 50 mM sodium formate and 10 mM 
magnesium chloride (pH 3.5). Gels were decolourised with 10 mM sodium acetate buffer 
(pH 5.5, 2x 30 min) and demineralised water (30 min). After air-drying, gels were rehydrated 
in MilliQ water and silver-stained in 15 mM AgNO3, 1.75 mM silicotungstic acid, 75 mM for-
maldehyde in 30 mM NH4NO3 and 0.24 M Na2CO3. Staining reaction was ceased by incu-
bating gels in demineralised water for 2 min, 1% acetic acid for 5 min, and demineralised 
water for 15 min. Gels were air-dried and scanned for analysis. For quantification, the me-
dian of the pixel intensity of each band was determined with an equally-sized selection area 
using Adobe Photoshop (Adobe Systems, CA, USA). Values were corrected for background 
intensity using an adjacent area and staining differences between gels were corrected for 
using a 5 ng heparin standard loaded on each gel. 
Immuno-dot blot  
This method is based on antibody recognition of heparin, bound to a nitrocellulose mem-
brane by virtue of small collagen fragments still attached to the heparin. Of a papain-
digested scaffold preparation (see papain digestion section), 50 µl was transferred to a Hy-
bond-ECL nitrocellulose membrane (Amersham Biosciences) using an Easy-Titer enzyme-
linked immunoflow assay system (ELIFA, Pierce Biotechnology, Rockford, IL, USA). After 30 
min at room temperature, non-specific binding was blocked with 1% bovine serum albumin 
(BSA) in phosphate-buffered saline (PBS, pH 7.2) for 16 h at 4ºC. Membrane-bound colla-
gen peptide-heparin was detected using the phage display-derived VSV-tagged antibody 
HS4C3 (1:50), which recognises heparin [21], followed by mouse anti-VSV tag antibody 
P5D4 (1:10), and a peroxidase conjugated goat anti-mouse IgG antibody (1:20,000, Pierce), 
all in 1% BSA in PBS, followed by the ECL Western Blotting Detection kit (Amersham). 
Scanned images of exposed films were used for determination of the relative pixel intensity. 
Pictures were inverted, and the median of the pixel intensity of equally-sized areas contain-
ing one spot was determined using Adobe Photoshop. Values were corrected for back-
ground intensity using a spot adjacent to the spot of interest and expressed as a percentage 
between background intensity (0%) and complete saturation (100%). 
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Immunofluorescence assay  
This method is based on the antibody recognition of heparin in scaffold sections. Scaf-
folds were carefully wetted in demineralised water, placed in TissueTek (Sakura Finetek, 
Alphen aan den Rijn, The Netherlands) and snap-frozen in liquid nitrogen-cooled isopen-
tane. Cryosections of 5 µm thickness were cut, placed on SuperFrost slides (Menzel-Gläser, 
Braunschweig, Germany), and air-dried for 16 h at room temperature. Non-specific binding 
was blocked using 1% BSA in PBS for 10 min and sections were stained with anti-heparin 
antibody HS4C3-VSV (1:5-50), followed by mouse anti-VSV tag antibody P5D4 (1:10), and 
an Alexa 488-labelled goat anti-mouse IgG antibody (Molecular Probes, Eugene, OR, USA, 
1:100), all in 1% BSA in PBS at room temperature. Staining was evaluated using a Leica 
DM6000 microscope. 
Results 
Porous collagen scaffolds of ~5 mm thickness were prepared in 24-well plates by lyophi-
lisation of a frozen collagen suspension. Scaffolds were chemically crosslinked in a solution 
containing a fixed concentration of EDC/NHS and different amounts of heparin (0-2%), and 
washed extensively. 
The amount of immobilised heparin was initially determined by a factor Xa assay on in-
tact scaffolds (Fig. 2A) and on papain digested scaffolds (Fig. 2B). The shape of both curves 
was comparable and showed an increasing amount of incorporated heparin starting from 
0.4% heparin in the crosslinking solution to a maximum at about 1%. However, a 500-fold 
difference was observed in the absolute values obtained (e.g. 0.022 units in intact scaffolds 
versus 10 units in digested scaffolds). Apparently, not all immobilised heparin can be meas-
ured in intact scaffolds, indicating the need for solubilisation of scaffolds for a reliable mea-
surement.  
This was also seen when scaffolds were assayed using the Farndale reagent. Incubation 
of intact scaffolds in the staining solution did result in metachromasia (i.e. a change from a 
blue into a purple colour, Fig. 3), thereby demonstrating the presence of heparin (the scaf-
folds without heparin are blue), but the intensity of the purple colour did not correspond to 
the amount of heparin immobilized (as assayed by a hexosamine assay, see below). To-
gether with the factor Xa data, this clearly indicates that the amount of heparin cannot be 
assayed correctly when the scaffolds is intact. We did, however, notice that the blue staining 
intensity of the surrounding solution, negatively correlated with the amount of heparin immo-
bilized. Therefore, this approach may be suitable for an indirect semi-quantitative determina-
tion of the amount of scaffold-bound heparin, but the development of standards will be chal-
lenging and we did not pursue this strategy. 
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Figure 2. Analysis of immobilised heparin by the factor Xa assay. Anticoagulant activity and deduced amount of 
immobilised heparin after crosslinking of collagen scaffolds in the presence of 0-2% heparin in the crosslinking solu-
tion, determined for intact (A) and papain digested scaffolds (B), showing the results of a typical experiment in séxtuplo 
(A) and duplo (B) ± S.D.. Heparin activity is given in units on the left y-axis, and the amount of heparin is given in 
micrograms on the right y-axis. Note the ~500-fold difference between the values in (A) and (B). 
 
 
 
Figure 3. Analysis of immobilised heparin by the Farndale assay. Scaffolds containing 0, 38, and 167 µg heparin/mg 
(based on hexosamine assay results, see below) were incubated using the Farndale reagent. Scaffolds containing 
heparin had a different colour than scaffolds without heparin, but no difference was observed between different 
amounts of bound heparin.  
 
Using papain-digested, solubilised, scaffolds, differences in the amount of heparin could 
be determined with the Farndale assay (Fig. 4A). The shape of the curve, however, differed 
from the Xa assay, with an increasing amount of incorporated heparin from 0-0.4% heparin 
in the crosslinking solution, to a decrease with increasing heparin content in the crosslinking 
solution.  
Heparin was also assessed by measuring specific monosaccharides obtained after acid 
solubilisation of the scaffolds. The shape of the curves obtained by a hexosamine and a 
uronic acid assay were generally comparable to that obtained by the Farndale assay, i.e. an 
initial increase of the amount of heparin immobilised, followed by a decrease (Figs. 4B and 
C). However, a difference was observed in absolute numbers (e.g. the peak values, ranging 
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from 60 µg/mg (Farndale, A), 119 µg/mg (hexosamine, B) to 171 µg/mg (uronic acid assay, 
C; see discussion)). In the uronic acid assay, a heparin-dependent brown colour was ob-
served in the samples containing scaffold collagen, but not in the samples containing hepa-
rin only (for the standard curve).  
The hexosamine assay appeared to be the most robust assay for the quantitative deter-
mination of scaffold-bound heparin possibly because, in contrast to the other assays, no 
delicate precipitation steps were required and no collagen interference with the measure-
ments was observed.  
  
 
 
Figure 4. Analysis of immobilised heparin assayed with (A) Farndale assay, (B) hexosamine assay, and (C) uronic 
acid assay. Scaffolds were crosslinked in the presence of 0-2% heparin in the crosslinking solution. Results are given 
as n=3 ± S.E.M., in µg heparin per mg scaffold. 
 
Agarose gel electrophoretic analysis of heparin using papain-digested scaffolds gave va-
riable results in our hands. Staining quality varied and therefore not all gels were suitable for 
quantification. Results (Fig. 5) indicated a trend comparable to the Farndale, hexosamine, 
and uronic acid assay, i.e. an initial increase of heparin immobilised followed by a decrease. 
The peak value observed in the gel presented in Fig. 5 (0.3% heparin in crosslinking solu-
tion) was about 224 µg heparin/mg. Please note that since one gel contained 7-8 slots, two 
gels were required to load all standards and samples once, which may limit accuracy.  
Immuno-dot blot analysis of papain digested samples provided comparable results (Fig. 
6). In line with Kreuger et al. no staining was observed when free heparin was applied to the 
membrane [22]. As a result, no heparin standards could be applied for quantification pur-
poses, but the relative staining intensity peaked at 0.3% heparin in the crosslinking solution.  
 
 
 
Figure 5. Analysis of immobilised heparin by agarose gel electrophoresis. Quantification (µg heparin/mg scaffold) 
based on heparin standards. Please note differences in background staining that may complicate quantification. This 
figure is a composite picture of two gels (gel 1=40 ng heparin-0.2, gel 2=0.3-2). 
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Figure 6. Analysis of immobilised heparin using an immuno-dot blot assay on papain-digested scaffolds, crosslinked 
with 0-2% heparin in the crosslinking solution, after incubation with anti-heparin antibody HS4C3. The relative pixel 
intensity of each spot was measured. No absolute amount of heparin could be calculated, since standards of free 
heparin do not bind to the membrane. 
 
Finally, an immunofluorescence assay (Fig. 7) was applied to obtain additional informa-
tion on the location of the immobilised heparin. Heparin was mainly localised at the scaffold 
surfaces for scaffolds crosslinked in the presence of 0.05% heparin. Scaffolds crosslinked in 
the presence of 0.4% heparin showed a more even distribution, while for scaffolds incubated 
in 1.0% heparin less intense staining was observed (especially at the inner side). These 
scaffolds contained 38, 80, and 58 µg heparin/mg, respectively (as determined with a hex-
osamine assay). Therefore, although semi-quantitative, results indicate the same trends as 
observed in figs. 4-6. 
 
 
Figure 7. Analysis of immobilised heparin by an immunofluorescence assay. Scaffolds crosslinked in the presence of 
0, 0.05, 0.4, and 1.0% heparin were evaluated. The amount of bound heparin as determined with a hexosamine assay 
on individual scaffolds is given in µg/mg scaffold. Crosslinking in the presence of 0.05% heparin resulted in staining 
mainly localised at the scaffold surfaces, whereas crosslinking in the presence of 0.4% heparin resulted in a more even 
distribution of heparin throughout the whole scaffold. Crosslinking in 1.0% heparin showed less intense staining of 
primarily the inner area, indicating the same trend as observed in figs. 4-6. Composite pictures, all taken with identical 
microscope settings. Bar is 500 µm. 
 
Chapter 3 
 
58 
To find an explanation for the shape of the curves seen in the above-mentioned assays 
(Figs. 2 and 4-7) we evaluated the content of free amine groups still present after the cross-
linking process, with respect to the percentage of heparin present in the crosslinking solu-
tion. Non-crosslinked scaffolds contained 270 nmol amine groups per mg, and this was 
reduced to ~150 nmol/mg when crosslinking took place in the presence of 0-0.4% heparin. 
Crosslinking in the presence of higher amounts of heparin resulted in a higher number of 
remaining amine groups, even though the EDC concentration was constant for all crosslink-
ing solutions. This may provide clues for the explanation of the results of the other assays 
(see discussion).  
 
 
Figure 8. Amine group content of the collagen scaffolds after crosslinking in the presence of 0-2% heparin. The amine 
group content of non-crosslinked scaffolds was 270 nmol/mg. Results of a typical experiment in triplo ±S.D.. 
Discussion 
In this study seven assays were evaluated for their suitability to quantify the amount of 
heparin immobilised to insoluble collagenous scaffolds. Both the factor Xa assay and the 
Farndale assay indicated that quantifying heparin when the scaffolds are intact, results to a 
gross underestimation of the amount of heparin present. For the factor Xa assay a ~500-fold 
difference was notices, when intact and papain digested scaffolds were measured, suggest-
ing that in an intact scaffold not all heparin is accessible. Therefore, scaffolds were solubi-
lised either using papain digestion or acid hydrolysis. 
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The hexosamine assay turned out to be the most robust assay and is therefore the pre-
ferred method for the quantification of immobilised heparin. It uses acid hydrolysis to digest 
the scaffold. It has the advantage over the uronic acid assay that it is not associated with an 
additional brown colouring. This additional colouring is not observed when heparin without 
collagen is assayed (e.g. for the standard curve), and may therefore result in an overestima-
tion of the amount of heparin immobilized to a collagen scaffolds (an up to about 50% higher 
value was found using the uronic acid assay). The Farndale assay, which uses papain di-
gestion to solubilise heparin, gave lower values compared to the assays which use acid 
hydrolysis. Papain digestion may result in some (solubilised) heparin which is still attached 
to collagen peptides, which may precipitate in the TCA protein precipitation, thereby leading 
to an underestimation of the amount of heparin (note that the heparin standards are not TCA 
precipitated). It is also possible that small heparin-bound collagen fragments interfered with 
the measurements, since protein (albumin) in a Farndale assay is able to reduce the read-
out with approximately 40% [16]. The inclusion of standards during each step of the assay 
and spiking experiments may elucidate the effect of the different steps. 
The immuno-dot blot method, using an antibody against heparin, gave data which can be 
compared to each other, but does not result in absolute numbers. The reason for this is that 
heparin alone will not bind to a nitrocellulose membrane [22], whereas heparin with some 
residual amino acid residues (as is the case with papain digestion) does. As a consequence, 
no free heparin standards could be loaded for quantification. Agarose gel electrophoresis, 
on the other hand, is not dependent on the presence of peptide residues. It provides infor-
mation on the backbone structure of the glycosaminoglycan under investigation and can be 
used quantitatively. A limiting factor is the relative small number of samples that can be 
assessed on a single gel and this makes high-throughput analysis challenging. Finally, the 
immunofluorescence assay, although at best semi-quantitative, provides information on the 
location of bound heparin. It was observed that at low heparin concentrations, its location 
was primarily at the scaffold surfaces, emphasising the importance of correct sampling. 
An interesting feature of the present study is the observation that, after a binding maxi-
mum, the amount of bound heparin decreased with increasing heparin concentration in the 
crosslinking solution. Wissink et al. showed that heparin binding correlated with the ratio of 
EDC molecules per heparin carboxylic groups (EDC:Hep-COOH) [23]. When the ratio 
EDC:Hep-COOH drops (as is the case when the concentration of heparin increases in the 
presence of a fixed EDC concentration), a point may be reached at which heparin molecules 
may not be sufficiently EDC-activated to bind to collagen. This may explain the observed 
decrease with increasing heparin concentrations and is in line with the observed decrease in 
the amount of amine groups used for cross-linking (and hence the increase in free amine 
groups, see Fig. 8). Results of the factor Xa assay, assessing functional anti-coagulation, 
differed from the other assays. In this assay, the accessibility of heparin for the protein anti-
thrombin III (and possibly factor Xa) is of crucial importance, and the way and the extent by 
which heparin is bound to collagen are likely important factors. It has been suggested that 
an increased number of covalent bonds between heparin and collagen may result in a de-
creased accessibility of heparin for the antithrombin III binding site and/or decreased throm-
Chapter 3 
 
60 
bin binding [23]. The conditions in our study at low EDC:Hep-COOH ratio‟s (obtained at 1-
2% heparin in the crosslinking solution) may have resulted in less binding of absolute num-
bers of heparin molecules, but an optimal accessibility of those heparin molecules that did 
bind, due to the limited number of covalent bonds between collagen and heparin. Maximal 
exposure of the heparin molecules to antithrombin III may have increased the functional 
anti-coagulation.  
The precise conditions used during the crosslinking are likely critical for the amount and 
mode of binding. For instance, Pieper et al. (2000) crosslinked in the presence of 2.75% 
heparin and reported 129 µg bound heparin/mg scaffold using a hexosamine assay, much 
higher than expected from our study [9]. They also crosslinked with 33 mM EDC, but used 4 
mg scaffold collagen per ml crosslinking solution instead of 8 mg, and 20 mM NHS (which 
forms a stable intermediate during crosslinking) instead of 6 mM, which may explain the 
observed differences.  
Heparin shares many characteristics with other glycosaminoglycans and the methods 
described here are therefore broadly applicable. For immuno-dot blot and immunofluores-
cence analysis, additional antibodies are available that recognise specific sugar modifica-
tions present in different glycosaminoglycans [24]. All methods may be applicable to a broad 
range of biomaterials that can be digested by proteases (like fibrin), hydrolysed (like polylac-
tic acid and polycaprolactone), and/or freeze-sectioned. 
Conclusion 
From seven methods evaluated, the hexosamine assay is the preferred method for the 
determination of the absolute amount of heparin bound to a scaffold. This robust method 
may also be applied for other acid-hydrolysable biomaterials. 
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Abstract 
Large-scale in vivo evaluation of biomaterials is time-consuming and limited by ethical 
considerations. The availability of a library of biomaterials would allow a fast and rational in 
vitro selection of those biomaterials to be evaluated in vivo. For this reason, we developed 
an array of 48 different, molecularly-defined films based on native fibrillar collagen. The films 
differed in the type and amount of extracellular matrix components (type I/IV collagens, 
fibrous/solubilised elastin, glycosaminoglycans (heparin, chondroitin sulfate or dermatan 
sulfate), method of preparation (homogenisation) and method and extent of crosslinking 
(carbodiimide (EDC/NHS) or glutaraldehyde). The array was evaluated by studying mor-
phology, proliferation and differentiation of primary human keratinocytes/fibroblasts. Major 
differences were observed. Only a small selection of films (especially those containing 
elastin fibres) specifically stimulated the proliferation of keratinocytes, but not fibroblasts. 
Such films may be the biomaterials of choice for in vivo evaluation for skin tissue engineer-
ing and regenerative medicine. 
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Introduction 
Biomaterials are generally constructed using a basic component such as collagen or 
synthetic polymers, which can be further functionalised by inclusion of other components. A 
large variety of different biomaterials can thus be produced. In addition, other parameters 
like production conditions and physical/chemical treatment can be varied, resulting in an 
even larger multiplicity of biomaterials. In vivo evaluation of the functionality of these bioma-
terial variables in animal studies would be expensive, time consuming and ethically chal-
lenging. The availability of a large array of biomaterials, each differing from one another in 
only one specific aspect, would enable an economical and fast in vitro pre-screening, allow-
ing a rational selection of potentially useful biomaterials for in vivo evaluation.  
For synthetic polymers, such arrays have been developed [1-6]. The most advanced ar-
rays are based on one basic surface with (chemically) modified spots and 2D gradients of a 
specific modification. However, arrays based on natural proteins require a specific approach 
due to the delicate nature of biomolecules. For that reason, only a few arrays have been 
developed that include natural extracellular matrix proteins, but the molecular composition of 
the basic extracellular matrix components used in these arrays has not been reported [7-10]. 
Therefore, there is a need for well-defined arrays based on natural extracellular matrix pro-
teins. In this study an array of different molecularly-defined collagen-based biomaterials was 
constructed, and evaluated for their potential in skin tissue engineering.  
Type I collagen is the most abundant extracellular matrix protein in the human body. Na-
tive, fibrillar type I collagen is therefore often used as scaffolding material for regenerative 
medicine. Collagen biomaterials possess many characteristics that can be modified [11], 
including the 3D-architecture (e.g. porous scaffold or dense film [12,13]), the type and de-
gree of crosslinking [14], the presence of other basic components (e.g. elastin [15]), and the 
incorporation of additives such as glycosaminoglycans [16,17] or growth factors [18,19].  
Each single modification of a biomaterial may result in a different response in vitro and/or 
in vivo. A number of studies have addressed this issue. For example, a decrease in pore 
size of a collagen-chondroitin sulfate scaffold resulted in an increase in the viability of mouse 
clonal osteogenic cells in vitro [20]. Addition of matrix proteins to basal lamina analogues 
enhanced attachment of keratinocytes in vitro [7]. Mild crosslinking with a carbodiimide re-
sulted in an optimal balance between scaffold strength and proliferation of a keratino-
cyte/fibroblast co-culture [21]. Chemical crosslinking also promoted scaffold integrity and 
reduced antigenicity in vivo, and the incorporation of heparan sulfate promoted angiogenesis 
[22]. Addition of FGF-2 or VEGF to scaffolds increased their angiogenic potential [18,23,24]. 
However, large-scale bioarrays based on collagenous biomaterials and simultaneously ad-
dressing various parameters including basic components, physical pre-treatment, type and 
amount of additives, and nature of crosslinking have not been reported. 
In this study, 48 defined collagen-based biomaterials were constructed, characterised 
and evaluated in vitro using primary human keratinocytes/fibroblasts. 
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Materials and Methods 
Purification of fibrillar collagen, elastin fibres and soluble elastin 
Insoluble type I collagen (COL) was purified from bovine achilles tendon using extrac-
tions with diluted acetic acid, aqueous NaCl and urea, and acetone as described [17]. In-
soluble elastin fibres (ELfibre) were purified from equine ligamentum nuchae using extractions 
with aqueous NaCl, organic solvents, 8% CNBr in formic acid, aqueous urea with 2-
mercaptoethanol, and a trypsin digestion [25]. Solubilised elastin (ELsol) was prepared from 
insoluble elastin fibres by oxalic acid hydrolysis [26,27]. 
Preparation of 48 different molecularly-defined, fibrillar collagen-based films 
For an overview of all films prepared, see Table 1. Films were prepared composed of 
collagen only (COL), collagen + insoluble elastin fibres in an 80:20 ratio (COL80:20EL fibre), 
and collagen with solubilised elastin in an 80:20 ratio (COL80:20ELsol). A suspension of 
0.8% (w/v) collagen for COL, 0.64% (w/v) collagen + 0.16% (w/v) elastin for COL80:20EL fibre 
and 0.64% (w/v) collagen for COL80:20ELsol was shaken overnight in 0.25 M acetic acid at 
4ºC. For COL-ELsol, 0.16% (w/v) elastin peptides was added after this incubation. The sus-
pensions were homogenised on ice using a Potter-Elvehjem homogeniser (Louwers Glass 
and Ceramic Technologies, Hapert, The Netherlands) with an intervening space of 0.35 mm, 
until homogenisation was completed. Air-bubbles were removed from the COL and COL- 
ELsol suspensions by centrifugation at 250 g for 10 min at 4ºC, and from the COL-ELfibre 
solution by incubation in a desiccator. Twelve ml of the suspensions were poured into a petri 
dish (Ø 86 mm) and air-dried at room temperature. 
 
Table 1. Overview of films prepared. 
Basic film 
Treatment 
nX PT nX EDClow EDChigh PT EDChigh GAlow GAmedium GAhigh CSlow CShigh DSlow DShigh Hlow Hhigh 
COL               
COL80:20ELfibre               
COL80:20ELsol               
COL50:50ELfibre               
COL20:80ELfibre               
COL50:50ELsol               
COL COLIV               
 
COL=type I collagen, ELfibre=elastin fibres, ELsol=solubilised elastin, COLIV=type IV collagen, nX=non-
crosslinked,EDC=EDC/NHS crosslinked, PT=Polytron homogenised (all other scaffolds were homogenised by Potter-
Elvehjem), GA=Glutaraldehyde crosslinked, CS=chondroitin sulfate, DS=dermatan sulfate, H=heparin, 
EDC/GAlow/medium/high=crosslinked with a low, medium or high concentration of EDC/NHS or glutaraldehyde, 
CS/DS/Hlow/high=crosslinked in the presence of a low or high amount of chondroitin sulfate, dermatan sulfate or heparin. 
For further explanation see text. 
 
The same methodology was used to produce COL50:50ELfibre, COL20:80ELfibre, and 
COL50:50ELsol films. COL20:80ELsol films were also produced, but too weak to handle and 
therefore not included in this study.  
To study the effect of different homogenisation procedures, additional COL, 
COL80:20ELfibre and COL80:20ELsol films were prepared by use of a Polytron device (PT) 
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(Kinematica, Luzern, Switzerland) at 2,500 rpm on ice until homogenisation was completed, 
rather than Potter-Elvehjem homogenisation. 
To study the effect of crosslinking, films were chemically crosslinked for 4 h with 12.5 
(EDClow) or 33 (EDChigh) mM 1-ethyl-3-(3-dimethyl aminopropyl)carbodiimide (EDC) and 6 
mM N-hydroxysuccinimide (NHS) in 50 mM 2-morpholinoethane sulphonic acid (MES, pH 
5.0) containing 40% ethanol. This was followed by washings with 0.1 M Na2HPO4, 1 M NaCl, 
2 M NaCl and demineralised water [28]. Alternatively, films were crosslinked in 0.025 (GA-
low), 0.1 (GAmedium) or 0.5% (GAhigh) (v/v) glutaraldehyde in 0.1 M Na-phosphate buffer (PB, 
pH 7.4) for 1 h at room temperature. Free aldehydes were subsequently quenched for 1 h at 
room temperature with respectively 2.5, 10 and 50 mM of glycine in 0.1 M PB. 
To study the effect of various glycosaminoglycans, these were covalently coupled by 
crosslinking films using a EDChigh EDC/NHS solution (see above) containing: 0.075 (Hlow) or 
0.375% (Hhigh) (w/v) heparin (Diosynth, Oss, The Netherlands), 0.05 (CSlow) or 0.25% 
(CShigh) (w/v) chondroitin sulfate (Sigma-Aldrich, St. Louis, MO, USA), and 0.05 (DSlow) or 
0.25% (DShigh) dermatan sulfate (Sigma-Aldrich). 
To study the effect of an additional type of collagen, a suspension containing 20 μg/ml 
type IV collagen (Fluka BioChemika, Switzerland) in 0.25 M acetic acid was applied to the 
non-crosslinked COL films and air-dried, resulting in a coating of 10 μg type IV collagen/cm
2
 
film (COL COLIV). 
Characterisation of the fibrillar collagen-based films 
The degree of crosslinking of the films was estimated spectrophotometrically by deter-
mining the amine group content using 2,4,6-trinitrobenzene sulfonic acid [29,30].  
The glycosaminoglycan content of the films was determined applying a hexosamine as-
say using p-dimethylamino-benzaldehyde, taking heparin as a standard [31,32]. 
Type IV collagen was visualised by immunofluorescence on cryosections using a goat 
anti-human type IV collagen antibody (1:200, Southern Biotech, USA) and donkey anti-goat 
Alexa Fluor 488 secondary antibody (1:200, Molecular Probes, Eugene, OR, USA).  
 For scanning electron microscopy, films were mounted on stubs, sputtered with an 
ultrathin layer of gold in a Polaron E5100 coating system and visualised with a JEOL JSM-
6310 scanning electron microscope (Tokyo, Japan) operating at 15 kV. To visualise the 
banding pattern of the collagen fibrils, films were mounted on stubs, sputtered with an ultra-
thin layer of gold/palladium in a Cressington 208HR coating system (Redding, CA, USA) and 
visualised with a JEOL JSM-6300 scanning electron microscope operating at 3 kV. 
Cell source and submerged cell culture 
Keratinocytes with some residual fibroblasts were obtained from human abdominal skin 
derived from donors who underwent surgery for abdominal wall correction, as described 
[33]. 
To culture cells, Ø 20 mm punches of films were taken and placed in Ø 10 mm Cell-
Crown24 inserts (ScaffDex, Tampere, Finland), disinfected with 70% ethanol (3x1h and 
once o/n), washed with sterile phosphate-buffered saline (pH 7.2, 5x1h and once o/n), 
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placed on the bottom of a 6-wells plate (Greiner Bio-One) and pre-incubated for 16 h in 
medium containing 5% calf serum (Hyclone), consisting of 2 parts DMEM (Gibco) and 1 part 
Ham‟s F12 medium (Gibco), L-glutamine (4 mM; Gibco), penicillin/streptomycin (50 IU/ml; 
Gibco), adenine (24.3 μg/ml; Calbiochem), ascorbic acid (50 μg/ml; Sigma), insulin (0.2 μM; 
Sigma), hydrocortisone (1 μM; Merck), triiodothyronine (1.36 ng/ml; Sigma) and cholera 
toxin (10
-10
 M; Sigma) at 37ºC. Cells were seeded at a density of 75,000 cells/insert and 
incubated in 2 ml medium per well at 37ºC under 8% CO2. At day three of the culture, me-
dium was refreshed. Cells were cultured on the films for six days. 
Cell proliferation assay 
Medium was replaced with 1.5 ml medium containing 10% water-soluble tetrazolium salt-
1 cell proliferation reagent (WST-1, Roche, Basel, Switzerland) and cells were incubated for 
1 h at 37ºC. Then, 100 μl of the supernatant was transferred to an empty plate and the ab-
sorbance was measured at 450 nm. The absorbance of the supernatant taken from cells 
grown on Thermanox coverslips was set at 1 and used to calculate the relative absorbance. 
Morphological evaluation 
Films were rinsed with 0.1 M PB (pH 7.4) and fixed with 4% paraformaldehyde in 0.1 M 
PB for 30 min at room temperature, washed with 0.1 M PB and divided into parts.  
Cells were visualised by standard haematoxylin-eosin (H&E) staining. For scanning elec-
tron microscopy, films were critical point dried using CO2 with a Polaron E3000 critical point 
drying apparatus (Watford, UK) and processed and visualised with a JEOL JSM-6310 as 
described above. 
Immunofluorescence was performed using antibodies against cytokeratins (rabbit poly-
clonal pKer, 1:200; Euro Diagnostics, and mouse anti-pancytokeratin clones AE1/AE3, 
1:100; Dako, Glostrup, Denmark), and vimentin (1:200, Sigma). Respectively, goat anti-
rabbit Alexa Fluor 594, goat anti-mouse Alexa Fluor 594 and goat anti-mouse Alexa Fluor 
488 (1:200, Molecular Probes) were used as a secondary antibody. Nuclei were visualised 
with DAPI (1:1000, Molecular Probes).  
To calculate the film area occupied by keratinocytes, at least 2 pictures per film (stained 
for cytokeratins) were taken with a Leica DM6000 microscope (Solms, Germany) at 50x 
magnification. The surface area of fluorescently labelled cells was calculated as a percent-
age of the total film surface area on the pictures using ImagePro software (Media Cybernet-
ics Inc., Bethesda, MD, USA). 
Results 
Characterisation of the array films 
Collagen-based films were prepared without elastin (COL) and with different ratios of 
elastin fibres (COL80:20ELfibre, COL50:50ELfibre, and COL20:80ELfibre) or solubilised elastin 
(COL80:20ELsol and COL50:50ELsol). The incorporation of an increasing amount of elastin 
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fibres resulted in brittle films, which, when wetted, were relatively weak and difficult to han-
dle. The incorporation of solubilised elastin resulted in opaque and weak films (in a dry as 
well as in a wet state) and COL20:80ELsol films were too weak to handle and therefore dis-
carded from this array. SEM analysis of films showed the characteristic banding pattern of 
the individual collagen fibrils, indicating that the spatial orientation of the collagen molecules 
was preserved after the purification and production process (fig. 1A). All films had a closed 
surface and were approximately 10 μm thick (fig. 1A and D). 
 
 
 
Figure 1. Morphological characteristics of the films used. A: scanning electron micrograph (SEM) of the top surface of 
a non-crosslinked collagen film (COL nX) illustrating the intact banding pattern of the collagen fibrils, and the closed 
surface of the films. B, C: SEM of the top surface of a Potter-Elvehjem (B, COL80:20ELfibre nX) and Polytron-
homogenised (C, COL80:20ELfibre PT nX) elastin fibre containing film visualising the embedded elastin fibres (note 
the difference in fibre dispersion). D: SEM of a cross-section of a non-crosslinked collagen film (COL nX) indicating its 
thickness. E: immunofluoresent-phase contrast image of a composite type I/type IV collagen film (COL COLIV) with 
type IV collagen (green) on top. F: a transparent film (arrow) in a CellCrown insert. Scale bars are 1 μm (A), 100 μm 
(B, C and E), 10 μm (D), and 1 mm (F). For other abbreviations, see Table 1. 
 
To obtain films with variable degrees and nature of crosslinking, crosslinking was per-
formed with different concentrations of EDC/NHS (EDC) and glutaraldehyde (GA). These 
differences in crosslinking procedure resulted in clear differences in the amount of free 
amine groups, an indication of the degree of crosslinking (Table 2A). Glutaraldehyde 
crosslinking resulted in a larger reduction of amine groups compared to EDC-crosslinking, 
and even the lowest concentration of glutaraldehyde used (0.025% ≈ 2.5 mM) resulted in 
fewer remaining amine groups compared to the highest concentration of EDC used (33 mM) 
(compare EDChigh and GAlow in Table 2A). Glutaraldehyde crosslinked films were more brittle 
(in a dry state) and had a brownish appearance compared to the EDC-crosslinked films. 
Films with elastin fibres possessed less amine groups than films of collagen only, because 
elastin fibres contain fewer amine groups [15].  
 
Chapter 4 
 
70 
Table 2. Amount of amine groups (A) and glycosaminoglycans (B) in the biomaterial array. 
 
 
Relative amount of amine groups as percentage of COL nX (A) and amount of incorporated glycosaminoglycans as 
μg/mg film (B). Results are given as n=3 ± S.E.M. See Table 1 for abbreviations. 
 
To obtain films prepared by different homogenisation methods, Potter-Elvehjem and 
Polytron homogenisation were compared. Polytron homogenisation resulted in films which 
were more difficult to hydrate in water and were more transparent when wetted. SEM analy-
sis indicated that elastin fibres were more fragmented and more equally dispersed in the 
Polytron homogenised films compared to films derived from a pottered suspension (compare 
figs. 1B and 1C). In addition, the degree of crosslinking was increased in films prepared by 
Polytron homogenisation (compare EDChigh and PT EDChigh in Table 2A). This is likely due to 
increase in fibre surface. 
To obtain films with different amounts and types of glycosaminoglycans, films were EDC-
crosslinked in the presence of different amounts of heparin, chondroitin sulfate and derma-
tan sulfate. Table 2B shows that it was possible to bind low and high amounts of these three 
glycosaminoglycans to collagen-based films. It was possible to incorporate up to 140 μg 
heparin per mg film, whereas the maximum amount of bound CS and DS was lower, about 
110 μg/mg and 80 μg/mg respectively. The maximum binding capacity for CS and DS was 
lower for the COL films than for the COL80:20ELfibre and COL80:20ELsol films. The degree of 
crosslinking of all glycosaminoglycan-containing films was comparable (57±6% (42-67%) 
reduction of amine groups).   
To obtain a composite, layered film with two types of collagens, type IV collagen was 
coated on top of the fibrillar type I collagen film. Such a construct resembles the extracellular 
matrix of skin which consists of (dermal) type I collagen fibrils and (epidermal) basement 
membrane associated type IV collagen. Type IV collagen coating resulted in a highly con-
fined layer on top of the type I collagen film (fig. 1E). Addition of type IV collagen did not 
significantly alter the amount of amine groups. 
Cell proliferation 
Films were placed in CellCrown inserts (fig. 1F) and primary human keratinocytes, con-
taining a small number of residual fibroblasts, were seeded on top of 48 different films. After 
six days of culture, cell proliferation was measured with a WST-1 assay (Table 3).  
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Table 3. Cell proliferation on the biomaterial array. 
 
 
 
Cell proliferation relative to cells cultured on plastic, which was taken as 1.0. Results are given as n=3, ± S.E.M. See 
Table 1 for abbreviations. 
 
Most films promoted cell proliferation compared to cells cultured on cell culture plastic. In 
general EDC crosslinking did not alter cell proliferation compared to non-crosslinked films. 
Amongst the most proliferation promoting films were the COL80:20ELfibre and COL80:20ELsol 
films both crosslinked with a low amount of EDC. Glutaraldehyde crosslinking resulted in a 
large reduction in cell proliferation, with low proliferation on the films crosslinked in a low 
concentration of glutaraldehyde and almost no proliferation on the films crosslinked in me-
dium or high concentrations of glutaraldehyde. Addition of glycosaminoglycans resulted in 
lower cell proliferation than their counterparts without glycosaminoglycans, i.e. the basic 
EDChigh films. The presence of a low amount of heparin resulted in a minor reduction in cell 
proliferation, but films with a high amount of incorporated heparin showed a larger reduction. 
A comparable negative effect on cell proliferation was observed for chondroitin sulfate, but 
without a clear dose-response relationship. Of the three glycosaminoglycans evaluated, the 
incorporation of dermatan sulfate resulted in the largest reduction in cell proliferation. This 
negative effect appeared to be less dramatic for the films with 20% solubilised elastin, but 
there was a large variation between individual experiments. Interestingly, the film which 
promoted cell proliferation to the largest extent (about 11-fold) was the type IV collagen 
coated film. 
Cell morphology 
Films with cultured cells were processed for SEM analysis. The observed cell numbers 
correlated with the values found in the cell proliferation assay. An example of a film with 
hardly any cells (COL GAlow), an intermediate number of cells (COL CShigh), and two films 
with a high number of cells (COL nX and COL50:50ELfibre nX), is shown in Figure 2. 
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Figure 2. Scanning electron micrographs of the cells cultured on various films. A: a glutaraldehyde-fixed collagen film 
(COL GAlow) representing a film with a very low proliferative index (see Table 3). B: an EDC/NHS-fixed collagen film 
containing chondroitin sulfate (COL CShigh) representing a film with intermediate proliferative index. C, D: a non-
crosslinked collagen film (COL nX; C) and a non-crosslinked collagen/elastin fibre film (COL50:50ELfibre nX, D), repre-
senting films with a high proliferative index. Arrows indicate single rounded cells and cell clumps; asterisks indicate 
spindle-shaped fibroblast-like cells; arrowheads indicate keratinocyte colonies. Scale bars are 100 μm. For other 
abbreviations, see text/Table 1. 
 
 
 
On the glutaraldehyde crosslinked films and the DS containing films, only some single 
round-shaped cells were visible (fig. 2A). The heparin and CS containing films showed inter-
connected fields of spindle-shaped cells (fig. 2B). All the other films had an almost confluent 
layer of spindle-shaped cells, containing islets of cobblestone-shaped flattened cells (fig. 2C 
and 2D). These islets represent keratinocyte colonies (see section 3.4), where the spindle-
shaped cells are fibroblasts, derived from a subpopulation that was present in the isolated 
primary cells. Large differences in the size of the keratinocyte colonies were observed be-
tween films with comparable cell proliferation values, as illustrated in fig. 2C and 2D. 
H&E staining of these films confirmed these findings, but observation of the cell mor-
phology was hampered by staining of the underlying collagen (data not shown). 
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Immunostaining for cytokeratins and vimentin 
To distinguish between keratinocytes and fibroblast-like cells, films were immunostained 
for cytokeratins („keratinocytes‟) and vimentin („fibroblasts‟). Nuclei were visualised with 
DAPI.  
 
 
 
Figure 3. Immunocytochemistry of keratinocytes/fibroblasts cultured on various films. A-C: Cells cultured on an 
EDC/NHS-fixed collagen film (COL Xhigh) simultaneously visualised for nuclei (A, DAPI staining), for keratinocytes (B, 
pancytokeratin), and for fibroblasts (C, vimentin). Note the nuclei-dense keratinocyte fields. The yellow autofluoresence 
is derived from the keratinocytes (asterisks). D-F: Cells cultured on three different films (D, COL80:20ELfibre GAlow; E, 
COL80:20ELfibre nX; F, COL80:20ELfibre PT nX) and stained for keratinocytes. Indicated is the percentage of coverage 
of the surface by immunopositive cells. Scale bars are 100 μm. 
 
The large islets showed pancytokeratin-positive staining, indicating that these are indeed 
keratinocyte colonies (fig. 3B). Some other large, rounded cells also showed pancytokeratin-
positive staining (fig. 3B). The remaining spindle-shaped cells all stained positive for 
vimentin (fig. 3C), but negative for cytokeratins. 
To analyse the potential of the different films to specifically stimulate keratinocyte (and 
not fibroblast) proliferation, the surface percentage of pancytokeratin positive cells (cover-
age) was calculated (Table 4, figs. 3D-F).  
 
When the cell proliferation index, reflecting proliferation of both keratinocytes and fibro-
blasts (Table 3) was compared to the film surface covered with keratinocytes (Table 4), it 
was noted that not all films with a high index contained many keratinocytes. This suggests 
that specific films differentially support either proliferation of keratinocyte or fibroblasts. Of 
the three films with the highest cell proliferation index (COL80:20ELfibre EDClow,  
COL80:20ELsol EDClow, and COL COLIV nX), only the film with elastin fibres was covered 
with a large area of keratinocytes (36%), whereas the other two films apparently did not 
specifically stimulate keratinocyte proliferation (18 and 19%, respectively).  
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Table 4. Surface area of the biomaterial array films covered with keratinocytes (pancy-
tokeratin-positive cells)..  
 
 
Film surface area covered with pancytokeratin positive cells as a percentage of the total film surface area. Results are 
given as n=3 ± S.E.M. See Table 1 for abbreviations. 
   
A large surface area covered with keratinocytes was also found for all non-crosslinked 
films containing elastin fibres and the EDC-crosslinked films with 50 or 80% elastin fibres, 
with a remarkable high value for the Polytron-homogenised non-crosslinked variant (52%). 
These results suggest that elastin fibres specifically stimulate keratinocyte proliferation, 
especially when these fibres are more fragmented and equally dispersed as in the Polytron-
homogenised film. A negative effect of EDC-crosslinking on keratinocyte proliferation was 
observed for the COL and COL80:20ELfibre films. For the COL80:20ELsol films this effect was 
less clear, possibly due to wash-out of solubilised elastin from the non-crosslinked films. All 
the glutaraldehyde-crosslinked and glycosaminoglycan-containing films possessed a rela-
tively small surface area covered with keratinocytes, corresponding with the observed low 
cell proliferation values. Only the size of the keratinocyte covered area on the Hhigh films was 
remarkably larger than what could be expected from their proliferation value. This suggests 
that, although the high amount of incorporated heparin had a negative effect on overall cell 
proliferation, it stimulated the proliferation of keratinocytes. 
Discussion 
The goal of this study was to construct an array of molecularly-defined biomaterials 
based on native fibrillar type I collagen to enable the fast in vitro pre-screening of these 
materials for any desired application. Collagen films consisting of different basic components 
were produced and it was possible to control the amount of amine groups present by 
crosslinking the films with different concentrations of EDC/NHS or glutaraldehyde. The latter 
resulted in less remaining amine groups because glutaraldehyde can react with virtually any 
primary amine group of the collagen molecule [34], whereas EDC-crosslinking needs an 
amine group in close proximity to a carboxylic group [35]. It was also possible to bind differ-
ent glycosaminoglycans in different amounts with EDC/NHS crosslinking by adjusting the 
glycosaminoglycan-concentration in the crosslinking solution. In total, a set of 48 different 
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molecularly-defined films was produced and characterised. The array can be easily ex-
tended by the introduction of growth factors and other effector molecules. 
Biomaterial arrays have been developed for the screening of synthetic polymers [1,4-6]. 
Arrays that include natural proteins have also been described, generally based on soluble, 
rather than insoluble extracellular matrix proteins. For example, the effect of combinations of 
(soluble) collagens type I, III and IV, laminin and fibronectin has been evaluated on rat hepa-
tocytes/mouse embryonic stem cells, the latter also in combination with growth factors, and 
another study evaluated three cell lines on different (solubilised) extracellular matrix proteins 
[8-10]. In the human body, however, extracellular matrix proteins like collagen and elastin 
are arranged in an insoluble, fibrillar and crosslinked configuration. Membranes containing 
insoluble collagen have been evaluated in e.g. cytotoxicity or cell-material interaction stud-
ies, but these were performed on a much smaller scale (max. 5 different membranes) than 
the array described in this paper [36-39]. Bush et al. evaluated keratinocyte attachment on 
an insoluble type I collagen-chondroitin sulfate membrane, coated with four different concen-
trations of soluble type I and IV collagen, laminin and fibronectin [7]. It is, however, not cer-
tain whether the type I collagen in the membrane represents its natural extracellular matrix 
form, because it was dehydrothermally crosslinked (105°C in a vacuum for 24 h). The array 
presented in this report is based on highly-purified and thoroughly characterised native fibril-
lar type I collagen and elastin [17,25]. It is also unique in the combination of the different 
basic proteins used and the types of modification applied, and the detailed characterisation 
of the films. The molecularly-defined character of the array allows a systematic analysis of 
parameters involved in specific cellular behaviour. 
We used cultures of primary keratinocytes to evaluate the biological effects of different 
array parameters. Keratinocyte cultures were obtained by the Rheinwald-Green method and 
usually contain a small amount of fibroblasts. In previous studies from our lab we have used 
these cells in model systems and culture media that are selective for keratinocytes, and 
outgrowth of fibroblasts was not observed when cultured on plastic or in 3-D reconstructed 
skin [33,40]. Here, these cells were seeded on the films and cultured in DMEM/F12 with 5% 
foetal calf serum which is not selective for keratinocytes and allows fibroblast outgrowth. 
This enables the evaluation of proliferation of two relevant skin cell populations simultane-
ously, and indeed significant differences were observed between the behaviour of keratino-
cytes and fibroblasts, depending on the composition of the film. On most of the films (38/48), 
cell proliferation was higher than on standard cell culture plastic. Two crosslinking agents 
were compared and it was noticed that EDC was superior to glutaraldehyde. This is in line 
with literature data which indicate that glutaraldehyde has a detrimental effect on cell prolif-
eration [41,42]. The proliferation of specifically keratinocytes (and not fibroblasts) was stimu-
lated to the largest extent by the presence of elastic fibres, especially when these fibres 
were equally dispersed throughout the film. The mechanisms behind this stimulation remain 
elusive, but it is known that the dermal-epidermal junction contains thin embranchments of 
the dermal elastin fibre network and cultured human keratinocytes express tropoelastin 
[43,44]. 
Chapter 4 
 
76 
Debate exists in the tissue engineering/regenerative medicine community as to what ex-
tent in vitro experiments are able to predict in vivo results [45-47]. Although efforts are made 
to standardise in vitro evaluation procedures, results are dependent on e.g. the culture con-
ditions used. In addition, in vivo other types of cells (e.g. immune cells) will be present, in-
creasing the level of complexity. Based on the in vitro evaluation of keratinocytes on the 
array, and taking best proliferation and highest area coverage as the parameters, the most 
optimal film would be a Polytron-homogenised type I collagen film containing 20% elastin 
fibres and without additional modifications like crosslinking or the incorporation of glycosa-
minoglycans. However, when crosslinking would be necessary, e.g. in order to strengthen a 
tissue-engineered construct, mild EDC/NHS crosslinking is the preferred method, and glu-
taraldehyde crosslinking has to be avoided. When glycosaminoglycans have to be incorpo-
rated, e.g. to enhance the binding of growth factors, a high heparin content is the best op-
tion.  
For future applications, other cell type(s) of interest may be evaluated with this array, or 
the array itself might be extended by the incorporation of additional modifications. It would, 
for example, be interesting to study the effect of growth factors combined with different gly-
cosaminoglycans. Also the combination of elastin fibres with type IV collagen coating would 
be worthwhile to investigate, as would be a Polytron homogenised film containing more than 
20% elastin fibres. 
Conclusion 
We developed an extracellular matrix array, consisting of 48 different, fully characterised 
films based on native fibrillar collagen and differing from each other in amount and type of 
matrix components, method of preparation, and amount and extent of crosslinking. The 
array was evaluated using cultured primary human keratinocytes/fibroblasts, and film-
specific differences in morphology, proliferation and differentiation were observed. Only a 
small selection of films (especially those containing elastin fibres) particularly stimulated the 
proliferation of keratinocytes without promoting fibroblast growth. Such films may be the 
biomaterials of choice for in vivo evaluation for skin tissue engineering and regenerative 
medicine. The array described may be generally applicable and instrumental for selection of 
the appropriate set of matrix molecules for use as biomaterials for regenerative medicine. 
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Abstract 
Large-scale production of recombinant rat vascular endothelial growth factor (rrVEGF-
164) is desirable for angiogenic studies. In this study, biologically active recombinant rat 
vascular endothelial growth factor (rrVEGF-164) was cloned and expressed in the yeast P. 
pastoris, and large-scale production was performed by fer-mentation. cDNA encoding 
VEGF-164 was prepared from embryonic rat tissue RNA, and a recombinant 
pPIC9HV/rVEGF-164 plasmid, containing an AOX1 promoter, was constructed. The methy-
lotrophic P. pastoris was used as the eukaryotic expression system. After transformation, 
rrVEGF-164 was produced by fermentation (~124 mg/L) and purified by heparin affinity 
chromatography. SDS-PAGE indicated that rrVEGF-164 was produced as a disulphide-
bridged dimer of 48 kDa which was purified to near homogeneity by heparin affinity chroma-
tography in a large quantity. A bioassay indicated a three to five-fold increase in endothelial 
cell proliferation after 3 days, due to the addition of the produced rrVEGF-164. The produced 
rrVEGF-164 showed a higher biological activity than a commercially available, mouse cell 
line-based, growth factor. In conclusion, using the P. Pastoris expression system we were 
able to produce biologically active rat VEGF-164 in high quantities and this may provide a 
powerful tool for basic and applied life sciences. 
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Introduction 
Vascular endothelial growth factor (VEGF) is one of the most celebrated mediators in the 
process of angiogenesis. VEGF is a hypoxia-inducible protein that promotes the proliferation 
and survival of vascular endothelial cells [1]). At least five different rat VEGF alternatively 
spliced isoforms have been identified originating from a single VEGF pre-mRNA: VEGF-120, 
-144, -164, -188 and -205 [2-4]). These isoforms resemble the human VEGF isoforms 
(VEGF-121, -145, -165, -189 and -206) and differ in length from them by one amino acid. 
VEGF is only active in its dimeric form [5,6]). All rat VEGF isoforms are mitogenic to vascu-
lar endothelial cells and induce permeabilisation of blood vessels [7]). VEGF-164, VEGF-
188 and VEGF-205 are able to bind heparin [7-9]). VEGF-164 binds to the VEGF receptor 
(VEGFR) present on endothelial cells, stimulating the production of matrix metallopro-
teinases (MMPs). MMPs degrade the basement membrane, allowing proliferation and mi-
gration of endothelial cells towards the interstitium, so-called sprouting. Subsequently, peri-
cytes proliferate and migrate towards the newly formed sprouts and induce maturation by 
forming a layer around the sprout [10,11]). 
Large-scale production and purification of rat VEGF-164 is desirable for angiogenic stud-
ies in vitro and in vivo, especially in rat animal models for tissue engineering in which en-
hanced angiogenesis is an issue. Since the source of natural (rat) growth factors is limited, 
attempts have been made to produce growth factors on a large-scale by recombinant DNA 
technology. Growth factors have been produced in Escherichia coli and have played an 
important role in basic research of rat angiogenesis [12,13]). E. coli is a prokaryote and its 
intrinsic characteristics such as protein processing, protein folding, and post translational 
modi-fications, differ from those of eukaryotes. In E. coli, dimeric growth factors such as 
VEGF are produced as a monomer and need to be dimerised after production. The Pichia 
pastoris yeast expression system allows correct folding of dimeric proteins in addition to 
efficient expression, intact secretion, large-scale production, and stable genetics [14,15]). 
Human VEGF has been efficiently expressed in P. pastoris [16]. Expression of biologically 
active rat VEGF in P. pastoris, however, has -to our knowledge- never been published. 
In this study, rrVEGF-164 was inserted into the pPIC9HV expression vector and trans-
fected into the P. pastoris yeast cells. RrVEGF-164 was secreted in large quantities, purified 
using heparin affinity chromatography, and it‟s biological activity was studied in vitro using 
human umbilical vein endothelial cells (HUVECs). 
Materials and Methods 
Materials 
Unless stated otherwise, all materials were from Merck (Darmstadt, Germany). The 
VEGF upstream (5‟-GTA GAA TTC GCA CCC ACG ACA GAA GG-3‟) and VEGF down-
stream (5‟-TAT GCG GCC GCT CAC CGC CTT GGC TTG T-3‟) primer containing EcoRI 
and NotI restriction sites were synthesised by Isogen Biosciences BV (Maarssen, The Neth-
erlands). The P. pastoris expression vector pPIC9 and P. pastoris host strain GS115 were 
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purchased from Invitrogen Corp. (Carlsbad, CA, USA). The commercial rrVEGF-164, pro-
duced in a mouse myeloma cell line (R&D Systems, Minneapolis, MN, USA) was used as a 
positive control and for reference. 
LB-medium consisted per litre of; 10 g NaCl, 10 g peptone (Gibco BRL), 5 g yeast ex-
tract (Difco Laboratories, Detroit, MI, USA), containing 10 g glucose and 0.1 g ampicillin 
(Sigma). 
Buffered Glycerol-complex Medium (BMGY) containing glycerol as the carbon source, 
consisted per litre of; 10 g yeast extract, 20 g peptone, 21.2 g potassium sulphate (pH 6.0), 
13.4 g yeast nitrogen base (YNB) (Sigma Chemical Co., St Louis, MO, USA), 0.4 mg biotin 
and 10 ml glycerol. 
Buffered Methanol-complex Medium (BMMY) is similar to BMGY, but with 5 ml methanol 
instead of glycerol. 
Basal salts medium (BSM) consisted per litre of; 26.7 ml phosphoric acid, 1.18 g calcium 
sulphate·2H2O, 18.2 g potassium sulphate, 14.9 g magnesium sulphate·7H2O, 4.1 g potas-
sium hydroxide and 40 ml glycerol. 
PTM1 trace salts (Invitrogen) consisted per litre of; 5 ml sulphuric acid, 6 g cupric sul-
phate·5H2O, 0.08 g sodium iodide, 3 g manganese sulphate·H2O, 0.2 g sodium molyb-
date·2H2O, 0.02 g boric acid, 0.5 g cobalt chloride, 20 g zinc chloride, 65 g ferrous sul-
phate·7H2O, and 0.2 g biotin. 
YPD-medium consisted per litre of; 10 g yeast extract, 20 g peptone, 20 g D-glucose, 
with 100000 U penicillin and 0.1 g streptomycin (Gibco BRL). 
YNB dropout plates consisted per litre of; 6.7 g YNB, 1.92 g yeast synthetic dropout me-
dium supplement (Sigma), 20 g glucose and 20 g agar (Gibco BRL). 
TYE agar plates consisted per litre of; 8 g NaCl, 10 g peptone, 5 g yeast extract, 15 g 
agar (Gibco BRL), 10 g glucose and 100 g ampicillin (Sigma). 
Preparation of rat VEGF-164 cDNA 
Total RNA was isolated from Rattus norvegicus embryonic tissue (17 days post-
conception) using the SV Total RNA Isolation System (Promega, Madison, WI, USA). After 
denaturation (10 min at 65°C) of the total RNA (~0.5 µg), cDNA (~0.4 µg) was synthesised 
using hexanucleotide primers. A reverse transcriptase reaction was performed for 90 min at 
37°C using the following reaction mixture; 200 units reverse transcriptase (Promega) in 50 
mM Tris-HCl (pH 8.3) containing 75 mM KCl, 3 mM MgCl2 [M-MLV Reversed Transcriptase 
buffer (Gibco BRL, Gaithersburg, MD, USA)], 1 mM deoxynucleoside triphosphates (dNTPs) 
and 10 mM DTT (Gibco BRL) in a total volume of 20 μl. PCR fragments of the full-length 
cDNA were prepared with 10 mM Tris-HCl (pH 8.3) containing 50 mM KCl, 1.5 mM MgCl2, 
100 μM dNTPs, 20 μM rrVEGF-164 primers and 1 unit Taq polymerase (Promega) in a total 
volume of 50 µL. The PCR was performed on a Peltier Thermal Cycler (PTC-200; MJ Re-
search and Biozym, Landgraaf, The Netherlands), with a 30 cycles program (95°C for 60s, 
65°C for 60s, 72°C for 90s and extension at 72°C for 5 min). The rrVEGF-164 cDNA was 
isolated from a 2% (w/v) agarose gel and purified with a QIAEX II gel extraction system 
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(QIAGEN, Hilden, Germany). The SMART-ladder marker (Eurogentec) was used to estimate 
the sizes of the PCR products. 
Construction of expression vector 
The purified cDNA was subcloned into the vector pPIC9HV (J.M.H. Raats, Dept. of Bio-
chemical Chemistry, Radboud University Nijmegen Medical Centre, Nijmegen, The Nether-
lands, unpublished data (pPIC9 expression plasmid was obtained from Invitrogen)) after 
digestion with EcoRI and NotI (Invitrogen) in the presence of 1x React® 3 buffer (GibcoBRL) 
for 1 h at 37°C. The pPIC9HV is similar to the original pPIC9 vector [17,18]), but contains a 
polyhistidine and VSV-tag for detection and purification. The rrVEGF-164 insert was ligated 
into pPIC9HV vector DNA using T4 ligase (Gibco BRL) in T4 ligase buffer (Gibco BRL) for 
24 h at 16°C. 
The host strain Escherichia coli (supE44ΔlacU169 (ф80lacZΔM15) hsdR17 recA1 endA1 
gyrA96 thi-1 relA1) was transformed with the expression vector by heat-shock (45 s at 
42°C). The E. coli cells were incubated for 1 h at 37°C in LB-medium. After 1 min of cen-
trifugation at 14000g, the transformed E. coli cells were applied to a TYE agar plates and 
incubated for 24 h at 37°C. The rrVEGF-164 positive transformants were selected by means 
of ampicillin antibiotic resistance due to the presence of ampicillin resistance gene (AMP) in 
the Pichia expression vector. Ampicillin resistant E. coli transformants were selected and 
suspended in LB-medium. After 24 h incubation at 37°C at 200 rpm in an orbital shaker, the 
suspension was centrifuged for 1 min at 14000g. Plasmid DNA was isolated using the 
QIAprep spin miniprep kit (QIAGEN) according to the manufacturer‟s instructions, and posi-
tive transformants were identified by automated sequencing using an α-factor primer (5‟-
ACTACTATTGCCAGCATTGCTGCT-3‟) at the DNA Sequencing Facility, Dept. of Human 
Genetics, Radboud University Nijmegen Medical Centre, The Netherlands. 
Transformation into P. pastoris yeast cells 
P. pastoris GS115 cells were grown in 100 ml YPD-medium overnight at 30°C at 200 
rpm in an orbital shaker, until an OD600 of 1.5 was reached, which corresponds to a cell 
density of approximately 109 cells/ml. Competent GS115 cells were freshly prepared before 
transformation by consecutive washings with ice-cold sterile MilliQ water and 1 M sorbitol 
according to the Invitrogen manual. The DNA was linearised by digesting 10 µg of plasmid 
DNA with SalI. Subsequently, the linearised DNA was purified using the QIAGEN PCR 
cleanup kit. To clone the expression vector into the P. pastoris yeast cells, cells were resus-
pended in 1 M sorbitol on ice, and 80 µl of competent cells were electroporated by means of 
pulse discharges (1.5 kV, 25 µF, 400 Ohm, Bio-Rad Gene Pulser, CA, USA) for 9 ms in the 
presence of 10 µg linearised plasmid DNA (20 µl). After electroporation, cells were put on 
ice for 5 min, 10x diluted in 1 M sorbitol and incubated for 1 h at 30°C (without shaking). 
Cells were spread on YNB dropout plates and incubated at 30°C. The plasmid contains the 
His4 gene (encoding histidinol dehydrogenase) which initiates the yeast cell to synthesise 
histidine (His+). Therefore, only positive transformants can grow on the histidine deficient 
plates (YNB dropout plates), which can be used for positive clone selection [19]). After 2 
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days of culturing, the positive transformants were counted, picked, and streaked on new 
dropout plates. After a 45 h incubation at 30°C, single colonies were picked and cultured in a 
baffled flask containing 25 ml BMGY-medium for an overnight period at 30°C at 200 rpm in 
an orbital shaker. To store the cultures, frozen stocks were prepared by adding 60% (v/v) 
glycerol (0.5 ml) to the P. pastoris recombinants in YPD-medium (0.5 ml) and freezing at -
80°C. 
Expression screening of rrVEGF-164 
To analyse the expression levels of the constructed transformants, a small-scale expres-
sion screening was performed using a fast induction method with methanol. His+ trans-
formants were picked and added to 15 ml BMGY-medium, and cultured in 200 ml baffled 
flasks overnight at 30°C, 200 rpm in an orbital shaker. To induce production of rrVEGF-164, 
cells were centrifuged (1500g, 4°C, for 10 min) and resuspended in BMMY-medium contain-
ing 25% (v/v) methanol as the major carbon source. Cells were incubated for 2 days at 
30°C, 200 rpm in an orbital shaker. After centrifugation (1500g, 4°C, 10 min), the secreted 
rrVEGF-164 was concentrated from the supernatant by adding 50 µl heparin-acryl beads 
(Sigma Chemical Co.) to 1 ml supernatant, and incubation for 1 h at 21°C under rotating 
conditions. Heparin beads were concentrated by centrifugation (1500g, 4°C, 10 min) and 
analysed using SDS-PAGE and Western blotting analysis as described below. 
Large-scale production of rrVEGF-164 
For large-scale rrVEGF-164 production, a 1 L baffled flask with 200 ml YNB-medium was 
inoculated with 1 ml thawed P. pastoris host strain GS115 containing the rrVEGF-164 ex-
pression vector. An overnight culture was incubated at 30°C at 200 rpm in an orbital shaker 
until an OD600 of approximately 6 was reached. The Bioflo® 3000 fermentor (New Bruns-
wick Scientific, Edison, NJ, USA), containing 2 L of basal salts medium, was sterilised by 
autoclaving for 45 min at 121°C. After autoclaving, 4.35 ml/L PTM1 trace salts (Sigma) were 
added aseptically to the initial fermentation volume. Ammonium hydroxide (28% (w/v), 
Sigma) was used as a nitrogen source and to increase the pH during the fermentation proc-
ess. The 200 ml inoculum was transferred into the fermentor after setting the dissolved oxy-
gen (DO) at 100%, the pH at 6.0 and the temperature at 30°C. Anti-foam solution 289 
(Sigma) diluted 1:500 in MilliQ water was used to reduce foam production during fer-
mentation. Yeast cells use oxygen for oxidative metabolism of glycerol. When glycerol is 
consumed the need for oxygen declines and as a consequence the DO rises. After approxi-
mately 24 h of batch culture, the glycerol was completely consumed which was indicated by 
a sharp rise in DO (up to 70%, see Fig. 4). The 5 h glycerol fed-batch was started by feeding 
50% (v/v) glycerol con-taining 12 ml/L PTM1 trace salts with feed rate of 18.15 ml/L/h. After 
the glycerol was used (DO of ~100%), the methanol feed (100% (v/v) methanol (Labscan) 
with 12 ml/L PTM1 trace salts) was started to fully induce the AOX1 promoter of the expres-
sion system. During the methanol feed, DO decreased rapidly from ~100% to 30% and was 
continued at 30% for another 30 h. The culture was then harvested and centrifuged (20 min 
at 5000 g). The supernatant was filtered using a 0.45 µm cellulose acetate membrane filter 
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(Schleicher and Schuell, Dassel, Germany) and dialysed against 10 mM phosphate buffered 
saline (pH 7.4). 
Purification and identification of rrVEGF-164 
For purification of rrVEGF-164, the dialysed supernatant (300 ml) was 1:1 diluted with 10 
mM phosphate buffer (PB) containing 0.2 M NaCl and adjusted to pH 7.0 with 1 M Na2HPO4. 
The solution was subjected to fast protein liquid chromatography (FPLC), using a 5 ml hepa-
rin-sepharose HiTrap™ column (Amersham Biosciences, Stockholm, Sweden). The 
rrVEGF-164 was eluted with 1 M NaCl in 10 mM PB (pH 7.0) for 20 min, followed by 2 M 
NaCl in 10 mM PB (pH 7.0) for 20 min at 2.5 ml/min for both solutions (see Fig. 5). Five 
fractions (2.5 ml/fraction) with highest A280 absorbance were collected, pooled and directly 
frozen at -80˚C. Purity and dimer formation were evaluated by sodium dodecyl sulphate 
poly-acrylamide gel electrophoresis (SDS-PAGE; 15% (w/v); Serva GmbH, Frankfurt, Ger-
many) [20]). Briefly, the supernatant was diluted 1:1 with sample buffer with and without 5% 
(v/v) β-mercaptoethanol (with and without reducing conditions) and denatured for 5 min at 
95˚C. Then 10 µl (~0.6 µg) of denatured rrVEGF-164 was loaded on the gel and was visual-
ised by Coomassie Brilliant Blue (0.1% (w/v)) staining or further identified by Western blot-
ting using goat anti-rat VEGF antibody (1:1000) (R&D Systems) [21]). The amount of puri-
fied rrVEGF-164 was determined by a Lowry analysis using bovine serum albumin (BSA) as 
a standard [22]). 
Biological activity of produced rrVEGF-164 
Human umbilical vein endothelial cells (HUVECs, ATCC, CRL-1730, Rockville, MD, 
USA) were grown in F12K medium (Gibco BRL, Carlsbad, CA, USA) with 20% (v/v) foetal 
calf serum (FCS), 1.5 % (w/v) calf brain extract (as a source for endothelial cell growth factor 
(ECGF)), 0.14 mg/ml heparin, 200 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml strep-
tomycin (Gibco BRL). After coating the 96-wells plate with 1% (v/v) gelatine, 4000 cells were 
seeded per well and these were left to attach overnight in the above medium without ECGF. 
Next, medium was replaced by F12K medium without ECGF and 0-100 ng/ml rrVEGF-164 
was added. A cell proliferation assay (WST-1, Roche, Mannheim Germany), based on the 
reduction of a tetrazolium salt to formazan by mitochondrial dehydrogenases in viable cells, 
was used to determine the relative number of cells at day 1 and 3 [23]). Proliferation of cells 
in medium without VEGF was set to 100%. A student‟s t-test was used for statistical analy-
ses and p<0.05 was considered statistically significant. 
Results and Discussion 
Preparation of rat VEGF-164 cDNA 
Total RNA was isolated from embryonic Rattus norvegicus tissue and transcribed into 
cDNA using random hexanucleotide primers. After amplification with VEGF specific primers, 
PCR products were separated on agarose gel, and three VEGF splice variants (VEGF-188 
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(564bp), VEGF-164 (492bp) and VEGF-120 (360bp)) could be identified on the basis of their 
molecular mass (Fig. 1A). The 492bp fragment was extracted from the gel, and reamplified. 
This fragment and the pPIC9HV vector were cut with EcoRI and NotI and put on an agarose 
gel for isolation and for further ligation (Fig. 1B). 
 
 
 
Figure 1. Agarose gel electrophoresis of PCR products. A) ethidium bromide-stained agarose gel shows in lane 1: 
DNA marker, lane 2: PCR products after amplification using VEGF specific primers, indicating three VEGF splice 
variants, VEGF-188 (564bp), VEGF-164 (492bp) and VEGF-120 (360bp). B) lane 1: DNA marker, lane 2: the rrVEGF-
164 insert (492 bp) and in lane 3 the pPIC9HV vector (8580 bp). 
Construction of expression vector 
After EcoRI and NotI digestion, purification and ligation, the resulting pPIC9HV-rrVEGF-
164 expression vector (Fig. 2) was transformed into E. coli. Positive clones were selected by 
means of ampicillin resistance. Eight of 64 colonies able to grow on ampicillin plates were 
sequenced. After verifying the nucleotide sequence of the insert using DNA sequencing (Fig. 
3) and a subsequent BLAST search, one colony was found identical with seven rrVEGF-164 
sequences published. The nucleotide sequence encoding the rrVEGF-164 (Genbank refer-
ence GQ423618) showed a 100% homology with the nucleotide sequence of rrVEGF-164 
published by Conn el al. 1990 [24]) (Genbank reference AAA41211) and Strausberg et al. 
2002 [25]) (Genbank reference AAI68708). 
Cloning and production of rat VEGF-164 
After isolation and linearisation of the plasmid DNA of the positive clone with SalI, the 
competent P. pastoris GS115 cells were transformed with plasmid DNA by means of elec-
troporation. The transformants were cultured in the absence of histidine and 6 colonies were 
picked and examined for rrVEGF-164 production. Western blot analyses indicated that 4 of 
the 6 clones produced rrVEGF-164 (data not shown). 
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Figure 2. Map of the rrVEGF-164 expression vector based on the pPIC9HV vector. MCS: multiple cloning site. The α-
factor directs VEGF to the secretory pathway. EcoRI and NotI restriction sites were used to insert rVEGF-164 into the 
multiple cloning site. The ampicillin resistance gene (AMP) was used for E. coli transformant selection. The histidine 
independent gene (His4) allows growth in the absence of histidine, and was used for P. pastoris transformant selec-
tion. The SalI restriction site was used to inactivate the His4 gene and only a successful ligation results in an intact 
His4 gene. 
Purification and identification of rrVEGF-164 
From the small production screening one clone with a strong band on Western blot was 
selected and used for large scale production. After the fermentor run, the bulk cell mass was 
separated from the supernatant and the expressed rrVEGF-164 was purified from the su-
pernatant. Because rrVEGF-164 is a heparin-binding protein, the expressed product was 
purified with a heparin column. The rrVEGF-164 was present in the 1 M NaCl elution peak 
(Fig. 5). The rrVEGF-164 content in the pooled peak fractions was ~124 mg/L as determined 
by Lowry protein assay [22]). Using non-reducing conditions, SDS-PAGE showed one broad 
band of about 48 kDa (dimer), whereas under reducing conditions a main band of about 24 
kDa band (monomer) was observed (Fig. 6A). It was to be expected that on an SDS-PAGE 
gel dimeric and monomeric rrVEGF-164 migrate at 45 kDa and 23 kDa, respectively [26]). 
Western blot analysis using an anti rat VEGF-164 antibody further indicated that the protein 
was rat VEGF-164 (Fig.6B). Under non-reducing conditions, the expressed rrVEGF-164 
existed in the biologically active form of a homodimer. Dimers of VEGF are disulphide-
bridged, which is essential for the biological activity of VEGF-164 [5]). These data indicate 
that rrVEGF-164 is produced as a disulphide-bridged dimer which can be purified to near 
homogeneity by heparin affinity chromatography. 
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Figure 3. Nucleotide sequence and the deduced amino acid sequence of the relevant part of P. pastoris rrVEGF-164 
expression vector, indicating α-Factor Signal Sequence, the EcoRI restriction site, the rVEGF-164 insert, the NotI 
restriction site and the polyhistidine-VSV tag. A stop codon was positioned between rVEGF-164 and NotI in order to 
produce VEGF without tags. The α-factor signal, the rVEGF-164, and the His/VSV tag are indicated by boxes. The α-
factor primer is also indicated. 
 
 
Figure 4. Profile of fermentation process describing the % methanol feed, pH, % dissolved oxygen level and % glyc-
erol feed in time (hours). In the culture phase a biomass of yeast cells was formed. In the fed-batch phase glycerol was 
accumulated in the yeast cells as a major carbon source. In the induction phase the VEGF-164 production was in-
duced with methanol. 
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Figure 5. FPLC flow chart of the purification of rrVEGF-164 by heparin affinity chromatography. In green the elution 
buffers are indicated; viz. 10 mM phosphate buffer (pH 7.0) containing 1M NaCl or 2 M NaCl. The Y-axis indicates 
absorbance at λ =280 nm expressed in arbitrary units (AU). On the X-axis, the collected fractions (each containing 2 
ml) are represented by the vertical dashed lines. 
 
 
Figure 6. Analysis of produced rrVEGF-164 by SDS-PAGE and Western blot analysis. A) Coomassie Brilliant Blue 
staining; lane 1: markers; lane 2: rrVEGF-164 under non-reducing conditions (about 48 kDa); lane 3: rrVEGF-164 
under reducing conditions (about 24 kDa). B) Western blot analysis of the produced rrVEGF-164; lane 1: markers; lane 
2: rrVEGF-164 under non-reducing conditions (about 48 kDa); lane 3: rrVEGF-164 under reducing conditions (about 24 
kDa). Figure A and B are both composite images of VEGF-164 monomer and dimer products, taken from separate 
reducing and non-reducing gels respectively. 
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Biological activity of produced rrVEGF-164 
The biological activity of the purified rrVEGF-164 was determined by a WST-1 prolifera-
tion assay using human endothelial cells (HUVECs). HUVECs are generally used to evalu-
ate the activity of VEGF from various species [16,27]). Already after 1 day, the 25 ng/ml 
content resulted in a three-fold increase in proliferation compared to medium without added 
VEGF (Fig 7A). After 3 days, the amount of proliferation at content of 12.5-25 ng/ml showed 
a three to five-fold increase (Fig 7B). We also compared our produced Pichia VEGF with 
commercial rrVEGF-164 which is produced in a mouse myeloma cell line. At amounts of 
12.5-100 ng/ml, the produced rrVEGF-164 showed a significantly higher proliferation than 
the commercial batch of rrVEGF-164 (p<0.05; Fig. 7A and B). 
 
 
Figure 7. Biological activity of the produced rrVEGF-164 and commercially available rrVEGF-164 analysed using a 
WST-1 assay. A) Proliferation after 1 day of culture. B) Proliferation after 3 days of culture. The proliferation without 
added VEGF was set to 100%. Results are mean ± SD for 3 separate experiments. All values were significantly in-
creased compared to the control values. * Indicates p<0.05 when comparing produced and commercial rrVEGF-164.  
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The difference in activity for the commercial VEGF and our Pichia-derived VEGF might 
be due to the presence of inactive forms as influenced by the production method. Until now, 
both mouse myeloma cell lines and E. coli have been used to produce rrVEGF-164 com-
mercially. The myeloma and E. coli production methods can result in heterogeneity of mole-
cules with variable biological activities [28]). Additionally, for E. coli the expressed product is 
present in inclusion bodies and in order to be active the protein must be refolded (dimerised) 
after purification. For rrVEGF-164 produced in P. pastoris, the protein has already been 
processed, including disulfide-linked dimers, before secretion into the cell medium. This pre-
processing can result in a potentially more homogeneous, more highly active population of 
the product. 
 
Conclusion 
In this study, we have cloned and expressed biologically active recombinant rat vascular 
endothelial growth factor (rrVEGF-164) in the yeast P. pastoris. Recombinant rat VEGF-164 
was successfully produced as an active dimer in a large quantity. The produced rrVEGF-164 
had a higher biological activity than commercially available growth factor (produced in a 
mouse myeloma cell line). The high level expression of biologically active recombinant rat 
VEGF-164 provides a useful tool for basic and applied research. 
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Abstract 
Skin substitutes are of great benefit in the treatment of patients with full-thickness 
wounds, but there is a need for improvement with respect to wound closure with minimal 
contraction, early vascularisation, and elastin formation. In this study, we designed and 
developed an acellular double-layered skin construct, using matrix molecules and growth 
factors to target specific biological processes. The epidermal layer was prepared using type 
I collagen, heparin and fibroblast growth factor 7 (FGF7), whereas the porous dermal layer 
was prepared using type I collagen, solubilised elastin, dermatan sulfate, heparin, fibroblast 
growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF). The construct was 
biochemically and morphologically characterised and evaluated in vivo using a rat full-
thickness wound model. Results were compared with the commercial skin substitute Inte-
graDRT and untreated wounds. The double-layered construct was prepared according to the 
design specifications. The epidermal layer was about 40 µm in thickness, containing 9% 
heparin and 0.2 µg FGF7/mg layer, localised at the periphery. The dermal layer was 2.5 mm 
thick, had rounded pores, and contained 10% dermatan sulfate + heparin, and 0.7 µg FGF2 
+ VEGF/mg layer. The double-layered skin construct was implanted in a skin defect and on 
day 7, 14, 28 and 112, the (remaining) wound area was photographed, excised and (immu-
no)histologically evaluated. The double-layered skin construct showed more cell influx, sig-
nificantly less contraction and increased blood vessel formation at early time points in com-
parison to IntegraDRT and/or the untreated wound. At day 14, the double-layered skin con-
struct also had the least myofibroblasts present. At day 112, the double-layered skin con-
struct contained more elastic fibres than IntegraDRT and the untreated wound. Structures 
resembling hair follicles and sebaceous glands were found in the double-layered skin con-
struct and the untreated wound, but hardly any were found in IntegraDRT. The results pro-
vide new opportunities for the application of acellular skin constructs in the treatment of 
surgical wounds. 
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Introduction  
Skin substitutes are of major importance to patients whose barrier function is compro-
mised due to trauma, surgical wounds or ulcera. The skin is the major organ involved in 
thermoregulation and hydration, and acts as a barrier against infection [1]. Human full-
thickness defects larger than 4 cm in diameter will not heal well without a graft [2]. Currently, 
autologous grafts present the most effective treatment modality, but their availability is li-
mited, and the harvest of autologous skin creates new wounds at the donor site. Therefore, 
intensive research is being conducted to the development of skin substitutes which can be 
used for immediate wound closure, without the risk of infection, necrosis, tissue hypertrophy 
and contraction [3,4]. 
Several skin substitutes have been developed and tested in vivo. A number of substi-
tutes obtained FDA approval and are available for clinical use, including Apligraf and Inte-
graDRT [2]. Apligraf is a cell-based construct consisting of an epidermal layer of human 
keratinocytes and a dermal layer composed of bovine type I collagen and human fibroblasts 
[5]. This construct is known to be a safe and effective graft for use in chronic wounds. The 
cellularity of constructs, however, makes it expensive to produce and difficult to handle [6]. 
IntegraDRT is an acellular construct composed of a collagen-chondroitin sulfate dermal 
layer and a silicon top layer. It is easy to handle with off-the-shelf availability, but requires a 
two stage operation, in which the dermal layer is first allowed to become vascularised [4]. In 
acellular constructs, angiogenesis, graft take and elastic fibre formation still need to be im-
proved, whereas contraction needs to be reduced [1,2]. In this study, we address these 
issues using a molecularly-defined construct, prepared from scratch.  
Using a subcutaneous implantation model, we have previously shown that a scaffold 
consisting of type I collagen supplemented with glycosaminoglycans and fibroblast growth 
factor 2 (FGF2) promotes angiogenesis [7,8]. In addition, we showed that a scaffold consist-
ing of collagen and solubilised elastin enhances angiogenesis and elastic fibre formation 
[9,10], and that combined addition of two growth factors (FGF2 and vascular endothelial 
growth factor (VEGF)) reduced the time span to obtain vasculature from a period of 3 weeks 
to ~7 days [11]. Fournier et al also showed that FGF2 requires additional components like 
hyaluronic acid to enhance its angiogenic effect [12]. Next to its role in angiogenesis, FGF2 
may also reduce wound contraction by inhibiting the phenotypic change of fibroblasts to 
myofibroblasts, which is likely involved in contraction [13-15]. Heparin is known to stimulate 
fibroblasts to produce FGF2 [16], influencing angiogenesis and myofibroblast formation. In 
vitro, TGF-β differentiates fibroblasts into myofibroblasts [15]. Lammers et al. showed that 
the extension and method of crosslinking influences the proliferation of keratinocytes [17]. 
 Based on this knowledge, a double-layered skin construct was designed and con-
structed containing specific factors to stimulate important biological processes in skin rege-
neration (Fig. 1). The construct consisted of two layers: a collagenous epidermal layer har-
bouring heparin and FGF7 (which stimulates keratinocyte proliferation), and a porous dermal 
layer consisting of type I collagen fibrils, solubilised elastin, dermatan sulfate, heparin, FGF2 
and VEGF. Both layers were chemically crosslinked using EDC/NHS. This molecularly-
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defined construct was characterised and evaluated in vivo using a rat full-thickness wound 
model, suitable to evaluate skin constructs [18,19]. Results were compared with commercial 
IntegraDRT and untreated wounds. 
 
 
Figure 1 Design and rationale of the double-layered skin construct, consisting of an epidermal (film) layer and a dermal 
(porous) layer. The epidermal layer contained type I collagen, heparin and recombinant rat FGF7. The dermal layer 
consisted of type I collagen, solubilised elastin, dermatan sulfate (DS), heparin and the recombinant rat growth factors 
FGF2 and VEGF. The construct was designed to resemble the architecture of normal skin and to contain specific 
effector molecules. Heparin was added to the epidermal layer for hydration and growth factor binding, and FGF7 to 
stimulate keratinocyte migration and proliferation. Solubilised elastin was added to the dermal layer to induce elastic 
fibre formation, DS and heparin to provide hydration and growth factor binding, VEGF to promote angiogenesis and 
FGF2 to enhance fibroblast proliferation and angiogenesis, and to decrease myofibroblast formation. 
Materials and methods 
Materials 
Unless stated otherwise, all chemicals were purchased from Merck Chemicals 
(Darmstadt, Germany). Type I collagen fibrils were purified from bovine achilles tendon as 
described [20]. Solubilised elastin was prepared from equine ligamentum nuchae as de-
scribed [9]. Heparin and dermatan sulfate (DS) were purchased from Sigma Chemical Co. 
(St Louis, MO, USA). Recombinant rat FGF2 was produced in E. coli M15 PQE16 [8] and 
recombinant rat VEGF-164 in P. pastoris GS115 [21]. Recombinant rat FGF7 was pur-
chased from QED Biosciences (San Diego, CA, USA). IntegraDRT (Integra® dermal rege-
neration template) was purchased from Integra Lifesciences Corporation (Plainsboro, NY, 
USA). Antibodies against bovine type I collagen, bovine elastin (cross-reacting with equine 
elastin), rat VEGF, rat elastin, rat type I collagen, rat type III collagen, bovine FGF2, human 
type IV collagen and α-smooth muscle actin (the last three cross-reacting with rat epitopes) 
were purchased and diluted as described [9,11]. Single chain variable fragment antibodies 
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against heparin (antibody HS4C3 [22]), DS (antibody GD3A12 [23]) and chondroitin sulfate 
(CS; antibody IO3H10 [24]) were prepared as described. Goat anti-human FGF7 (cross-
reacting with rat FGF7) was purchased from R&D Systems (Minneapolis, MN, USA). 
Preparation of the double-layered skin construct 
The double-layered skin construct consisted of a dermal and epidermal layer. The der-
mal layer was prepared by freezing a suspension containing 0.64% (w/v) type I collagen and 
0.16% (w/v) solubilised elastin in 0.25 M acetic acid at -20°C [9,25], followed by lyophilising 
using a Zirbus lyophiliser (Bad Grund, Germany). The resulting scaffold was chemically 
crosslinked with 33 mM 1-ethyl-3-dimethyl aminopropyl carbodiimide (EDC) and 6 mM N-
hydroxysuccinimide (NHS) in the presence of 0.375% (w/v) DS and 0.125% (w/v) heparin for 
4 h in 50 mM 2-morpholinoethane sulphonic acid (pH 5.0) containing 40% ethanol, and 
washed with 0.1 M Na2HPO4, 1 M NaCl, 2 M NaCl, and demineralised water [9]. Growth 
factors were bound to the dermal layer by incubation (1 ml per 8 mg scaffold) in 3.5 µg 
FGF2/ml and 3.5 µg VEGF/ml phosphate buffered saline (PBS) pH 7.4 for 60 min, followed 
by 5x15 min washings with PBS. 
The epidermal layer was produced by air-drying a 0.8% type I collagen suspension in 
0.25 M acetic acid [17], followed by EDC/NHS crosslinking in the presence of 0.5% heparin 
as described above. The epidermal layer (1 ml solution per 20 mg scaffold) was incubated in 
0.5 µg FGF7/ml PBS, followed by 5x15 min washings with PBS. 
The wet dermal and epidermal layer were glued to each other using a 0.5% collagen 
suspension in 0.25 M acetic acid. The total construct was quickly frozen at -80°C and lyophi-
lised. 
Characterisation of construct 
A number of morphological and biochemical techniques was applied to characterise the 
double-layered skin construct and commercial IntegraDRT. 
 
The ultrastructure of the constructs was analysed using scanning electron microscopy 
(SEM) [11]. 
The extent of crosslinking was estimated by determination of the amount of amine 
groups, which was analysed using 2,4,6-trinitrobenzene sulphonic acid [26]. 
The glycosaminoglycan content (dermatan sulfate, chondroitin sulfate and heparin) of 
the epidermal layer, dermal layer and IntegraDRT, was determined by a hexosamine assay 
using p-dimethyl-aminobenzoaldehyde [20]. Because the standard curves of heparin and 
chondroitin sulfate /dermatan sulfate had different slopes, two calibration curves were used. 
The total glycosaminoglycan content of the dermal layer was calculated by adding the num-
bers obtained for dermatan sulfate and heparin (in a 3:1 ratio).  
The amount of growth factor bound to the epidermal and dermal layer was determined 
by Western blotting [27] using antibodies against FGF2 (1:2000), VEGF (1:1000) and FGF7 
(1:400). Bound antibodies were visualized using peroxidase-conjugated secondary antibo-
dies and a chemiluminescent detection kit (ECL; Amersham Biosciences) and analysed with 
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Gene Tools software (Syngene, Cambridge, UK). The calibration curves ranged from 0-100 
ng growth factor. Scaffolds without growth factors were taken as controls. 
The distribution of type I collagen, elastin, dermatan sulfate, chondroitin sulfate, heparin, 
FGF7, FGF2 and VEGF was determined by an immunofluorescence assay using specific 
antibodies as described [9,11]. For DS and CS, the secondary antibody was mouse anti-
VSV tag (1:5) [22] and the tertiary antibody goat anti-mouse IgG Alexa488 (1:200). For 
FGF7, the secondary antibody was rabbit anti-goat IgG Alexa488 (1:200). Omission of the 
primary antibody was taken as a negative control. 
Implantation of construct  
NIH guidelines for the care and use of laboratory animals (NIH publication 85-23 Rev. 
1985) were observed. The study was approved by the Ethics Committee of the Radboud 
University Nijmegen. Wistar rats (male, 3 months) were purchased from Harlan (Horst, The 
Netherlands). The rats were housed separately, fed pelleted diet (RMH-B 10 mm) and water 
ad libitum. The rats were anaesthetized with isoflurane. 
7 days prior to the operation, the wound area was marked intradermally with 8 dots of 
tattoo ink (Hauptner, Germany). 
Before surgery, analgesia (injection with midazolam, morphine and carprofen) was given. 
Also postoperative analgesia was given (injections with carprofen for two days, twice a day). 
Constructs (1.5x1.5 cm) were disinfected in 70% ethanol (3x30 min and one overnight incu-
bation) and washed with sterile PBS (6x60 min). Two full-thickness wounds of 1.5x1.5 cm, 
including the panniculus carnosus, were made on each side of the back of the rat and the 
constructs were placed in the wounds. The wounds were treated either with the double-
layered skin construct, IntegraDRT or left untreated. The double-layered skin construct and 
IntegraDRT were placed in the wound in such a way that they fitted exactly and touched the 
wound edge, without overlap with the wound edge. The constructs were kept in place by 4 
resorbable sutures (5-0 Vicryl). The wounds were dressed with a gauze, Tensoplast and 
Leukoplast. The bandage was applied for 14 days. Each individual rat received two different 
treatments (double-layered skin construct and/or IntegraDRT and/or no treatment). Per time 
point, each treatment was applied four times, resulting in a total of 6 rats per time point. After 
14 days, the silicon layer of IntegraDRT was removed. At day 7, 14, 28 and 112, the rats 
were sacrificed and the implants and surrounding tissues were removed. The explants were 
divided in several parts and processed for conventional histology and immunohistochemi-
stry. 
Analysis of contraction  
At day 7, 14, 28 and 112, wound contraction was evaluated by determination of the re-
maining wound area using photographs and a ruler at each time point (n=4). Day 0 was 
taken as 100% (no wound contraction). Results were represented as mean ± SD. The effect 
of the different treatments on the size of the wound area was analysed by factorial analysis 
of variance (ANOVA) followed by a post-hoc test (Duncan's multiple range test) using the 
Statistica software package (StatSoft, Tulsa, OK, USA). 
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Processing of explants 
Histology: Paraffin sections were cut and stained with haematoxylin-eosin (HE), Elastin 
von Gieson (EVG) [28] and a Elastic Masson‟s stain [29]. Phase contrast microscopy was 
used to study the location and direction of newly-formed collagen fibres. Histology of the 
explants was evaluated independently by at least two experienced investigators. Sections 
were scored using a - (not present) to +++ (abundant) scale. 
 
Immunostaining: To study construct degradation, extracellular matrix formation, pres-
ence of blood vessels and amount of myofibroblasts, cryosections were stained with specific 
antibodies. Antibodies against bovine type I collagen, bovine elastin, heparin, dermatan 
sulfate and chondroitin sulfate were used to evaluate the (remains of) the construct. No 
major cross-reactivity was found between bovine and rat collagen, and between bovine and 
rat elastin, and in combination with the size and the position of the collagen fibres and elas-
tin material, the difference between the two species could easily be distinguished. Antibo-
dies against rat type I and type III collagen were used to analyse the presence of rat colla-
gen, an antibody against rat elastin to visualise elastin formation, and an antibody against 
dermatan sulfate to evaluate glycosaminoglycan production. An anti-type IV collagen anti-
body was used to visualise blood vessels, and an anti-smooth muscle actin (SMA) antibody 
to analyse the presence of myofibroblasts and the maturity of blood vessels. Sections were 
scored using a scale ranging from - (not present) to +++ (abundant). 
Results  
Characterisation of the constructs 
Double-layered skin construct The morphology of the construct was analysed using SEM 
(Fig. 2A-D). The epidermal top layer was a thin non-porous collagen layer with a thickness 
of ± 40 µm (Fig. 2A and C, Table 1). The dermal layer was approximately 2.5 mm thick with 
rounded pores of generally 75-125 µm (Fig. 2A and D, Table 1). The glue layer of collagen 
had a thickness of 25-30 µm and contained pores of ± 10 µm (Fig. 2B).  
 
Table 1. Pore size and biochemical properties of the implanted constructs.  
 
 
 
Pore size and biochemical analysis of the epidermal layer, dermal layer and IntegraDRT. The amine group content was 
determined using 2,4,6-trinitrobenzene sulphonic acid [22], the percentage crosslinking in comparison to non 
crosslinked scaffold is displayed between brackets. The glycosaminoglycan (heparin, DS and CS) content was deter-
mined using p-dimethyl-aminobenzoaldehyde [15]. Non-crosslinked collagen contained 298 ± 57 nmol amine 
groups/mg scaffold Results are the mean ± SD of 3 independent experiments. Please note that no controls could be 
taken for the IntegraDRT construct. 
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Figure 2 Electron microscopical and immunological evaluation of the double-layered skin construct and IntegraDRT.  
A-D: Scanning electron micrographs of the double-layered skin construct: (A) cross-section, the arrow indicates the 
epidermal layer, (B) glue layer, indicated by a double-headed arrow, (C) top of epidermal layer, and (D) dermal layer. 
E-L: Immunolocalisation of (E) type I collagen, (F) heparin, (G) FGF7, (H) negative control, (I) elastin, (J) dermatan 
sulfate, (K) FGF2 and (L) VEGF. The epidermal (top) layer is indicated by a dashed line. M-P: Scanning electron 
micrographs of IntegraDRT: (M) cross-section, (N) close-up of M, (O) top of (silicon) layer and (P) top of dermal layer. 
In M and N, # indicates the silicon layer and * the dermal collagen layer. Bar is 100 µm in A, D, E-N and P; 10 µm in B 
and C, and 1 µm in O. 
 
The layers were individually crosslinked with EDC/NHS to covalently bind the glycosami-
noglycans (94 µg heparin/mg epidermal layer, 103 µg dermatan sulfate + heparin/mg dermal 
layer) (Table 1). In the crosslinking process about 50% of the free amine groups were used 
(Table 1). The amount of growth factor bound to each layer (0.2 µg FGF7/mg epidermal 
layer and 0.7 µg FGF2 + VEGF/mg dermal layer) was determined by Western Blotting and 
Gene Tools (Table 1).  
The distribution of all components in the construct was visualised using immunostaining 
(Fig. 2E-L), and was in accordance with the original design (Fig. 1). Both the epidermal and 
dermal layer contained type I collagen, whereas solubilised elastin was only present in the 
dermal layer. Heparin was distributed throughout the whole construct, with more intense 
staining of heparin in the epidermal layer. Dermatan sulfate, FGF2 and VEGF were found 
distributed throughout the dermal layer, the growth factors showing a more intense staining 
at the epidermal side. FGF7 was only present at the periphery of the epidermal layer.  
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IntegraDRT SEM indicated that in commercial IntegraDRT the collagen part was ~750 
µm thick with 50-100 µm pores, and that the silicon layer was ~300 µm thick (Fig. 2M-P, 
Table 1). IntegraDRT is dehydrothermally crosslinked [30]. The analysis of the collagen 
layer indicated that 1 mg contained about 164 nmol amine groups and about 24 µg chon-
droitin sulphate (Table 1, note that a control without crosslinking or without chondroitin sul-
fate was not available). Immunostaining was used to analyse the distribution of type I colla-
gen and CS and both were equally distributed throughout the collagen layer (data not 
shown). 
Evaluation of constructs in full thickness wounds  
No infections or illnesses were observed in the rats and they stayed healthy without con-
siderable weight loss. Rats scratched more on IntegraDRT-covered wounds with the silicon 
layer present. Some rats even removed the layer, indicating that the silicon layer caused 
irritation. The tattoo ink was used to mark the wound area, but the dots were generally too 
large and too unequal in size to use for an accurate determination of the remaining wound 
area.  
The double-layered skin construct was constructed from two layers, an epidermal film 
layer and a porous dermal layer. The two layers were attached to each other by a thin colla-
gen “glue” layer, which firmly attached both layers in such a way that during all procedures 
(e.g. disinfection and suturing) the construct stayed intact and was easy to handle. During 
the experiment, we noticed that at day 7 and 14 the epidermal layer was still attached to the 
dermal layer, but that at later time points, the layer was loosened by epidermal cells that 
tended to migrate between the two layers. 
At day 40, the wounds of all groups were closed (data not shown).  
 
Wound contraction At day 7, a significant difference in wound contraction was found be-
tween the double-layered skin construct versus the untreated wound (p<0.05). The double-
layered skin construct occupied a larger area (90 ± 8% of the original wound area) in com-
parison to the untreated wound (65 ± 23%). IntegraDRT had 84 ± 16% of the original wound 
area (Fig. 3B).  
At day 14, the double-layered skin construct had significantly less contraction than Inte-
graDRT and the untreated wound (p<0.008 and p<0.002 respectively). The double-layered 
skin construct (80 ± 16%) occupied a larger area than IntegraDRT (47 ± 19%) and the un-
treated wound (39 ± 22%) (Fig. 3A, B).  
At day 28 and 112, the remaining wound areas for all treatments ranged from 12-31% 
and no major differences were observed between the groups. 
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Figure 3 Degree of wound contraction as analysed by the remaining wound area. A) Macroscopical images of the 
wound area at day 0 and day 14. B) Quantitative data of remaining wound area. Values are mean ± SD (n=4). At day 
7, a significant difference was found between the untreated wound versus the double-layered skin construct (p < 
0.05*). At day 14, the double layered skin construct was found to have significantly less contraction than IntegraDRT 
and the untreated wound (p<0.008^ and p<0.002
#
, respectively). 
 
Table 2. Cellular response in wound area after treatment, compared to normal skin. 
 
 
The cells were scored from absent (-) to abundantly present (+++). The absolute numbers of granulocytes are much 
lower than for phagocytic cells. * Phagocytic cells include macrophages and giant cells. 
# 
The myofibroblasts were 
visualised using an antibody against smooth muscle actin. More myofibroblasts were found at the wound edges, 
indicated as 
1
moderate or 
2
abundant. 
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Microscopical evaluation  
Cellular response Table 2 presents a semi-quantitative analysis of cells present in the 
wound area. 
At day 7, little epidermis had been formed in all three groups (data not shown). The 
double-layered skin construct had the largest number of granulocytes. The numbers of pha-
gocytic cells and fibroblasts were equal for all three groups.  
At day 14, partial coverage by epidermal tissue was observed in all three groups. The 
double-layered skin construct and the untreated wound showed some granulocytes, whe-
reas larger numbers were observed in IntegraDRT. No differences were observed with re-
spect to macrophages and fibroblasts. 
At day 28, all groups showed a further coverage, but complete wound closure was not 
yet seen. Keratinocytes had generally migrated under the epidermal layer of the double 
layered skin construct, resulting in the release of the dense layer of the construct (as a 
scab). The double-layered skin construct and IntegraDRT contained more granulocytes and 
phagocytic cells than the untreated wound. No differences in fibroblasts were found between 
the three groups. 
At day 112, all three groups had a fully developed epidermis, but no rete ridge structures 
were present in the newly-formed epidermis. The thickness of the epidermis (measured as 
number of cell-layers) was found to be variable within each group, but no major differences 
were observed. Granulocytes were absent. Compared to normal skin, slightly more macro-
phages appeared to be present in the healed area of all three groups (Table 2 and Fig. 4A). 
Structures resembling hair follicles and sebaceous glands were observed in the double-
layered skin construct and the untreated wound, but hardly any were found in IntegraDRT. 
Most of these structures were located in the vicinity of the wound edges in the newly formed 
matrix (Fig. 4B-C). 
None of the groups showed newly-formed skeletal muscle tissue (replacing the excised 
panniculus carnosus) at any time point examined. 
 
Myofibroblasts At day 7, the overall score for myofibroblasts was comparable between 
the treatments (Table 2). Only at the wound edges, the double-layered skin construct had 
more myofibroblasts present than IntegraDRT and the untreated wound. At day 14, howev-
er, the double layered skin construct overall contained less myofibroblasts than IntegraDRT 
and the untreated wound. At day 28, the untreated wound showed the least myofibroblasts. 
In general, more myofibroblasts were observed at the wound edges than in the middle of the 
wound area. No myofibroblasts were observed at day 112 and in normal skin. 
 
Construct components, Collagen: Immunostaining for construct type I collagen showed 
that at day 7 most of the material of the double-layered skin construct and IntegraDRT was 
still present (Table 3). At day 14, collagen remnants were found in both the double-layered 
skin construct and in IntegraDRT, whereas at day 28, only few collagen remnants were 
observed. At day 112, no scaffold collagen could be observed. 
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Figure 4 Histological images of the centre of the wound area at day 112. A) Haematoxylin & eosin staining (HE), B) 
Elastic Masson‟s staining (EM), C) phase-contrast (PH) of the double-layered skin construct, IntegraDRT and un-
treated wound compared to normal skin. A: a closed epidermis was present in all cases and no differences were found 
in the number of cell layers. Rete ridge structures were absent. The dermis of the double-layered skin construct, 
IntegraDRT and the untreated wound showed higher numbers of cells than the normal skin (nuclei of the cells are 
stained in blue). B) In the double-layered skin construct and the untreated wound, hair follicle-like and gland-like 
structures (arrows) were observed (also visible in C). Mature collagen fibres stain red, whereas the newly formed fibres 
are light blue. C) Phase contrast microscopy revealed that collagen fibres were more randomly oriented in the double-
layered skin construct and untreated wound than in IntegraDRT. Bar in A is 25 µm, bar in B and C is 100 µm. 
 
 
Table 3. Overview of immunostaining for matrix molecules in wound area after treatment, compared to 
normal skin. 
 
 
The sections were scored from absent (-) to abundantly present (+++) 
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Elastin: At day 7 and 14, the elastin staining of the double-layered skin construct showed 
small fragments, indicating degradation of the scaffold elastin. No scaffold bound elastin 
staining was seen at days 28 and 112. 
Glycosaminoglycans: At day 7 and 14, heparin was mainly visible in the epidermal layer 
of the double-layered skin construct, whereas dermatan sulfate was only found on the colla-
gen fibrils of the dermal layer (data not shown). At day 28, hardly any staining was observed 
of construct glycosaminoglycan remnants. IntegraDRT showed staining for chondroitin sul-
fate on the collagen fibrils at day 7 and 14. 
 
Newly-formed extracellular matrix components The presence of rat extracellular matrix 
components is summarized in Table 3. Using immunostaining, it was shown that the normal 
skin contained randomly oriented type I collagen fibres, a small amount of type III collagen, 
a moderate amount of elastic fibres at the top of the dermal layer, and an ample amount of 
DS scattered throughout the dermis. 
Type I collagen: The amount of rat type I collagen increased with time, being abundant 
for all three groups at day 112. At day 7 and 14, the double-layered skin construct and the 
untreated wound contained more type I collagen than IntegraDRT, whereas at day 28, the 
untreated wound contained most type I collagen. Phase contrast microscopy was used to 
analyse the location and orientation of newly-formed collagen bundles at day 112. The 
double-layered skin construct and the untreated wound had a more randomly oriented colla-
gen deposition, whereas the collagen bundles in IntegraDRT were found to be more aligned 
(Fig. 4C). When comparing the results of the treatments with normal skin, the double-
layered skin construct and the untreated wound resembled the normal skin at day 112 more 
closely than IntegraDRT.  
Type III collagen: At day 7, the double-layered skin construct contained a moderate 
amount of rat type III collagen, whereas IntegraDRT and the untreated wound contained 
less. From day 14 on, a moderate amount was found in all three groups. 
Elastin: The amount of elastic fibres increased with time, being most abundant in the 
double-layered skin construct at day 112 (Fig. 5). At day 7, 14 and 28, IntegraDRT con-
tained the least elastic fibres, while the untreated wound had the same or more elastic fibres 
than the double-layered skin construct.  
At day 7, 14 and 28, the least dermatan sulfate was found in IntegraDRT. At day 28, the 
double-layered skin construct contained most dermatan sulfate, whereas at day 112, the 
untreated wound contained most dermatan sulfate, similar to normal skin. 
 
Blood vessels At day 7 and 14, the double-layered skin construct and the untreated 
wound contained more blood vessels than IntegraDRT (Fig. 6). The blood vessels already 
invaded the double-layered skin construct at day 7, whereas hardly any blood vessels were 
found inside the collagen layer of IntegraDRT. At day 28, the double-layered skin construct 
still had many blood vessels present, whereas the untreated wound and IntegraDRT con-
tained a moderate amount. The blood vessels were evenly distributed throughout the wound 
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area. At day 112, all groups had moderate amounts of blood vessels present in the wound 
area. These were smaller, but more abundant than in normal skin. 
 
 
 
Figure 5 Immunohistochemical evaluation of newly formed elastin at day 112, analysed using an antibody for elastin. 
The double-layered skin construct showed elastin around blood vessels and hair follicle-like structures, and a large 
amount of elastic fibres throughout the upper dermis. IntegraDRT and the untreated wound contained a moderate 
amount of elastic fibres that were mainly located in the upper part of the dermis. The untreated wound also showed 
elastic fibres surrounding hair follicle-like structures. Normal skin showed elastic fibres around blood vessels and hair 
follicles in the dermis. Bar is 25 µm. 
Discussion 
In this study, an acellular double-layered skin construct was prepared from purified com-
ponents, according to a pre-defined design. The biological components and their location 
were chosen to reflect the skin‟s extracellular environment. Growth factors were positioned 
in such a way to locally exert their activity, e.g. FGF7 at the periphery of the flat epidermal 
layer, and FGF2 and VEGF throughout the porous dermal layer. The double-layered skin 
construct was developed to accelerate and improve wound healing. In the clinic, acellular 
constructs may be preferred over cellular constructs for their ease of handling, transport and 
storage.  
The performance of the double-layered skin construct was compared to IntegraDRT and 
to an untreated wound (no skin construct). The double-layered construct had significantly 
less contraction at the first two time points (day 7 and 14) compared to the untreated wound, 
and at day 14, compared to IntegraDRT. At later points, no significant differences were 
found. The number of smooth muscle actin-positive myofibroblasts, likely involved in wound 
contraction [14], was also the least in the double layered construct at day 14. This suggests 
an inhibition of the differentiation of fibroblasts to myofibroblasts by the construct. FGF2 is 
known to inhibit myofibroblast formation and promote a fibroblast phenotype [31]. The FGF2 
present in the double-layered skin construct may have been instrumental in diminishing the 
amount of myofibroblasts present on day 14. The fibroblasts are involved in the production 
of extracellular matrix (for instance collagens, elastin), and growth factors, and play a crucial 
role in regulating the skin physiology [32]. Boehnke et al. described an equivalent consisting 
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of fibroblasts in a 3-D scaffold; they showed the importance of the interaction between fi-
broblasts and keratinocytes for the proliferation, regeneration and organogenesis of a skin 
equivalent [33]. The double-layered skin construct contained FGF2 to increase fibroblast 
proliferation in order to enhance wound repair and regeneration. However, no differences 
were observed in the amount of fibroblasts in the wound, suggesting that the FGF2 was 
more involved in angiogenesis and inhibition of myofibroblast formation. 
 
 
 
Figure 6 Presence of blood vessels in the wound area as visualised using an antibody against type IV collagen. The 
top of the dermis/epidermal layer is indicated by a dashed line. In the double-layered skin construct and untreated 
wound, more blood vessels were present on day 7 and 14, and they had penetrated more towards the epidermis in 
comparison to IntegraDRT. On day 28, the double-layered skin construct possessed more blood vessels than Inte-
graDRT and the untreated wound. On day 112, all treatments showed a similar number of blood vessels, more abun-
dant and with a smaller diameter compared to normal skin. Bar is 100 µm.  
 
In addition, the random orientation of the pores in the construct may have prevented the 
remaining myofibroblasts from contracting the wound area. When cells are randomly bound 
to the scaffold the sum of the contracting forces is near zero [34]. However, at day 28 more 
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myofibroblasts were found than at day 14 in the double-layered skin construct. FGF2 has a 
short life span which is increased by binding to heparin [35], but after 28 days most of the 
construct was degraded, and a lack of FGF2 may eventually have revoked the active inhibi-
tion of differentiation into myofibroblasts. Fournier et al. determined that a fibrin gel with 
hyaluronic acid and FGF2 gave burst release in vivo [12]. A more sustained release of FGF2 
may reduce the degree of contraction for a longer period of time. The decrease in mechani-
cal properties of the construct, due to degradation, may have added to this effect. 
The addition of effector molecules to a scaffold generally results in an increased early in-
filtration of cells [8,11]. Indeed, at day 7, the double-layered skin construct showed more 
influx of e.g. granulocytes compared to IntegraDRT and the untreated wound (however, at 
day 14, IntegraDRT showed more granulocyte influx). For good and rapid wound healing, 
infiltration of cells is necessary in order to boost the wound healing process. Cytokines that 
are produced by the infiltrating cells promote angiogenesis, extracellular matrix production 
and remodelling [36,37]. Currently used acellular scaffolds such as IntegraDRT lack growth 
factors, but our study suggests that growth factors may be necessary to induce early angi-
ogenesis and extracellular matrix production.  
In commercially available acellular skin substitutes, it takes several weeks to develop a 
well-developed vasculature. This results in impaired wound healing, due to a lack of oxygen, 
nutrients and the presence of waste products [38]. Angiogenesis can be promoted by the 
incorporation of glycosaminoglycans or solubilised elastin to a scaffold, as we have pre-
viously shown in a subcutaneous implantation model in rat [8,9]. In addition, the combination 
of two growth factors (FGF2 and VEGF) in an acellular collagen-heparin scaffold induced a 
mature vasculature already at day 7 [11]. In the double-layered skin construct, many blood 
vessels were found on day 7, in contrast to IntegraDRT which did not develop a similar 
amount of blood vessels on any of the time-points examined. Moiemen et al. found that 
IntegraDRT was only fully vascularised after 4 weeks in humans [39]. This is in line with our 
findings that it took until day 28 before the newly-formed vasculature in IntegraDRT had 
reached the top of construct. The addition of growth factors in an acellular construct may 
thus greatly improve angiogenesis. 
The orientation of collagen fibres in normal skin has a basket weave pattern, whereas in 
scars the fibres are very much aligned in a parallel way [40]. We and others have seen that 
the micro architecture of the original scaffold influences the orientation of newly-formed 
collagen fibrils [41,42]. In the double-layered skin construct, the dermal layer had large ran-
domly oriented pores to allow random collagen deposition, which indeed occurred, as indi-
cated by phase contrast microscopy. 
An interesting feature was the presence of structures resembling hair follicles and seba-
ceous glands in the double-layered skin construct and untreated wound at day 112. These 
structures were mainly found at the outer region of the healed wound, though some were 
found in the centre. The group of Ito et al. demonstrated that in adult mice, de novo hair 
follicle formation was found after an excision of 1 cm
2
 full-thickness back skin [43]. Growth 
factors (e.g. epidermal growth factor and FGF) are involved in hair follicle sebaceous gland 
development [44]. Therefore, there is a possibility that some of the hair follicles and glands 
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observed were generated de novo, although most of the structures are likely derived from 
adjacent healthy tissue. Further research will establish whether the addition of (a combina-
tion of) growth factors to an engineered skin construct can indeed induce hair follicle forma-
tion. 
Conclusion 
A double-layered skin construct was designed, developed and evaluated in a rat full-
thickness wound model. The construct contained positioned growth factors and resulted in a 
reduction of contraction and an increase in angiogenesis in the early phase of skin regene-
ration. 
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Abstract 
The in vivo performance of tissue-engineered constructs is often based on generally ac-
cepted read-out parameters, like (immuno)histology. In this study, high-density gene ex-
pression microarrays and gene ontology (GO) analysis were used as a read-out tool to iden-
tify the biological processes occurring after implantation of an acellular collagen-based skin 
construct using a rat full-thickness wound model. A freely-available program (DAVID) was 
used to identify up/downregulated biological processes (GO-terms) and results were com-
pared to wound healing/regeneration without a construct. The entire process from RNA 
isolation to biological interpretation is explained step-by-step. Conventional (im-
muno)histology was used to validate the biological processes identified and indicate that 
microarray analysis may provide a valuable, fast and unbiased tool to evaluate the in vivo 
performance of tissue-engineered constructs. However, challenges remain e.g. with regards 
to the development of specific GO-terms and annotation of the (rat) genome. 
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Introduction 
The general aim of regenerative medicine is to restore organs after they have been 
damaged or lost. One approach to reach this goal is to implant a suitable scaffold at the site 
of injury, often combined with the appropriate cells [1]. Worldwide, numerous research 
groups and companies are developing new or improved scaffolds, that are extensively stud-
ied both in vitro and in vivo [2-4]. In most cases, in vivo evaluation is based on generally 
accepted read-out parameters, like transplant „take‟, organ-specific functionality and (im-
muno)histology. 
In order to further understand the observed process of regeneration, it is important to 
identify biological processes that take place in tissue-engineered constructs. The information 
thus obtained may provide clues for improvements e.g. in scaffold design. Currently, histo-
logical evaluation is one of the main methodologies to identify these processes. It is gener-
ally accepted, relatively easy to perform, and most laboratories have access to the required 
equipment. In addition, extensive histological data is available, facilitating the interpretation 
of novel data. However, histology comes with a number of drawbacks including the subjec-
tivity of the scoring process, the expertise required to link histological observations to bio-
logical processes, the use of relatively small tissue samples (with the risk of missing impor-
tant data), and the time-consuming nature of the process. In addition, in the case of immu-
nohistochemistry, optimisation of the staining procedure for each individual antibody is re-
quired, and the high cost of individual antibodies (usually €200-400 per antibody of <500 μg) 
may limit the number of biomolecules analysed. 
Gene expression microarrays may bypass some of these drawbacks. Using high density 
microarrays, virtually all known (and yet unknown) genes can be analysed in a single ex-
periment. Sophisticated and user-friendly software to analyse the large amount of data is 
becoming available, and the knowledge on array analysis and biological interpretation is 
rapidly expanding, allowing objective high-throughput analysis. The technique requires no 
more than five days from RNA isolation to the identification of biological processes, and the 
computerised workflow enables an objective, unbiased analysis. Costs of the arrays (cur-
rently approximately €100-500 per array, depending on e.g. complexity) are dropping, and 
the same goes for the advanced equipment required to run a microarray experiment, the 
equipment generally being available at microarray core facilities. The genome of a growing 
number of species has been sequenced, and arrays have been developed for laboratory 
animals often used in tissue engineering research, including rat and pig [5]. 
In this paper we used a high-density microarray-based approach to identify biological 
processes up/downregulated in vivo in a double-layered skin construct applied in a rat full-
thickness wound model studying at various time points after implantation. Results were 
compared to wound healing without construct, and a freely-available program (DAVID) was 
used for data analysis. The entire process from RNA isolation to biological interpretation is 
explained step-by-step and the identified processes are compared with observations using 
conventional immunohistology. 
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Materials and Methods 
A schematic overview of the whole procedure from tissue sampling to the identification of 
biological processes is given in Fig. 1. 
 
 
 
Figure 1. Schematic overview of the complete procedure for the identification of biological processes occuring in vivo 
in constructs used for tissue engineering. In short, mRNA was isolated from tissue samples and processed for hybridi-
sation on rat exon arrays. The amount of hybridised RNA, reflecting the amount of specific mRNA‟s, was compared 
between groups, resulting in lists with up- and downregulated genes. Lists were uploaded in the DAVID functional 
annotation tool and the enrichment in biological process gene ontology (GO) terms was analysed. Up/down regulated 
biological processes were validated by conventional histology. The minimal time required for each step is indicated on 
the right. See text for more details. 
1
Randomise/balance samples when multiple runs are necessary; 
TD
Tissue-
dependent; T7=T7 promoter. Picture of microarray is courtesy of Affymetrix. 
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High density microarrays 
The Affymetrix® GeneChip® rat exon 1.0 sense target (ST) array (from here called: exon 
array) was used, containing 1.0 million probe sets. A probe is an antisense sequence of 25 
nucleotides, of which millions of molecules are spotted on a defined physical location on the 
array. One probe set consists of 4 (sometimes partially overlapping) probes and covers an 
annotated or predicted exon. About 10% of the probe sets contain fewer than 4 probes, due 
to the length of the probe selection region or sequence constraints (e.g. highly repeated 
sequences) [6]. 
Because all exons of a gene are covered, gene-level analysis on exon arrays is more 
accurate than on e.g. GeneChip 3‟ expression arrays, which only covers the 3‟ end of the 
gene. In addition, it allows the evaluation of alternative splicing by analysing the correlation 
of the expression level of one exon with the expression levels of the whole gene. 
Double-layered skin construct 
The double-layered skin construct consisted of a dense film of type I collagen containing 
heparin and recombinant rat fibroblast growth factor 7 (rrFGF-7), and a porous scaffold of 
type I collagen containing solubilised elastin, dermatan sulfate, heparin, rat recombinant 
fibroblast growth factor 2 (rrFGF-2) and rat recombinant vascular endothelial growth factor 
(rrVEGF). 
Animal study 
This study was approved by the Ethics Committee of the Radboud University Nijmegen. 
Two 1.5x1.5 cm full-thickness wounds were created on both sides of the back of three-
month old male Wistar rats. The wounds were treated with the construct or remained un-
treated. Per time point, each treatment (construct or no construct) was applied to four indi-
vidual rats. The implants were removed on day 7, 14, 28 and 112 and processed for RNA 
isolation and histological evaluation. In case of RNA samples, surrounding skin was re-
moved and the tissue was snap-frozen in liquid nitrogen and stored at -80ºC until RNA isola-
tion. Samples from normal skin of 3 three-month old (called from here: day 0 normal skin) 
and 3 seven-month old (called from here: day 112 normal skin) rats were also collected. 
RNA isolation and evaluation 
Frozen tissue was pulverised with a chromium steel grinding ball in a Teflon chamber in-
serted in a Micro-Dismembrator (Sartorius AG, Goettingen, Germany), and dissolved in 
Trizol reagent (Invitrogen Ltd, Paisley, UK). Total RNA was isolated with a phe-
nol/chloroform extraction and purified using a Qiagen RNeasy mini kit according to the 
manufacturer‟s RNA cleanup protocol, including an on-column DNase digestion. 
The RNA concentration and purity were measured with a Nanodrop spectrophotometer 
(Thermo Scientific, Waltham, MA, USA). The 260/280 ratio was used as an indicator for 
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RNA purity (RNA has a maximum absorbance at 260 nm). A 260/280 ratio of ~2.0 is gener-
ally accepted as „pure RNA‟ and the samples used ranged from 2.00-2.10. 
RNA integrity was analysed on an Agilent Bioanalyser (Santa Clara, CA, USA), which 
electrophoretically separates samples based on size, applying a microfabricated chip. The 
resulting peak pattern is represented by the RNA integrity number (RIN), which is calculated 
by a built-in algorithm in the Bioanalyser software [7]. The RIN can vary between 1 (totally 
degraded RNA) to 10 (completely intact RNA). Alternatively, the base of the 18s and 28s 
ribosomal RNA peaks can be used to calculate the 28s/18s ratio. Theoretically, intact RNA 
has a ratio of 2.0, but this ratio is known to be tissue-dependent and often lower for tissues 
than e.g. for cultured cells [8]. Based on a combination of the RIN, 28s/18s ratio, and visual 
inspection of the peak pattern (a low baseline and no major additional peaks), the three 
qualitatively best samples were chosen out of the four biological replicates. The samples all 
had a RIN ranging from 5.5-8.0 and a 28s/18s ratio between 0.8 and 1.8. 
RNA processing 
From the isolated total RNA, 1 μg was further processed for microarray analysis. To re-
duce the ribosomal RNA (rRNA) content, the Invitrogen RiboMinus transcriptome isolation 
kit was applied. Removal is based on hybridisation of rRNA with biotinylated rRNA-
sequence specific oligonucleotide probes, and subsequent removal of hybridised rRNA 
using streptavidin-coated magnetic beads. 
The probes on the array are in an anti-sense configuration. Therefore, a labelled single-
stranded sequence in the sense orientation has to be produced from the isolated (sense) 
RNA before hybridisation. This was accomplished using the GeneChip whole transcript (WT) 
sense target labelling assay, which produces labelled single-stranded sense DNA. This DNA 
results in less cross-hybridisation with the DNA probes on the array than labelled RNA, 
which is used for other array types [9]. First, double-stranded complementary DNA (cDNA) 
was synthesised from all RNA molecules. The first strand of this cDNA was synthesised by 
SuperScript II Reverse Transcriptase using T7 promoter-coupled random hexamer oligonu-
cleotide sequences, the second strand using DNA polymerase I without T7-random hexam-
ers. This cDNA was then used for in vitro transcription (IVT) to amplify the product, creating 
complementary RNA (cRNA). This cRNA was then used in a second cycle of cDNA synthe-
sis to create single-stranded DNA in the sense orientation, using random primers and Su-
perScript II Reverse Transcriptase. Of this DNA, 5.5 μg was enzymatically fragmented and 
fluorescently labelled. Pre-labelled hybridisation controls (e.g. bacterial sequences in known 
amounts) were added to the mixture and this was hybridised on an exon array chip. 
A total set of 30 arrays was hybridised in three separate runs. Experimental groups were 
randomised over the different runs, but with a few exceptions (see results section). 
Data processing, quality control and statistical analysis 
The arrays were scanned and converted to a processed image, which was converted to 
one fluorescence intensity value per probe, using Affymetrix GeneChip Operating Software 
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(GCOS). The values of individual probes belonging to one probe set (four probes/set in 90% 
of the cases) were averaged and normalised using Partek Genomics Suite 6.4 (Partek Inc., 
St. Louis, MO, USA, www.partek.com).  
The distribution of the intensity values on the individual arrays was visualised in a signal 
histogram and no obvious outliers were detected. The intensity values of probe sets specific 
for the pre-labelled hybridization controls were analysed and they corresponded with the 
expected values. To check overall data quality, the array contained probe sets for exonic 
(“positive”) and intronic (“negative”) regions of reference genes (genes known to be constitu-
tively expressed in many different samples). Their probe set intensities were used to calcu-
late the difference between the area under the curve of the positive and negative probe sets 
(pos_vs_neg_auc). This value is known to be tissue-specific, but generally varies between 
0.80 and 0.95 for good quality samples, and ranged from 0.81-0.94 for the 30 arrays [10]. 
The average fluorescence intensity of all annotated rat genes (=core dataset, 8,264 
genes at the moment of analysis) was calculated using the Robust Multiarray Analysis 
(RMA) algorithm [11], including a quantile normalisation (all arrays are considered to have 
an equal intensity distribution) and using a background correction for GC-content (probes 
with high GC content hybridise better, corrected for with built-in probes with different known 
GC-contents). 
Analysis of the sources of variation revealed that the hybridisation date (one of the three 
dates the samples were processed) was the main source of variation, a known cause of 
variation, indicating that despite e.g. standard protocols and solutions it is nearly impossible 
to control each variable that may influence RNA processing and hybridisation. Therefore, the 
hybridisation date was included in the subsequent statistical analysis as a covariate.  
To identify differentially expressed genes between the different experimental groups, a 
two-way analysis of variance (ANOVA) was performed for sample group times time point 
(i.e. normal skin, untreated wound or construct-treated day 0, 7, 14, 28 or 112), including 
hybridisation date as a correction factor. The resulting p-values were corrected for multiple-
testing with the Benjamini-Hochberg false discovery rate procedure [12]. To correct for pos-
sible changes in normal skin for the duration of the animal experiment, day 7, 14 and 28 
untreated and construct-treated wound were compared with day 0 normal skin, whereas day 
112 untreated and day 112 construct-treated wound were compared with day 112 normal 
skin. For each comparison between two experimental groups (e.g. construct-treated day 7 
vs. normal skin day 0), the fold-change of every annotated gene, together with their corre-
sponding p-value, was exported to Microsoft Office Excel. 
Gene lists of interest (all >2-fold up/downregulated genes (p<0.05)) were analysed using 
the Database for Annotation, Visualization and Integrated Discovery functional annotation 
tool (DAVID, http://david.abcc.ncifcrf.gov/) with main focus on the enrichment in GO-terms of 
biological processes on level 5 (GOTERM_BP5 chart). Bonferroni multiple testing p<0.05 for 
enrichment p-values was used as a cut-off threshold. As reference list (dubbed the back-
ground), a list of the 8,264 annotated genes on the array was uploaded. See results section 
for more information. 
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 (Immuno-)histological validation 
The findings of the microarray/DAVID analysis were validated (immuno-)histochemically, 
under the assumption that gene expression levels generally correlate with the amount of the 
corresponding protein.  
Samples were either fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) 
for 24 h and embedded in paraffin, or frozen in liquid nitrogen-cooled isopentane and 
mounted in TissueTek (Sakura Finetek, Zoeterwoude, The Netherlands). 
Immunohistochemistry 
Paraffin sections were deparaffinised and boiled for 10 min in 10 mM citrate buffer (pH 
6.0) for antigen retrieval, and incubated with mouse anti-desmin (1:200; Biogenex, San 
Ramon, CA, U.S.A.) or mouse anti-rat CD8 alpha (1:400; clone OX-8) for 16 h at 4ºC. Biotin-
conjugated horse anti-mouse IgG (1:400; Vector Laboratories, Burlingame, CA, USA) was 
used as a secondary antibody. The Vectastain Elite ABC kit (Vector Laboratories) was used 
for signal amplification according to the manufacturer‟s protocol. Bound antibody was visua l-
ised using 3,3'-diaminobenzidine (DAB) and sections were counterstained with haematoxy-
lin. [13] 
Cryosections were incubated with goat anti-human type IV collagen (Southern Biotech-
nology, Birmingham, AL, USA) followed by an Alexa 488-labelled donkey anti-goat IgG anti-
body (Molecular Probes, Eugene, OR, USA), as described [14]. 
TUNEL assay  
Paraffin sections were incubated with terminal deoxynucleotidyl transferase-mediated 
deoxyuridinetriphosphate-biotin nick end labelling (TUNEL) reaction mixture (Roche, Basel, 
Switzerland) according to the manufacturer‟s labelling protocol for “difficult” tissues, which 
included a 1 min boiling step performed in 0.1 M citrate buffer (pH 6.0) for antigen retrieval. 
Results 
RNA isolation  
Frozen samples were processed for RNA isolation. Normal skin and day 112 samples 
were difficult to pulverise in comparison with day 7, 14 and 28 samples, probably due to the 
larger amount of connective tissue present. The amount of total RNA isolated was 30-55 μg 
for day 7 and 14 untreated wounds and day 7, 14 and 28 construct-treated samples, ~20 μg 
for day 28 construct-treated, and 5-10 μg for day 112 untreated and construct-treated 
wounds and all normal skin samples. The size of the samples varied due to contraction 
(smaller samples at later time points), but yield differences were most likely caused by the 
number of cells present in the different samples (higher cell densities at early time points), 
since relatively large normal skin samples also gave low yields. 
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Correlation between biological replicates 
The RNA was processed into labelled DNA fragments and each sample was hybridised 
on an individual exon array. Pictures from the arrays were taken and processed to one fluo-
rescence intensity value per gene by averaging the intensity values of the probe sets be-
longing to one gene. 
To evaluate the variation between the biological replicates in an experimental group and 
to compare the experimental groups with normal skin, the correlation between the arrays 
was examined. Pearson‟s correlation plots were generated, in which the fluorescence inten-
sity of each transcript („gene‟; average intensity of all probe sets belonging to one gene) on 
the first array is plotted against the fluorescence intensity of the same transcript on the sec-
ond array. The linear correlation of these plots was expressed with a Pearson‟s correlation 
coefficient, ranging from 1 (perfect positive correlation, meaning that there is a linear func-
tion that perfectly translates values from one array to the corresponding values on the other 
array) to -1 (perfect negative correlation). In this way, a Pearson‟s correlation coefficient was 
calculated for all combinations of the 30 arrays. Figure 2 shows the average correlation 
between the three biological replicates of each experimental group (three comparisons) and 
the average correlation of each group with normal skin (nine comparisons). 
A high Pearson correlation reflects correlated gene expression levels. The correlation 
between the three biological replicates was 0.91 or higher in all cases. A tendency was 
observed for higher correlation when the three biological replicates were hybridised in the 
same microarray run (untreated wound day 7, 28 and 112). However, the least correlation 
was found for the day 112 normal skin replicates, which was the only group of which the 
biological replicates were processed in one single RNA isolation and microarray hybridisa-
tion run, indicating that other factors probably also influenced this correlation. 
 
 
Figure 2. Average Pearson‟s correlation coefficient values (± S.D.) representing the correlation of three biological 
replicates of each experiment group and the correlation of each group with normal skin (*day 112 untreated and con-
struct-treated wounds were compared with day 112 normal skin). Correlation between the replicates was always higher 
than between an experimental group and normal skin. The day 7 and 14 samples differed most from normal skin, as 
did the construct-treated wounds on day 28. The day 28 untreated wound was more similar to normal skin, as were all 
day 112 samples. 
Differences in gene expression 
The Pearson‟s correlation plots were also used to visualise the differences between the 
experimental groups and normal skin (Fig. 2). As expected, the arrays with untreated and 
construct-treated wound samples showed less correlation with normal skin (0.82-0.87) than 
the correlation between replicates as described before. The correlation with normal skin 
increased in time, likely reflecting the skin regeneration process. On day 28, the correlation 
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with the day 0 normal skin arrays was higher for the untreated than for the construct-treated 
wounds.  
The differences in gene expression between the experimental groups and normal skin 
were analysed with an ANOVA. For every gene, the average intensity on the three arrays of 
an experimental group (e.g. construct-treated day 7) was compared with the average inten-
sity on the three arrays of the normal skin (e.g. normal skin day 0). 
The number of differentially expressed genes with more than 2-fold change (p<0.05) 
compared to normal skin is listed in Table 1. Lists were divided in number of down- and 
upregulated genes. Fold change ranged from the 2-fold cut-off to 232-fold change (matrix 
metalloproteinase 12 upregulation in construct-treated day 28). Generally, the number of 
differentially expressed genes decreased with time (Table 1). The difference on day 28 be-
tween untreated and construct-treated wounds (numbers for untreated wound were already 
dropping while those for the construct-treated were still high) reflect the trends observed in 
the Pearson correlation values of Fig. 2.  
 
Table 1. Number of differentially expressed genes between (A) the construct-treated wounds versus 
normal skin or (B) the untreated wounds versus normal skin (p<0.05; >2-fold change) at various time 
points. Upregulated means higher expression in the wounds, downregulated means higher expression 
in normal skin. (C) Shows the number of genes that are present in both the list of (A) the construct-
treated and (B) untreated wound. 
 
  
(A) Construct-treated vs. normal 
skin (analysed in Table 2A) 
(B) Untreated wound vs. normal 
skin (analysed in Table 2B) 
(C) Shared between (A) con-
struct-treated and (B) untreated 
wounds 
Day 
upregulated downregulated upregulated downregulated upregulated downregulated 
7 550 487 514 468 420 412 
14 656 545 414 408 367 352 
28 600 439 272 334 174 274 
112 299 408 254 360 204 317 
Identification of biological processes: Gene ontology terms and DAVID 
Analysis of each individual differentially expressed gene in the wound healing process is 
time consuming. Since the focus of this study lies on the identification of biological proc-
esses rather than individual genes, gene lists were analysed as a whole. Several (proprie-
tary, downloadable or web-based) applications exist that enable the identification of biologi-
cal processes that are under- or overrepresented in a given gene list, compared to the oc-
currence of these processes in a reference gene list. Most of these applications use gene 
ontology (GO)-terms (http://www.geneontology.org/) for analysis. A GO-term represents a 
certain biological process (e.g. angiogenesis), cellular component (e.g. plasma membrane), 
or molecular function (e.g. kinase activity) [15]. A set of genes associated with a particular 
biological process is labelled to a specific GO-term. GO-terms are assigned by an active 
consortium of database researchers, of which the rat genome database consortium (RGD, 
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http://rgd.mcw.edu/) is responsible for the submission of Rattus norvegicus annotations. GO-
terms are connected with each other in a tree structure with different levels in which a spe-
cific term can have more than one (more general) parent terms. The GO-terms can be 
browsed in AmiGO (http://amigo.geneontology.org) to learn more about their definition, posi-
tion in the tree, etc. [16]. As an example, the biological process GO-term „skin development‟ 
(GO:0043588) is depicted in its tree format (Fig. 3). 
 
 
 
Figure 3. Compact tree view with the different levels (0-7) of the rat biological process GO-term „skin development‟ 
(GO:0043588, in CAPITALS). When a given term is listed for the second time (e.g. GO:0008544 epidermis develop-
ment), then the tree continues as depicted the first time (for clarity visualised in smaller text size only for GO:0008544). 
Figure based on information from the AmiGO website (http://amigo.geneontology.org) [1]. 
 
DAVID is an open web-based tool to facilitate the biological interpretation of large (mi-
croarray) datasets [17,18]. Any gene list of interest can be uploaded in DAVID‟s functional 
annotation tool, and the program compares the gene distribution in this list with the gene 
distribution in a list with reference genes (dubbed “background”). DAVID then calculates the 
GO-terms, protein domains, pathways, etc. (based on default external databases) that are 
overrepresented in the input list (fold enrichment plus corresponding p-value).  
Because this study focuses on the biological processes occurring in the regenerating 
wounds, the gene lists with up- and downregulated genes were analysed for their enrich-
ment in biological process GO-terms (and not cellular component or molecular function) on 
the most specific level available in DAVID (level 5). A generally accepted cut-off of p<0.05 
after multiple testing correction and a >2-fold change was used (Table 1). This cut-off re-
sulted in gene lists with reasonable length (several hundred genes) with respect to the 
length of the reference list (all 8,264 well-annotated genes on the array). Gene lists with too 
little or too many genes (e.g. <100 or >2,000 in this case) may result in less informative GO-
terms and corresponding p-values [18]. Please note that in DAVID the gene lists consist only 
of gene identifiers and that the actual gene-specific fold-change and p-value is not taken into 
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account. This implies that e.g. both a 2- and 100-fold changed gene expression contribute 
equally to the enrichment in GO-terms. Table 2 gives an overview of all enriched level 5 GO-
terms (Bonferroni p<0.05) after DAVID analysis for the construct-treated (Table 2A) and 
untreated wound (Table 2B). Also given is the associated fold enrichment score with respect 
to a random gene list of the same length, as calculated by the DAVID program. This fold 
enrichment is calculated by dividing the percentage of genes with a specific GO-term in the 
up/down regulated list by the percentage genes with the same GO-term in the reference list. 
For example a 5-fold enrichment is obtained when 10% of the genes in the upregulated list 
is associated with the GO-term „angiogenesis‟ versus 2% of the genes in the reference list. 
 
Table 2A. Enrichment in biological process GO-terms (level 5) of the gene lists (numbers in Table 1) 
with up- and downregulated expression in the construct-treated wound versus normal skin (Bonferroni 
p<0.05; day 7, 14 and 28 vs. day 0 normal skin, day 112 vs. day 112 normal skin). Listing is according 
to significance. F.E.=Fold enrichment.  
 
UPREGULATED IN CONSTRUCT 
day 7  day 14 
Term F.E. 
Bon-
ferroni 
 
Term F.E. 
Bon-
ferroni 
GO:0030097~hemopoiesis 4.8 2.7E-14  GO:0048534~hemopoietic or lymphoid 
organ development 
4.6 1.2E-17 
GO:0048534~hemopoietic or lymphoid 
organ development 
4.7 3.9E-14  GO:0030097~hemopoiesis 4.7 3.5E-17 
GO:0006935~chemotaxis 6.3 4.1E-14  GO:0006935~chemotaxis 5.9 1.1E-15 
GO:0030099~myeloid cell differentiation 5.6 1.7E-09  GO:0002521~leukocyte differentiation 5.8 5.5E-14 
GO:0002521~leukocyte differentiation 5.5 2.4E-09  GO:0042110~T cell activation 5.7 1.5E-12 
GO:0050900~leukocyte migration 8.6 3.2E-09  GO:0050900~leukocyte migration 7.5 4.4E-09 
GO:0030595~leukocyte chemotaxis 9.6 3.2E-07  GO:0030099~myeloid cell differentiation 4.8 1.4E-08 
GO:0042110~T cell activation 5.1 4.0E-07  GO:0030098~lymphocyte differentiation 5.8 4.1E-08 
GO:0030593~neutrophil chemotaxis 11.5 4.8E-06  GO:0030595~leukocyte chemotaxis 8.5 1.8E-07 
GO:0042035~regulation of cytokine 
biosynthetic process 
7.4 5.1E-06  GO:0002449~lymphocyte mediated 
immunity 
5.8 3.4E-07 
GO:0019724~B cell mediated immunity 6.6 7.6E-06  GO:0030217~T cell differentiation 7.0 4.3E-07 
GO:0002449~lymphocyte mediated 
immunity 
5.9 1.4E-05  GO:0019724~B cell mediated immunity 6.2 1.1E-06 
GO:0042108~positive regulation of cyto-
kine biosynthetic process 
9.0 2.6E-05  GO:0050776~regulation of immune 
response 
4.0 1.7E-05 
GO:0045727~positive regulation of trans-
lation 
7.3 9.7E-05  GO:0030593~neutrophil chemotaxis 9.6 2.8E-05 
GO:0042107~cytokine metabolic process 6.0 1.1E-04  GO:0042035~regulation of cytokine 
biosynthetic process 
6.1 5.4E-05 
GO:0019221~cytokine and chemokine 
mediated signaling pathway 
6.5 1.4E-04  GO:0008219~cell death 1.9 6.8E-05 
GO:0002573~myeloid leukocyte differen-
tiation 
7.0 1.6E-04  GO:0045727~positive regulation of 
translation 
6.5 7.2E-05 
GO:0006508~proteolysis 2.2 2.0E-04  GO:0051249~regulation of lymphocyte 
activation 
4.9 7.6E-05 
GO:0008219~cell death 2.0 2.1E-04  GO:0002684~positive regulation of 
immune system process 
4.2 9.8E-05 
GO:0050776~regulation of immune re-
sponse 
4.0 5.4E-04  GO:0002573~myeloid leukocyte differ-
entiation 
6.3 1.2E-04 
GO:0030098~lymphocyte differentiation 5.0 5.4E-04  GO:0019221~cytokine and chemokine 
mediated signaling pathway 
5.8 1.4E-04 
GO:0030217~T cell differentiation 6.4 5.7E-04  GO:0051247~positive regulation of 
protein metabolic process 
4.4 2.3E-04 
GO:0051247~positive regulation of protein 
metabolic process 
4.7 6.0E-04  GO:0050778~positive regulation of 
immune response 
4.1 3.1E-04 
GO:0031328~positive regulation of cellular 
biosynthetic process 
6.0 1.2E-03  GO:0050801~ion homeostasis 2.5 4.6E-04 
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GO:0002526~acute inflammatory re-
sponse 
3.8 1.2E-03  GO:0030003~cellular cation homeosta-
sis 
2.8 5.3E-04 
GO:0009891~positive regulation of biosyn-
thetic process 
4.8 2.7E-03  GO:0046651~lymphocyte proliferation 4.8 8.8E-04 
GO:0006915~apoptosis 1.9 2.9E-03  GO:0042107~cytokine metabolic proc-
ess 
5.0 1.0E-03 
GO:0048514~blood vessel morphogenesis 3.1 3.5E-03  GO:0031328~positive regulation of 
cellular biosynthetic process 
5.4 1.2E-03 
GO:0046651~lymphocyte proliferation 5.0 4.2E-03  GO:0006915~apoptosis 1.8 1.4E-03 
GO:0030003~cellular cation homeostasis 2.8 5.2E-03  GO:0055082~cellular chemical homeo-
stasis 
2.5 1.5E-03 
GO:0001944~vasculature development 2.9 5.4E-03  GO:0042098~T cell proliferation 5.7 1.8E-03 
GO:0008285~negative regulation of cell 
proliferation 
2.7 9.1E-03  GO:0042108~positive regulation of 
cytokine biosynthetic process 
6.9 2.2E-03 
GO:0006897~endocytosis 3.1 1.1E-02  GO:0051251~positive regulation of 
lymphocyte activation 
5.5 2.7E-03 
GO:0050801~ion homeostasis 2.5 1.3E-02  GO:0002253~activation of immune 
response 
4.0 4.1E-03 
GO:0001568~blood vessel development 2.8 1.4E-02  GO:0002526~acute inflammatory 
response 
3.4 4.7E-03 
GO:0042098~T cell proliferation 5.8 2.0E-02  GO:0050863~regulation of T cell activa-
tion 
4.7 7.1E-03 
GO:0055082~cellular chemical homeosta-
sis 
2.5 2.0E-02  GO:0006508~proteolysis 1.9 1.0E-02 
GO:0006417~regulation of translation 3.6 3.0E-02  GO:0006417~regulation of translation 3.3 1.9E-02 
GO:0006909~phagocytosis 7.1 3.4E-02  GO:0050864~regulation of B cell activa-
tion 
6.2 2.3E-02 
GO:0001525~angiogenesis 3.1 4.9E-02  GO:0009891~positive regulation of 
biosynthetic process 
4.0 2.3E-02 
    GO:0046968~peptide antigen transport 8.1 3.6E-02 
       day 28  day 112 
Term F.E. 
Bon-
ferroni 
 
Term F.E. 
Bon-
ferroni 
GO:0048534~hemopoietic or lymphoid 
organ development 
5.0 4.1E-19  GO:0001501~skeletal development 3.5 5.8E-03 
GO:0042110~T cell activation 7.0 8.3E-18  GO:0008361~regulation of cell size 3.6 3.4E-02 
GO:0030097~hemopoiesis 5.0 1.1E-17     
GO:0006935~chemotaxis 6.2 9.5E-16     
GO:0002521~leukocyte differentiation 5.7 6.2E-12     
GO:0002449~lymphocyte mediated 
immunity 
6.9 7.4E-10     
GO:0051249~regulation of lymphocyte 
activation 
6.5 3.6E-09     
GO:0030098~lymphocyte differentiation 6.2 9.4E-09     
GO:0030217~T cell differentiation 7.9 9.5E-09     
GO:0019724~B cell mediated immunity 7.1 2.7E-08     
GO:0050863~regulation of T cell activation 6.9 4.8E-08     
GO:0046651~lymphocyte proliferation 6.4 5.6E-08     
GO:0051251~positive regulation of lym-
phocyte activation 
7.3 1.0E-06     
GO:0030099~myeloid cell differentiation 4.4 5.6E-06     
GO:0050776~regulation of immune re-
sponse 
4.2 2.2E-05     
GO:0050900~leukocyte migration 6.4 3.3E-05     
GO:0046968~peptide antigen transport 10.9 5.0E-05     
GO:0019886~antigen processing and 
presentation of exogenous peptide antigen 
via MHC class II 
 14.1   1.4E-04   
GO:0002684~positive regulation of im-
mune system process 
4.3 1.6E-04     
GO:0008219~cell death 1.9 4.3E-04     
GO:0019221~cytokine and chemokine 
mediated signaling pathway 
5.8 4.8E-04     
GO:0050778~positive regulation of im- 4.2 5.2E-04     
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mune response 
GO:0042098~T cell proliferation 6.1 7.9E-04     
GO:0042113~B cell activation 5.2 2.2E-03     
GO:0030595~leukocyte chemotaxis 6.8 3.1E-03     
GO:0030003~cellular cation homeostasis 2.7 3.8E-03     
GO:0006915~apoptosis 1.8 4.5E-03     
GO:0045576~mast cell activation 8.5 5.3E-03     
GO:0043067~regulation of programmed 
cell death 
1.9 5.8E-03     
GO:0042981~regulation of apoptosis 1.9 7.6E-03     
GO:0002253~activation of immune re-
sponse 
4.1 8.2E-03     
GO:0006508~proteolysis 1.9 1.2E-02     
GO:0043065~positive regulation of apop-
tosis 
2.5 1.3E-02     
GO:0051247~positive regulation of protein 
metabolic process 
4.0 1.3E-02     
GO:0043068~positive regulation of pro-
grammed cell death 
2.4 1.4E-02     
GO:0016310~phosphorylation 1.9 1.6E-02     
GO:0006897~endocytosis 2.9 1.6E-02     
GO:0006664~glycolipid metabolic process 7.5 1.8E-02     
GO:0050670~regulation of lymphocyte 
proliferation 
5.4 3.6E-02     
GO:0032944~regulation of mononuclear 
cell proliferation 
5.4 3.6E-02     
GO:0002768~immune response-regulating 
cell surface receptor signaling pathway 
  8.1     4.0E-02 
GO:0002757~immune response-activating 
signal transduction 
8.1 4.0E-02     
GO:0050851~antigen receptor-mediated 
signaling pathway 
8.1 4.0E-02     
GO:0045619~regulation of lymphocyte 
differentiation 
6.7 4.8E-02     
       
DOWNREGULATED IN CONSTRUCT 
day 7  day 14 
Term F.E. 
Bon-
ferroni 
 
Term F.E. 
Bon-
ferroni 
GO:0006941~striated muscle contraction 11.3 3.7E-09  GO:0006941~striated muscle contrac-
tion 
11.1 4.5E-10 
GO:0032787~monocarboxylic acid meta-
bolic process 
3.5 8.0E-09  GO:0032787~monocarboxylic acid 
metabolic process 
3.4 1.6E-09 
GO:0006631~fatty acid metabolic process 3.5 1.9E-05  GO:0019318~hexose metabolic process 3.7 6.6E-06 
GO:0016126~sterol biosynthetic process 8.1 3.1E-05  GO:0005996~monosaccharide meta-
bolic process 
3.7 8.1E-06 
GO:0008610~lipid biosynthetic process 3.1 6.6E-05  GO:0006631~fatty acid metabolic 
process 
3.3 3.0E-05 
GO:0019318~hexose metabolic process 3.6 1.1E-04  GO:0007517~muscle development 3.7 6.7E-05 
GO:0005996~monosaccharide metabolic 
process 
3.6 1.3E-04  GO:0016126~sterol biosynthetic proc-
ess 
7.4 8.0E-05 
GO:0007517~muscle development 3.7 2.9E-04  GO:0014706~striated muscle develop-
ment 
4.1 1.9E-03 
GO:0006084~acetyl-CoA metabolic 
process 
6.7 1.3E-03  GO:0046365~monosaccharide catabolic 
process 
4.7 1.0E-02 
GO:0014706~striated muscle develop-
ment 
4.0 1.6E-02  GO:0008610~lipid biosynthetic process 2.5 1.5E-02 
    GO:0006084~acetyl-CoA metabolic 
process 
5.7 2.4E-02 
       day 28  day 112 
Term F.E. 
Bon-
ferroni 
 
Term F.E. 
Bon-
ferroni 
GO:0006941~striated muscle contraction 13.1 3.8E-11  GO:0006941~striated muscle contrac-
tion 
11.6 2.6E-07 
GO:0007517~muscle development 4.7 7.1E-08  GO:0046365~monosaccharide catabolic 6.4 7.3E-05 
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process 
GO:0014706~striated muscle develop-
ment 
5.4 3.9E-06  GO:0019318~hexose metabolic process 3.9 1.1E-04 
GO:0019318~hexose metabolic process 3.9 2.3E-05  GO:0005996~monosaccharide meta-
bolic process 
3.9 1.3E-04 
GO:0005996~monosaccharide metabolic 
process 
3.9 2.8E-05  GO:0007517~muscle development 4.0 3.8E-04 
GO:0046365~monosaccharide catabolic 
process 
5.5 1.6E-03  GO:0044275~cellular carbohydrate 
catabolic process 
5.2 4.6E-04 
GO:0006084~acetyl-CoA metabolic 
process 
6.7 5.4E-03  GO:0006099~tricarboxylic acid cycle 10.9 1.0E-03 
GO:0044275~cellular carbohydrate cata-
bolic process 
4.5 7.9E-03  GO:0009109~coenzyme catabolic 
process 
10.3 1.8E-03 
GO:0032787~monocarboxylic acid meta-
bolic process 
2.6 2.1E-02  GO:0006084~acetyl-CoA metabolic 
process 
7.3 2.5E-03 
    GO:0009060~aerobic respiration 9.2 4.7E-03 
    GO:0014706~striated muscle develop-
ment 
4.4 1.1E-02 
    GO:0032787~monocarboxylic acid 
metabolic process 
2.7 1.3E-02 
 
Table 2B. Enrichment in biological process GO-terms (level 5) of the gene lists (numbers in Table 1) 
with up- and downregulated expression in the untreated wound versus normal skin (Bonferroni p<0.05; 
day 7, 14 and 28 vs. day 0 normal skin, day 112 vs. day 112 normal skin). Listing is according to signi-
ficance. F.E.=Fold enrichment.  
 
UPREGULATED IN UNTREATED WOUND 
day 7  day 14 
Term F.E. 
Bon-
ferroni 
 
Term F.E. 
Bon-
ferroni 
GO:0042110~T cell activation 5.6 6.6E-08  GO:0006935~chemotaxis 6.7 4.0E-11 
GO:0030097~hemopoiesis 4.0 1.3E-07  GO:0030097~hemopoiesis 4.6 8.3E-09 
GO:0048514~blood vessel morphogenesis 
4.1 3.0E-07 
 GO:0048534~hemopoietic or lymphoid 
organ development 4.4 3.9E-08 
GO:0048534~hemopoietic or lymphoid 
organ development 3.8 5.9E-07 
 GO:0042110~T cell activation 
6.1 1.5E-07 
GO:0001944~vasculature development 3.8 7.1E-07  GO:0050900~leukocyte migration 9.3 2.4E-07 
GO:0006935~chemotaxis 4.9 8.9E-07  GO:0030595~leukocyte chemotaxis 11.6 2.6E-07 
GO:0002521~leukocyte differentiation 5.1 1.2E-06  GO:0002521~leukocyte differentiation 5.8 3.5E-07 
GO:0019724~B cell mediated immunity 7.2 2.1E-06  GO:0030593~neutrophil chemotaxis 13.7 1.2E-05 
GO:0001568~blood vessel development 3.7 2.3E-06  GO:0030098~lymphocyte differentiation 6.2 1.3E-04 
GO:0002449~lymphocyte mediated 
immunity 6.5 3.6E-06 
 GO:0002449~lymphocyte mediated 
immunity 6.4 2.6E-04 
GO:0050776~regulation of immune re-
sponse 4.6 2.2E-05 
 GO:0019724~B cell mediated immunity 
7.0 2.7E-04 
GO:0001525~angiogenesis 
4.2 3.0E-05 
 GO:0050776~regulation of immune 
response 4.7 2.8E-04 
GO:0009887~organ morphogenesis 2.6 1.3E-04  GO:0030217~T cell differentiation 7.7 3.4E-04 
GO:0042035~regulation of cytokine 
biosynthetic process 7.0 2.1E-04 
 GO:0042035~regulation of cytokine 
biosynthetic process 7.7 3.4E-04 
GO:0002526~acute inflammatory re-
sponse 4.2 3.0E-04 
 GO:0030099~myeloid cell differentiation 
4.8 6.1E-04 
GO:0050900~leukocyte migration 6.8 3.1E-04  GO:0042107~cytokine metabolic process 6.3 3.3E-03 
GO:0019221~cytokine and chemokine 
mediated signaling pathway 6.6 4.6E-04 
 GO:0006909~phagocytosis 
9.2 4.7E-03 
GO:0030098~lymphocyte differentiation 
5.2 1.2E-03 
 GO:0019221~cytokine and chemokine 
mediated signaling pathway 6.6 6.5E-03 
GO:0030099~myeloid cell differentiation 
4.2 1.3E-03 
 GO:0042108~positive regulation of 
cytokine biosynthetic process 8.8 7.3E-03 
GO:0002684~positive regulation of im-
mune system process 4.4 1.5E-03 
 GO:0002684~positive regulation of 
immune system process 4.4 2.8E-02 
GO:0030217~T cell differentiation 
6.5 2.0E-03 
 GO:0044254~multicellular organismal 
protein catabolic process 15.4 2.8E-02 
GO:0042108~positive regulation of cyto- 8.2 2.3E-03  GO:0030574~collagen catabolic process 15.4 2.8E-02 
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kine biosynthetic process 
GO:0042107~cytokine metabolic process 
5.7 2.5E-03 
 GO:0051247~positive regulation of 
protein metabolic process 4.7 3.0E-02 
GO:0050778~positive regulation of im-
mune response 4.3 5.4E-03 
 GO:0008361~regulation of cell size 
3.2 3.1E-02 
GO:0030595~leukocyte chemotaxis 
7.5 5.8E-03 
 GO:0048514~blood vessel morphogene-
sis 3.2 4.0E-02 
GO:0006508~proteolysis 2.1 7.6E-03   
  GO:0006958~complement activation, 
classical pathway 9.2 2.0E-02 
  
  GO:0030593~neutrophil chemotaxis 9.2 2.0E-02   
  GO:0002253~activation of immune re-
sponse 4.4 2.3E-02 
  
  GO:0051247~positive regulation of protein 
metabolic process 4.2 3.5E-02 
  
  GO:0030003~cellular cation homeostasis 2.7 3.5E-02   
  GO:0006897~endocytosis 3.1 3.6E-02   
  GO:0045727~positive regulation of trans-
lation 6.1 3.8E-02 
  
         day 28  day 112 
Term 
F.E. 
Bon-
ferroni 
 Term 
F.E. 
Bon-
ferroni 
GO:0000902~cell morphogenesis 2.7 7.8E-03  GO:0001501~skeletal development 4.0 1.7E-03 
GO:0001501~skeletal development 3.6 1.7E-02  GO:0000902~cell morphogenesis 2.8 2.6E-03 
GO:0001944~vasculature development 3.7 2.2E-02  GO:0001944~vasculature development 3.7 4.6E-02 
       DOWNREGULATED IN UNTREATED WOUND 
day 7  day 14 
Term 
F.E. 
Bon-
ferroni 
 Term 
F.E. 
Bon-
ferroni 
GO:0032787~monocarboxylic acid meta-
bolic process 5.2 4.4E-14 
 GO:0006941~striated muscle contraction 
14.3 1.0E-11 
GO:0006941~striated muscle contraction 
14.2 1.1E-09 
 GO:0032787~monocarboxylic acid 
metabolic process 3.9 7.6E-10 
GO:0006631~fatty acid metabolic process 
5.1 3.0E-08 
 GO:0006084~acetyl-CoA metabolic 
process 10.0 8.1E-08 
GO:0016126~sterol biosynthetic process 13.5 1.3E-07  GO:0019318~hexose metabolic process 4.6 1.2E-07 
GO:0006084~acetyl-CoA metabolic 
process 11.3 2.6E-07 
 GO:0005996~monosaccharide metabolic 
process 4.6 1.5E-07 
GO:0008610~lipid biosynthetic process 4.0 3.3E-07  GO:0007517~muscle development 4.4 1.4E-05 
GO:0019318~hexose metabolic process 4.6 4.4E-07  GO:0006099~tricarboxylic acid cycle 12.1 5.0E-05 
GO:0005996~monosaccharide metabolic 
process 4.5 6.2E-07 
 GO:0009109~coenzyme catabolic 
process 11.4 9.6E-05 
GO:0007517~muscle development 4.6 1.1E-05  GO:0009060~aerobic respiration 10.3 3.0E-04 
GO:0006694~steroid biosynthetic process 
6.4 1.7E-04 
 GO:0014706~striated muscle develop-
ment 5.0 3.2E-04 
GO:0014706~striated muscle develop-
ment 5.4 5.5E-04 
 GO:0044275~cellular carbohydrate 
catabolic process 5.2 4.4E-04 
GO:0016125~sterol metabolic process 
5.8 1.7E-03 
 GO:0046365~monosaccharide catabolic 
process 6.0 5.8E-04 
GO:0046365~monosaccharide catabolic 
process 4.7 6.9E-03 
 GO:0006631~fatty acid metabolic proc-
ess 3.3 3.2E-03 
GO:0006099~tricarboxylic acid cycle 10.8 1.4E-02   
  GO:0008203~cholesterol metabolic proc-
ess 5.4 2.8E-02 
  
  GO:0044275~cellular carbohydrate cata-
bolic process 3.9 3.0E-02 
  
  GO:0009109~coenzyme catabolic process 9.2 4.1E-02   
         day 28  day 112 
Term 
F.E. 
Bon-
ferroni 
 Term 
F.E. 
Bon-
ferroni 
GO:0006941~striated muscle contraction 15.0 1.0E-09  GO:0006941~striated muscle contraction 15.6 4.5E-11 
GO:0046365~monosaccharide catabolic 
process 8.7 5.1E-08 
 GO:0007517~muscle development 
4.6 3.0E-05 
GO:0006084~acetyl-CoA metabolic 11.1 1.4E-07  GO:0019318~hexose metabolic process 4.2 1.9E-04 
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process 
GO:0006099~tricarboxylic acid cycle 
15.9 3.3E-07 
 GO:0005996~monosaccharide metabolic 
process 4.1 2.2E-04 
GO:0044275~cellular carbohydrate cata-
bolic process 7.0 5.3E-07 
 GO:0046365~monosaccharide catabolic 
process 6.5 8.8E-04 
GO:0019318~hexose metabolic process 
4.9 6.2E-07 
 GO:0014706~striated muscle develop-
ment 5.1 1.8E-03 
GO:0009109~coenzyme catabolic process 
15.0 7.3E-07 
 GO:0044275~cellular carbohydrate 
catabolic process 5.3 3.1E-03 
GO:0005996~monosaccharide metabolic 
process 4.9 7.4E-07 
  
  GO:0009060~aerobic respiration 13.5 2.9E-06   
  GO:0007517~muscle development 5.0 2.9E-06   
  GO:0014706~striated muscle develop-
ment 5.6 1.9E-04 
  
  GO:0042775~organelle ATP synthesis 
coupled electron transport 17.2 1.7E-03 
  
  GO:0032787~monocarboxylic acid meta-
bolic process 3.0 5.3E-03 
  
  GO:0006100~tricarboxylic acid cycle 
intermediate metabolic process 11.5 3.3E-02 
  
   
To facilitate the interpretation of the lists with enriched GO-terms, the individual terms 
can be divided into a number of user (self)-defined major categories. For example, the en-
riched GO-terms in the construct-treated wounds at day 7 could be grouped into three major 
categories: inflammation, apoptosis and angiogenesis (Table 2A). The majority of the GO-
terms is related to inflammation. For example, terms like „T cell activation‟, „B cell mediated 
immunity‟ and „acute inflammatory response‟ are clearly inflammation-related. Please note 
that also terms like „hemopoiesis‟ and „hemopoietic and lymphoid organ development‟ de-
scribe processes that include the maturation and activation of e.g. macrophages and granu-
locytes. The second category comprises the closely-related terms „cell death‟, „apoptosis‟ 
and „negative regulation of cell proliferation‟. The third major category consists of GO-terms 
related to blood vessel formation viz.: „blood vessel morphogenesis‟, „vasculature develop-
ment‟, „blood vessel development‟, and „angiogenesis‟. At day 14 and 28, the terms for the 
construct-treated wounds still contained inflammation- and apoptosis-related terms, but 
lacked those for angiogenesis. At day 112, „skeletal development‟ and „regulation of cell 
size‟ were the two remaining terms. The untreated wound at day 7 and 14 also contained 
inflammation- and angiogenesis-related terms, but lacked those related to apoptosis (Table 
2B). At day 28 and 112, „cell morphogenesis‟, „skeletal development‟, and „vasculature de-
velopment‟ were the three remaining terms. 
The lists with downregulated genes for both construct-treated and untreated wounds 
were enriched for the muscle-related terms „striated muscle contraction‟ (GO:0006941) and 
„(striated) muscle development‟ (GO:0007517/GO:0014706) on all time points examined 
(Table 2A and 2B). The remaining terms are closely linked to cellular metabolism, highly 
active in muscle cells, and lipid production.   
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(Immuno)histological validation 
To validate the results of the microarray-DAVID approach, a number of the up or down-
regulated biological processes were evaluated (immuno)histologically. 
The downregulated GO terms “muscle development”, “striated muscle development” and 
“striated muscle contractions” observed in both construct-treated and untreated tissue hint to 
a lack of skeletal muscles. Desmin staining was used for evaluation, since this is a muscle-
specific protein and one of the genes associated with the GO-term „muscle development‟ 
(GO:0007517), (Fig. 4). Indeed, tissue sections of day 112 untreated and construct-treated 
wounds (which had the longest time to potentially develop new muscle tissue) were negative 
in contrast to the strong staining of the subcutaneous panniculus carnosus muscle layer 
present in normal rat skin.  
Similar observations were made for the subcutaneous fat layer that did not regenerate in 
time after wounding, likely explaining the downregulated GO-terms related to lipid produc-
tion. 
 
 
 
Figure 4. Immunostaining for muscle-specific desmin (A-C) and its gene expression indicated as microarray 
fluorescence intensities (D). In day 112 untreated (A) and construct-treated (B) wounds, no staining was visible, while a 
clear brown-stained muscle layer (the panniculus carnosis) was visible in normal skin (C). Bar is 100 µm. Desmin gene 
expression (in log2 fluorescence intensity) showed lower expression in construct-treated and untreated wounds than 
normal skin on all time-points examined (D).  
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Cluster of differentiation 8 alpha (CD8 alpha) is one of the genes associated with im-
mune response related GO-terms like „T cell activation‟ (GO:0042110). CD8 alpha is the 
subunit of the T-cell receptor co-receptor and an established marker for immune reaction in 
tissues. Therefore, it was used to validate the enrichment for immune response-related 
terms in the upregulated gene lists of the early untreated and construct-treated wounds (Fig. 
5). Staining for CD8 alpha showed many positive cells on early time points and few at day 
112 and in normal skin, confirming the microarray/DAVID analysis. 
 
 
Figure 5. Immunostaining of tissue sections using an anti-CD8 alpha antibody to visualise the presence of immune 
cells (A-E), and its gene expression given as microarray fluorescence intensity (F). At day 7, both the untreated and 
construct-treated wounds contained numerous CD8 positive cells (A-B). Fewer CD8 positive cells were found at day 
112 (C-D). Normal skin also showed some CD8 positive cells (E). Bar is 100 µm. 
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The presence of apoptosis-related terms in the upregultated gene lists of the early 
construct-treated wounds (and not the untreated) was validated using a TUNEL assay, 
which visualises fragmented DNA. Indeed, at day 7, staining was more abundant in the 
construct-treated wounds directly under the crust (Fig. 6). This staining corresponded with 
the areas where granulocytes were most abundant. At day 112 and in normal skin 
considerable less staining was found. 
 
 
 
Figure 6. Tissue sections stained using the TUNEL assay to detect fragmented DNA as a marker for apoptosis. At day 
7, the area directly under the crust of the construct-treated wounds stained heavily, while staining in the untreated 
wounds was less and more dispersed. At day 112 and in normal skin, staining was also dispersed and less abundant. 
 
Type IV collagen is one of the proteins present in the basement membranes in skin, in-
cluding that of blood vessels. Therefore, staining for type IV collagen was used as a method 
to visualise angiogenesis in the regenerating wounds (Fig. 7). At day 7 and 14, a large num-
ber of blood vessels was observed in both the untreated and construct-treated wounds. At 
later time points, this diminished to normal skin levels, except for the construct-treated 
wounds at day 28, which still had a large number of blood vessels. The microarray/DAVID 
analysis of upregulated gene lists, shows enrichment of angiogenesis- and blood vessel-
related GO-terms for the untreated wounds on all time points examined, while for the con-
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struct-treated wounds these terms were only present at day 7. This apparent discrepancy 
may be explained by accelerated blood vessel maturation using growth factor- containing 
scaffolds, as observed earlier [19], and indicating that the processes of blood vessel forma-
tion/development are diminished at an earlier time point compared to untreated wounds. 
Type IV collagen staining visualises both newly formed blood vessels as well as those al-
ready fully developed. 
 
 
 
Figure 7. Tissue sections stained with an anti-type IV collagen antibody to visualise blood vessels (A-I) At day 7 and 
14, blood vessels were abundantly present in the untreated and construct-treated wounds (A-B and F-G). This 
diminished to normal skin levels at later time-points (C-D and I), except for the construct-treated wounds at day 28 (H), 
which still contained many blood vessels. In normal skin, the basal lamina of appendages stained intensely and few 
blood vessels were present (E). Epidermal side on top, bar is 100 µm. 
Discussion 
Using gene expression microarrays, we identified biological processes occurring in rat 
full-thickness wounds treated with a collagen-based construct, or left untreated. Lists of 
genes differentially expressed in comparison to normal skin were analysed in the context of 
biological process GO-terms. By using relatively stringent thresholds (p<0.05, >2-fold 
change for gene lists and Bonferroni p<0.05 for enriched terms), the most significantly 
up/down regulated biological processes compared to normal skin were identified viz.: in-
crease in inflammatory response and angiogenesis, lack of skeletal muscle and adipocyte 
(formation), and an increase in apoptosis in the construct-treated wounds at early time-
points. Processes were validated by immunohistochemistry, indicating the usefulness of 
microarrays.  
We focussed on general processes rather than individual genes, although the latter en-
ables the identification of novel players involved in wound healing and may provide a wealth 
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of information with regard to specific pathways. The use of microarrays/GO analysis allows 
automation and high-throughput analysis of tissue engineered constructs. A number of steps 
involved (Fig.1) can be automated including the hybridisation and scanning of the microar-
rays, and the computational analysis. As costs for microarrays are dropping, it becomes 
appealing to evaluate the complex processes associated with the body‟s response to tissue 
engineered constructs using comprehensive microarrays and GO terms. An alternative ap-
proach to analyse processes at the mRNA level is by quantitative real-time PCR (qRT-PCR). 
This technique has been rapidly adopted by the field of tissue engineering to evaluate in 
vitro and in vivo experiments [20,21]. It is a reliable method to study gene expression, but 
only a small number of genes can be analysed. Methods are being developed to perform 
qRT-PCR on a more high-throughput scale, but evaluation is still limited to a subset of 
genes of interest [22].  
Although analysis of the performance of tissue engineered constructs by microarrays 
and gene ontology software is appealing, the technology is still in its infancy, and a number 
of cautionary notes should be given. In this study we used rat, an organism widely used in 
tissue engineering. For rat, however, the number of genes assessed in the microarray core 
dataset is relatively small in comparison to human and mouse. Only 8,264 of the total num-
ber of ~21,000 predicted rat genes are included [23]. This in contrast to e.g. the human exon 
arrays, where ~18,000 of max. 25,000 predicted genes are available in the core dataset [24]. 
Therefore, in case of rat, the DAVID analysis is not optimal, and will become better when 
gene annotation and addition to the core dataset proceeds. For instance, and focussing on 
epidermal regeneration, important genes involved in epidermal maintenance (e.g. filaggrin, 
loricrin, some of the late cornified envelope genes, and transglutaminase 3) were not pre-
sent on the exon array core dataset and could therefore not contribute to GO-enrichment of 
epidermis-related terms. However, probesets for these genes are present on the full array, 
so when annotation of these genes proceeds, inclusion in the core dataset will be possible. 
A number of GO terms are not yet well defined, and there is a need for firm assignment 
of a set of genes associated with processes in the context of specific organs. For instance, 
using the microarray/DAVID approach the GO term „skeletal development‟ (GO:0001501) 
was indicated as an enriched biological process in the late untreated and construct-treated 
wounds. Skeletal development is not a likely process in regenerating skin and a Von Kossa 
staining for calcification was negative in day 112 skin samples (data not shown). „Skeletal 
development‟ has 302 associated genes and most of them are known to play a role in skin 
development and/or remodeling (e.g. types I and III collagen, fibronectin-1, fibrillin-1, fibro-
blast growth factor receptor 1 [25], and cathepsin K [26]). Obviously, the upregulation of the 
expression of genes associated with „skeletal development‟ have a different meaning in the 
context of skin versus e.g. the context of bone. In general, a large number of proteins in-
volved in skin development are also present in bone development and homeostasis [27]. For 
instance, Klingenberg et al. addressing gene expression profiles of in vitro cultured human 
skin substitutes in athymic mice, found gene expression previously known to be associated 
with cartilage and bone (cartilage intermediate layer protein, periostin, and osteoglycin) in 
their microarray analysis of cultured skin substitutes, and proved immunohistochemically 
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that they were actually present in (engineered) skin [28]. As more gene expression data 
becomes available on skin development, the GO-terms will become more suitable for organ 
specific analysis. In this respect, skin researchers may actively update GO-terms and their 
gene association, as did e.g. the muscle research community when (re)defining their GO-
terms of interest [29].  
The microarray approach should be regarded as complementary to other methodologies 
like histology. Regenerating skin is a highly heterogeneous tissue containing different cell 
types and structures, depending on the stage of regeneration. For instance, immune re-
sponses are major processes occurring shortly after implantation. Processes may go unno-
ticed if upregulation in one area of the specimen compensates for the downregulation of the 
same process in another area.  
Since GO-terms are still in development, some terms do not yet contain all genes that 
are known to be involved in that specific process. For example, the GO-term „elastic fiber 
assembly‟ (GO:0048251) contains only four genes, viz: elastin, lysyl oxidase, Cu++ trans-
porting ATPase alpha polypeptide, and smooth muscle myosin heavy chain 11. A review of 
Kielty et al. lists 31 additional genes that code for structural and associated molecules of 
microfibrils and elastic fibres [30]. When we used this list to search for rat orthologs, 14 were 
found to be present in the analysed microarray core dataset, i.e. were well-annotated (Table 
3). To calculate a fold enrichment, the number of these elastin-related genes in the >2-fold 
upregulated (p<0.05) lists was divided by the number of genes that was expected when a 
random gene list of the same length would have been analysed. This approach, with more 
elastin-related genes analysed, did not per se change the absolute fold enrichment values, 
e.g. at day 112 still approximately half of the genes assessed is present (elastin and lysyl 
oxidase of the four genes in the original GO-term and 9/17 genes in the updated term), but 
the increase in the number of genes in this GO-term would in this case result in a decrease 
in associated p-value. In that case, it would be an increase in probability that the GO-term 
„elastic fiber assembly‟ was identified as an upregulated biological process with the microar-
ray/DAVID approach. 
In this respect it is encouraged that the tissue engineering/regenerative medicine society 
actively participates in the development and update of relevant GO-terms like angiogenesis, 
inflammatory and foreign body response, etc.. Each individual organ will require its own 
unique GO-terms, but once established the microarray/DAVID approach may be broadly 
applied to analyse the in vivo outcome and effectiveness of tissue-engineered constructs.  
The future availability of more sophisticated options in analysis programs, the evolution 
of gene annotation and GO-terms, and other (new) techniques like RNA-sequencing may 
further improve the bioinformatics approach to analyse biological processes in tissue-
engineered constructs [31]. This may also contribute to a better understanding of the effect 
of specific scaffold modifications on the tissue regeneration process. Eventually, these in-
sights may help us to improve tissue-engineered constructs for optimal performance in re-
generative medicine.  
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Table 3. Elastic-fibre associated rat genes, based on Kielty et al. [2], and fold enrichment for this group 
of genes calculated based on their presence () in the (>2-fold) upregulated gene lists (p<0.05) vs. 
normal skin. See Discussion for more information.  
U=Untreated wound, C=Construct. 
 
 day 7 day 14 day 28 day 112 
U C U C U C U C 
amyloid beta (A4) precursor protein         
ATPase, Cu++ transporting, alpha polypeptide         
decorin         
latent transforming growth factor beta binding 
protein 2 
        
microfibrillar-associated protein 3         
microfibrillar-associated protein 3-like         
vitronectin         
latent transforming growth factor beta binding 
protein 1 
        
fibulin 5         
collagen, type XVI, alpha 1         
biglycan         
tenascin C         
versican         
lysyl oxidase-like 1         
elastin         
fibrillin 1         
lysyl oxidase         
Total # of genes in >2-fold upregulated list (p<0.05) 514 550 414 656 272 600 254 299 
Expected # of hits with random gene distribution 
[E] 
1.1 1.1 0.9 1.4 0.6 1.2 0.5 0.6 
Actual # of elastin-related genes present in list [P] 7 4 6 5 9 5 9 9 
Fold enrichment ([P]/[E]) 6.6 3.5 7.0 3.7 16.1 4.0 17.2 14.6 
Conclusion 
Gene expression microarrays and gene ontology analysis were used to identify biological 
processes occurring in vivo after implanting of an acellular skin construct. Identified proc-
esses were confirmed with conventional (immuno)histology. Microarrays provide fast and 
unbiased tools to evaluate the performance of tissue-engineered constructs, and holds 
promise for automated high throughput analysis. However, a number of challenges remain, 
especially with respect to the development of specific GO-terms and annotation of the rat 
genome. 
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Abstract 
Tissue-engineered constructs are used to stimulate skin regeneration after wounding, 
but improvements are warranted in epithelialisation and dermis formation. At the boundary 
of epidermis and dermis, a specific rete-ridge/dermal papillae structure is present, which is 
generally lacking in regenerated skin. Dermal papillae supply the epidermis with oxygen and 
nutrients, tighten the dermal-epidermal junction and may form specific cellular niches. In this 
study we constructed and evaluated a papillary-structured collagen fibril membrane mimick-
ing the 3D-architecture of the human papillary dermis, thus templating rete-ridge architec-
ture. A polydimethylsiloxane mould containing cone-shaped structures with a depth of 100 
µm and a diameter of 175 µm was fabricated, and papillary-structured collagen membranes 
were prepared using a suspension of type I collagen fibrils. The effect of the papillar struc-
tures on cellular behaviour was evaluated by comparison of primary human keratinocytes 
cultured to confluency on papillary membranes and on flat membranes. Microscopical 
evaluation revealed the presence of morphologically distinct keratinocytes at the base of the 
papillar structures, not observed on flat membranes. Gene expression microarrays and RT-
qPCR indicated that these cells were in a more proliferative/migrational state in comparison 
to keratinocytes cultured on flat membranes which had a more differentiated gene expres-
sion profile. Immunohistochemical stainings confirmed these results, and also indicated that 
keratinocytes on the top of the papillary structures expressed fibrillin 2. In conclusion, spe-
cific collagen architecture can direct keratinocyte behaviour, and this may be used to further 
improve skin regeneration. 
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Introduction 
The healing of large full-thickness wounds and deep burns often results in contraction 
and scar tissue formation [1]. To guide and improve the wound healing process, tissue-
engineered skin constructs based on natural and synthetic biomaterials have been devel-
oped [2,3]. Results of treatment with these constructs are promising, but not optimal and 
there is still space for improvement. For example, regeneration of the characteristic rete 
ridge morphology of the dermal-epidermal-junction may result in better skin regeneration 
(Fig. 1).  
 
 
 
Figure 1. (A) The dermal-epidermal junction of normal porcine skin showing rete ridges and dermal papillae (arrows) 
on microscopic sections. (B) These structures are not observed in regenerated skin (in this example 55 days after 
treatment with a porous collagen scaffold). Bar is 100 µm. 
 
Rete ridges are thickenings of the epidermis that extend downwards between the dermal 
papillae. The papillae provide epidermal cells with oxygen and nutrients, and reinforce the 
attachment of the epidermis to the dermis. In addition, several studies have indicated that 
defined locations in rete ridges serve as potential niches for epidermal stem cells [4,5]. 
These locations may provide a specific microenvironment that is required for stem cell sur-
vival. However, the proposed relationship between rete ridge location and cellular 
„stemness‟ remains controversial [6-8]. 
Microstructured biomaterials may be used to stimulate the formation of epidermal rete 
ridges and dermal papillae. In addition, the availability of papillary-structured membranes 
may facilitate fundamental research to the relationship between keratinocyte niche and func-
tion. Cells including keratinocytes have been evaluated on three-dimensional microstruc-
tured surfaces, including grooved membranes composed of natural collagen and glycosami-
noglycans [9,10]. However, the latter study used parallel grooves, which are technically less 
complex to produce than more natural rounded structures. In one study, polydimethylsilox-
ane pillars were coated with fibronectin and it was found that the interspace distance deter-
mined keratin 1 expression in cultured keratinocytes [11].  
In this study, a microstructured collagen membrane was constructed and evaluated, 
mimicking the natural 3D-architecture of the papillary dermis of human skin [12]. The in vitro 
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response of primary human keratinocytes to this papillary-structured membrane was studied 
using high density gene expression microarrays, quantitative PCR, electron micro-scopy and 
(immuno)cytochemistry. This study is unique in its use of a combination of natural materials 
and dimensions, and the comprehensive analysis of the biological effects. 
Materials and Methods 
Design and construction of the papillary-structured mould 
A papillary-structured mould was designed, implementing dimensions extracted from a 
published in vivo analysis of human skin using near-infrared confocal microscopy (Fig. 2) 
[12]. Dimensions of the inner forearm dermal papilla were deduced from histological pictures 
and quantitative data presented in this publication and a mould was designed to produce 
collagen membranes containing cones (microstructures) of 100 µm height and 175 µm width 
at the base, and an intercone distance of ~165 µm.  
The collagen mould is made from a polydimethylsiloxane (PDMS) structure. The genera-
tion of PDMS masters as moulds of a microstructured polycarbonate master is a typical work 
flow in the manufacturing of microfluidic systems or microstructured foils and thin films [13]. 
For master fabrication, a Ø 115 mm and 4 mm thick polycarbonate disk was machined using 
a Minitech Mini-Mill 3PRO 3-Axis CNC milling machine (Norcross, GA, USA) and a 15° V-
shaped engraving bit with 100 µm tip width to remove all material except the intended 
cones. A spindle turning speed of 50,000 rpm and a feed rate of 600 mm/min was applied. 
Vertical and horizontal milling paths were constructed in a defined pattern using Autodesk 
AutoCAD 2007. 
The PDMS moulding was realised as casted resin by moulding an addition-curing two 
component PDMS (Elastosil RT 607, Wacker, Munich, Germany) from the polycarbonate 
master in a brass form of an hot embossing machine (Schmidt Technology, Cranberry Twp., 
PA, USA). Elastosil components A and B were mixed at a 9:1 ratio (w/w) at room tempera-
ture. The mixture was degassed in a desiccator and then poured onto the polycarbonate 
master in the brass form. The form was put into the hot embossing machine and pressed for 
30 min under vacuum at 80°C to solidify. After demoulding, the PDMS was washed with 
100% ethanol. The final template for the construction of papillary-structured collagen mem-
branes was thus a 12 mm x 12 mm PDMS mould containing slightly sloped, cone shaped 
holes of 175 µm width and 100 µm depth, with an in between distance of 165 µm (fig. 2 C 
and D).  
Production of papillary-structured and flat collagen membranes 
Type I collagen fibrils were purified from bovine Achilles tendon using extractions with di-
luted acetic acid, aqueous NaCl and urea, and acetone [14]. A suspension of 0.8% (w/v) 
collagen fibrils in 0.25 M acetic acid was shaken overnight at 4ºC and homogenised on ice 
using a Potter-Elvehjem homogeniser (Louwers Glass and Ceramic Technologies, Hapert, 
The Netherlands) with an intervening space of 0.35 mm until homogenisation was com-
pleted. Air-bubbles were removed by centrifugation at 250 g for 10 min at 4ºC. To obtain a 
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container, a Ø 35 mm Petri dish (Greiner Bio-One) with the bottom removed was fixed on 
the papillary-structured PDMS cast and filled with 2 ml of collagen suspension. Air en-
trapped in the indentations was removed by placing the cast with collagen suspension in a 
vacuum desiccator for 3x1 min. The suspension was air-dried at room temperature. As a 
control, flat collagen membranes were produced on an adjacent surface of non-structured 
PDMS cast, using the same procedure. 
 
 
 
Figure 2. Design of the polydimethylsiloxane (PDMS) mould based on the architecture of the human papillary dermis. 
(A) Cross-section of normal human skin (inner forearm) showing the rete ridge architecture with keratinocytes (KC) and 
a dermal papilla (DP). (B) Top view of a longitudinal (en face) section at the height of the arrow in (A) showing the 
organisation of the dermal papillae (DP). Dimensions were obtained from in vivo reflectance confocal microscopy 
measurements taken from [12] A-B adapted with permission from Macmillan Publishers Ltd: The journal of Investiga-
tive Dermatology, copyright (2001) [12]. (C) Side view and (D) top view of the PDMS casting mould design that was 
produced from a micromilled polycarbonate master. 
 
 For morphological analysis, the papillary-structured and flat membranes were 
mounted on stubs, sputtered with an ultrathin layer of gold in a Polaron E5100 coating sys-
tem and visualised with a JEOL JSM-6310 scanning electron microscope (Tokyo, Japan) 
operating at 15 kV. 
Production of a papillary-structured double-layered construct  
To demonstrate the feasibility of preparing a composite dermal substitute composed of a 
papillary dermal and a reticular dermal component, the papillary-structured papillary mem-
brane was combined with a porous (dermal) scaffold. A collagen fibril suspension was 
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poured on the papillary-structured PDMS cast (see production section), and air-dried for 8 h 
resulting in near dry membranes. This layer was covered with 2 ml collagen suspension 
(resulting in a 1-2 mm layer), directly frozen at -20 ºC, and lyophilised.  
This double-layered construct was analysed by scanning electron microscopy (see pro-
duction section). 
Culture of primary human keratinocytes on papillary-structured membranes 
Keratinocytes were obtained from human abdominal skin derived from donors who un-
derwent surgery for abdominal wall correction [15]. Three papillary-structured and three flat 
membranes were evaluated. To ensure that seeded cells remained on top of the mem-
branes, films were placed in Ø 10 mm CellCrown24 inserts (ScaffDex, Tampere, Finland), 
disinfected with 70% ethanol (3x 1 h and 1x 16 h), washed with sterile phosphate buffered 
saline (pH 7.2, 5x 1 h, and 1x 16 
h), placed on the bottom of a 6-well plate (Greiner Bio-One) and pre-incubated for 16 h in 
keratinocyte growth medium (KGM) [16]. Cells were seeded at a density of 100,000 
cells/insert and incubated in 2 ml medium per well at 37ºC and 5% CO2. Cells were cultured 
to confluency on the membranes for ten days and medium was refreshed on day three and 
six. Membranes + cells were removed from the inserts, divided in two and processed for 
microscopical evaluation and RNA analysis.  
Microscopical evaluation 
One half of the membranes with cultured keratinocytes was rinsed with 0.1 M phosphate 
buffer (PB, pH 7.4), fixed with 4% paraformaldehyde in 0.1 M PB for 30 min at room tem-
perature, washed with 0.1 M PB and divided in three pieces for (electron) microscopical 
evaluation and (immuno)cytochemistry. 
For scanning electron microscopy, one piece was dehydrated in an ascending graded 
series of ethanol up to 100% ethanol, critical point dried using CO2 with a Polaron E3000 
critical point drying apparatus (Watford, UK), processed and visualised with a JEOL JSM-
6310.  
For light and transmission microscopy, one piece was further fixed in 2% glutaraldehyde 
in 0.1 M phosphate buffer (pH 7.4), post-fixed with 1% osmium tetroxide, dehydrated in an 
ascending series of ethanol, and embedded in Epon 812. To obtain a general overview by 
light microscopy, 1 µm sections were stained with toluidine blue and basic fuchsin. For a 
more detailed analysis, ultrathin sections (60 nm) were cut and picked up on Formvar-
coated grids, post-stained with lead citrate and uranyl acetate, and examined in a JEOL 
1010 electron microscope. 
For immunocytochemical evaluation, a third piece of the fixed membrane part was 
placed in TissueTek (Sakura Finetek, Zoeterwoude, The Netherlands), frozen in liquid nitro-
gen-cooled isopentane and sectioned. Cryosections were incubated in rabbit anti-human 
fibrillin 2 (1:200) [17], rabbit anti-human loricrin (1:500, Berkeley Antibody Company 
(BAbCO), Richmond, CA, USA), and rabbit anti-human cystatin M/E (1:200 [18]), followed 
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by an Alexa 488-labelled goat anti-rabbit IgG antibody (Molecular Probes, Eugene, OR, 
USA) [19]. 
RNA isolation 
The other unprocessed half of the membrane with cultured keratinocytes was placed di-
rectly in 350 µl Qiagen lysis buffer RLT for RNA isolation, vortexed for 1 min, and processed 
according to the Qiagen RNeasy mini kit protocol for the purification of total RNA from ani-
mal cells using spin technology (Qiagen, Hilden, Germany), including an on-column DNase 
digestion. The RNA concentration and purity was measured with a Nanodrop spectropho-
tometer (Thermo Scientific, Waltham, MA, USA) and RNA integrity was analysed on an 
Agilent Bioanalyser (Santa Clara, CA, USA). Per half of a membrane, 1.5-8 µg RNA was 
isolated with an RNA integrity number (RIN) between 8.7 and 9.6, indicating excellent RNA 
quality. 
High-density gene expression microarray analysis 
A comprehensive gene expression analysis was performed of keratinocytes cultured on 
papillary-structured and on flat membranes using high density gene expression microarrays. 
Microarray analysis was performed as described before, with minor modifications [20]. From 
the isolated total RNA, 100 ng was further processed according to the Affymetrix GeneChip 
whole transcript sense target labelling assay manual (Affymetrix, Santa Clara, CA, USA). 
First, the ribosomal RNA content was reduced using the Invitrogen RiboMinus transcriptome 
isolation kit. Then, double-stranded complementary DNA (cDNA) was synthesised from 
RNA, which was used for in vitro transcription, creating complementary RNA. This RNA was 
then used to create fluorescently-labelled single-stranded DNA fragments in the sense ori-
entation, which was hybridised on Affymetrix GeneChip human exon 1.0 sense target (ST) 
microarrays. These microarrays contain defined spots of oligonucleotide probes targeting a 
specific nucleotide sequence. Four spots with different probes form (in 90% of the cases) a 
probe set, covering every known and putative exon of the human genome. Using current 
annotation data, the 1.4 million probe sets (exons) on this array can be combined to analyse 
the expression of 17,859 individual genes. 
The arrays were scanned and converted to a processed image, which was converted to 
one fluorescence intensity value per probe, using Affymetrix GeneChip Operating Software 
(GCOS). The values of individual probes belonging to one probe set were averaged using 
Partek Genomics Suite 6.4 (Partek Inc., St. Louis, MO, USA, www.partek.com). The aver-
age fluorescence intensity of all 17,859 genes on the microarrays was calculated using the 
Robust Multiarray Analysis (RMA) algorithm [21], including a quantile normalisation and 
background correction for GC-content. Human genome version HG18 was used for annota-
tion [22].  
To identify differentially expressed genes, a one-way analysis of variance (ANOVA) was 
performed for gene expression in keratinocytes cultured on papillary-structured versus flat 
membranes. Gene lists of interest were analysed for known direct interactions between their 
gene products using Pathway studio 7.1 software (Ariadne, Rockville, MD, USA). 
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RT-qPCR validation 
Microarray data were validated by reverse transcriptase quantitative polymerase chain 
reactions (RT-qPCR) on skin-related genes [18,23-26]. For this 170 ng RNA was converted 
to cDNA using an Invitrogen SuperScript III first-strand synthesis system kit for RT-PCR by 
incubation at 65 ºC for 5 min in the presence of 50 ng random hexamers and 1 mM de-
oxynucleotide triphosphate (dNTP) mix. After incubation on ice, the reaction mix was diluted 
1:1 to a total volume of 20 µl containing 5 mM MgCl2, 0.01 M dithiothreitol (DTT), 40 U 
RNaseOUT, and 200 U SuperScript II Reverse Transcriptase in 20 mM Tris-HCl (pH 8.4) 
and 50 mM KCl. This mixture was incubated for 10 min at 25 ºC, and cDNA was synthesised 
for 50 min at 50 ºC. Reaction was terminated at 85 ºC for 5 min, placed on ice, and samples 
were stored at -20 ºC.  
In a 20 µl reaction, 1 ng cDNA was mixed with 10 µl SYBR green 2x supermix (Bio-Rad), 
12 pmol forward and 12 pmol reverse primer (Table 1). RT-qPCR was performed in a Bio-
Rad (Hercules, CA, USA) C1000 thermal cycler with a CFX96 real-time PCR detection sys-
tem using a hot start at 50 ºC for 2 min and 95 ºC for 10 min, followed by 40 cycles of 95 ºC 
for 15 s, 60 ºC for 1 min, including a plate read after every cycle, followed by 95 ºC for 15 s, 
and a melt curve from 60 ºC to 95 ºC, incrementing 0.5 ºC every 5 s accompanied by a plate 
read. 
The cycle in which the fluorescence intensity passed a threshold (Ct) was determined 
using Bio-Rad CFX manager. The ΔCt of a sample was then calculated by subtraction of the 
Ct value of the reference gene large ribosomal protein P0 (RPLP0) from the Ct value of the 
gene of interest. To calculate the ΔΔCt, the average ΔCt of keratinocytes cultured on flat 
membranes was subtracted from the average ΔCt of keratinocytes cultured on papillary-
structured membranes. The fold change was calculated as 2
-ΔΔCt
. RT-qPCR products were 
checked on agarose gel and were of expected size. To identify statistically significant 
changes in gene expression, an unpaired t-test was performed on the 2
-ΔCt
 values of the 
individual genes assessed on papillary-structured versus flat membranes, and p<0.05 was 
considered significant. 
 
Table 1. Primer sequences and amplicon size of the genes assessed by RT-qPCR. 
 
Primer name  Gene 
symbol 
Forward primer (5’-3’) Reverse primer (5’-3’) Amplicon 
size (bp) 
Dickkopf homolog 1 
(Xenopus laevis) 
DKK1  atcatagcaccttggatgggtatt cttcttgtcctttggtgtgatacattt 75 
Interleukin 6 (interferon, 
beta 2) 
IL6 agccctgagaaaggagacatgta ggcaagtctcctcattgaatcc 140 
Vanin 1 [27] VNN1 gaacccagtatgtctttcct catacaacctcccaaacaga 147 
Lumican  LUM cttcaatcagatagccagactgc agccagttcgttgtgagataaac 151 
Late cornified envelope 2B 
[23] 
LCE2B ggttgactaaactctgccagg cactggggcaggcattta 128 
Defensin, beta 1 [25] DEFB1 atggcctcaggtggtaactttc cacttggccttccctctgtaac 146 
Cystatin E/M [24] CST6 tccgagacacgcacatcatc ccatctccatcgtcaggaagtac 75 
Ribosomal protein, large, 
P0 (reference gene) [24,27] 
RPLP0 caccattgaaatcctgagtgatgt tgaccagcccaaaggagaag 116 
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Results 
Construction of microstructured collagen membranes mimicking the papillary dermis 
A polycarbonate master was constructed based on literature values for dermal papillae 
architecture in the human inner forearm [12] (Fig. 2). The master closely matched the gen-
eral architecture of the dermal papillae and could be used to produce multiple PDMS 
moulds. One PDMS mould (Fig. 3A) was used to produce multiple papillary-structured colla-
gen membranes (Fig. 3B-D). It was found essential to completely fill the dips of the mould by 
de-aeration of the collagen suspension before air-drying. Dry membranes could easily be 
pealed off and it was possible to reuse the mould multiple times without complications. The 
architecture of the papillary-structured membranes adequately reflected the dimensions of 
the original design, thereby reproducing the natural morphology of dermal papillae. The 
potential of creating a two-layered dermal substitute with a papillary dermis architecture 
combined with a porous reticular dermis layer was demonstrated (Fig. 3E). For this con-
struct, the papillary-structured membrane was prepared as described, but care was taken to 
prevent complete air-drying the collagen suspension on the mould. A fresh collagen suspen-
sion was poured on top of the slightly hydrated papillary-structured membrane, followed by 
freezing and lyophilisation. In this way, a porous construct was created mimicking the entire 
dermis with a papillary-structured semi-closed surface on top (Fig. 3E). 
Morphological differences related to collagen film topography of keratinocytes cultured on 
papillary-structured collagen membranes 
To investigate the effect of the papillary membrane architecture on cell growth and dif-
ferentiation, primary human keratinocytes were cultured submerged on papillary-structured 
and flat membranes. 
Scanning electron microscopical analysis showed the presence of a confluent cell layer 
on both the papillary-structured and flat membranes (the papillary-structured membrane is 
shown in Fig. 4). Cells showed the typical morphology of cultured keratinocytes and com-
pletely covered the membrane including the side and top of the papillar structures. 
Staining of sections with toluidine blue and basic fuchsin showed the presence of pre-
dominantly a single layer of cells on the flat membranes and horizontal surfaces of the papil-
lary-structured membranes (Fig. 5 A and B) . At the base of the papillar structures, multiple 
cell layers were observed consisting of larger and more rounded cells, especially those in 
the corner regions. 
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Figure 3. (A) Macroscopic picture of the microstructured PDMS mould and (B-E) scanning electron micrographs of 
papillary-structured collagen membranes produced with this mould. (B) Top view and (C) side view of a collagen 
membrane showing multiple papillar structures. (D) Close-up view of a single collagen papillar structure. (E) Double-
layered collagen construct mimicking the two layers of the dermis: the papillary dermis (upper layer) and the reticular 
dermis (lower layer) . Bar in (A) is 1 cm, bars in (B-E) are 100 µm. 
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Figure 4. Scanning electron micrographs of human keratinocytes cultured on papillary-structured collagen mem-
branes. Membranes were covered with a confluent layer of cells. (A) Top overview, (B) and (C) keratinocytes on a 
single papillar structure, (D) cross-sectional view of a single papillar structure. Typical cultured keratinocytes were 
visible (arrows). The collagen membrane in (D) is indicated with double arrow heads. Bars are (A) 100 µm and (B-D) 
10 µm. 
 
Transmission electron microscopy confirmed these morphological differences (Fig. 5 C-
F). The flat membranes and the horizontal parts of the papillary-structured membranes con-
tained a single layer of cultured keratinocytes with their typical morphology (Fig. 5C). Cells 
were closely attached to each other and contained intracellular keratin filaments and micro-
villi on top that extended into the cell culture medium. Melanin granules were visible, some 
subjected to autophagic fusion, which is known to occur in cultured keratinocytes. A base-
ment membrane was observed at the interface between the cells and the collagen mem-
brane (Fig. 5D). At the base of the papillar structures, the cultured sheet thickened up to 
approximately 6-7 cell layers, containing morphologically diverse cells (Fig. 5E). This in-
cluded cells with the typical morphology of cultured keratinocytes, but also cells with a lobed 
nuclear membrane, and a mitochondria-rich and electron-light cytoplasm. Closer examina-
tion of these cells showed the presence of keratin filaments peripheral in their cytoplasm 
(Fig. 4F), confirming that these were also keratinocytes. Together with the observed nuclear 
membrane looping, which is characteristic for young cells, this demonstrated the presence 
of young keratinocytes at the base of the papillar structures. 
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Figure 5. Morphology of keratinocytes cultured on papillary-structured and flat collagen membranes. A, B: Cross-
sections of papillary-structured membranes with keratinocytes stained with toluidine blue and basic fuchsin. C-F: 
Electron microscopy of (C,D) flat and (E,F) papillary-structured membranes with keratinocytes. The horizontal parts of 
the membranes were covered with a single layer of flat keratinocytes, while at the bottom of the papillar structures 
multiple layers of larger, more rounded cells were visible. Please note that (B) is derived from a pilot experiment where 
75,000 cells were cultured on the membrane for 7 days in another culturing medium [28]. The dotted lines in C-E 
indicate the border between collagen membrane and cell layer. (C) Flat membranes were covered with a single layer of 
keratinocytes containing melanin granules and keratin filaments. (D) Higher magnification showing the basement 
membrane (thin line, arrow) of the keratinocytes. (E) At the base of the papillar structures up to 6-7 cell layers were 
present containing morphologically different cells. (F) The presence of keratin filaments (K) inside the cytoplasm of a 
cell with lobed nucleus demonstrates that this was also a keratinocyte, and the looping in the nuclear membrane 
(arrowhead) is characteristic for young cells. 
N=nucleus; n=nucleolus, M=melanin granules, K=keratin filaments, col=collagen membrane. (A) is composed of two 
pictures. Bars in (A) and (B) are 100 µm, bars in (C), (E) and (F) are 10 µm, and bar in (D) is 1 µm. 
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Gene expression profile of keratinocytes on papillary-structured collagen membranes 
Gene expression microarrays provide an unbiased and comprehensive approach to gain 
insight into the nature of the different cells observed at different positions on the papillary-
structured membrane (e.g. the morphological distinct cells observed at the base of the papil-
lar structures vs. on flat surfaces). An attempt was made to separate cells associated with 
the papillar structures from cells associated with the flat surface in between the papillar 
structures, using laser dissection. Membranes with cultured keratinocytes were placed on 
crosslinked polyethylene naphthalate (PEN) membrane slides (Leica Microsystems, Wetzlar, 
Germany) and subjected to a Leica AS LMD microdissection system with a UV laser (Leica 
Microsystems). However, collagen membranes were too thick to cut out a ring at the base of 
the papillar structures without damaging the cultured cell layer. As an alternative, we com-
pared RNA isolated from all the cells on the papillary-structured membranes to RNA isolated 
from cells on the flat membranes. Genes were ranked on their fold-change and of the 
17,859 genes assessed, 88 were >1.5-fold higher expressed in keratinocytes cultured on 
papillary-structured membranes (Table 2A), and 168 were >1.5-fold higher expressed on flat 
membranes (Table 2B). It should be noted that since the papillary-structured membrane 
consists of both flat surfaces and papillar structures, specific gene profiles of cells of interest 
(e.g. those present at the base of the papillar structures) are diluted by the majority of asso-
ciated flat surface. For instance, if cells at the base of papillar structures represent only 5% 
of the cell population, a 21 x differential gene expression in these cells will only give a 2-fold 
change for the entire cell population. This probably explains the small fold-changes ob-
served and the absence of statistical significance for the differentially expressed genes. 
However, this analysis nevertheless provided a valuable starting point for further analyses 
using RT-qPCR and immunohistochemistry. 
 
Table 2A. List of all 88 genes > 1.5x higher expressed in keratinocytes cultured on papillary-structured 
collagen membranes than on flat membranes. 
 
# Gene symbol Gene name Fold 
change 
1  TSPAN7   tetraspanin 7  2.7 
2  C6orf155   chromosome 6 open reading frame 155  2.7 
3  IL13RA2   interleukin 13 receptor, alpha 2  2.5 
4  TAS2R4   taste receptor, type 2, member 4  2.2 
5  TFPI2   tissue factor pathway inhibitor 2  2.1 
6  CCBE1   collagen and calcium binding EGF domains 1  2.1 
7  ZNF737   zinc finger protein 737  2.0 
8  TAS2R20   taste receptor, type 2, member 20  2.0 
9  PTGS2   prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 2.0 
10  ABI3BP   ABI family, member 3 (NESH) binding protein  2.0 
11  IL24   interleukin 24  2.0 
12  GSR   glutathione reductase  1.9 
13  IFNE   interferon, epsilon  1.9 
14  OC554202   hypothetical LOC554202  1.9 
15  AMY2B   amylase, alpha 2B (pancreatic)  1.9 
16  ANO1   anoctamin 1, calcium activated chloride channel  1.9 
17  ABCC3   ATP-binding cassette, sub-family C (CFTR/MRP), member 3 1.8 
18  NRCAM   neuronal cell adhesion molecule  1.8 
19  IL1R2   interleukin 1 receptor, type II  1.8 
20  LCP1   lymphocyte cytosolic protein 1 (L-plastin)  1.8 
21  STEAP1   six transmembrane epithelial antigen of the prostate 1  1.8 
22  RPL31   ribosomal protein L31  1.8 
23  AKR1C1   aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-
hydroxysteroid dehydrogenase) 1.8 
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24  CYP4F11   cytochrome P450, family 4, subfamily F, polypeptide 11  1.8 
25  MRPS17   mitochondrial ribosomal protein S17  1.8 
26  PTGS1   prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 1.8 
27  C20orf197   chromosome 20 open reading frame 197  1.8 
28  TRIM52   tripartite motif-containing 52  1.8 
29  TSPAN4   tetraspanin 4  1.8 
30  GUSBL2   glucuronidase, beta-like 2  1.8 
31  SD17B7P2   hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2  1.7 
32  TAGLN3   transgelin 3  1.7 
33  MMP3   matrix metallopeptidase 3 (stromelysin 1, progelatinase)  1.7 
34  DNAJB4   DnaJ (Hsp40) homolog, subfamily B, member 4  1.7 
35  FBN2   fibrillin 2  1.7 
36  PLA2G4A   phospholipase A2, group IVA (cytosolic, calcium-dependent) 1.7 
37  CTNNAL1   catenin (cadherin-associated protein), alpha-like 1  1.7 
38  ACAT2   acetyl-Coenzyme A acetyltransferase 2  1.7 
39  GPR39   G protein-coupled receptor 39  1.7 
40  DKK1   dickkopf homolog 1 (Xenopus laevis)  1.7 
41  TFRC   transferrin receptor (p90, CD71)  1.7 
42  ADAMTS6   ADAM metallopeptidase with thrombospondin type 1 motif, 6 (Affymetrix transcript cluster 1) 1.7 
43  POPDC3   popeye domain containing 3  1.7 
44  ANKRD36B   ankyrin repeat domain 36B  1.7 
45  WNT7B   wingless-type MMTV integration site family, member 7B  1.7 
46  TUBA1B   tubulin, alpha 1b  1.6 
47  C6orf105   chromosome 6 open reading frame 105  1.6 
48  ADAMTS6   ADAM metallopeptidase with thrombospondin type 1 motif, 6 (Affymetrix transcript cluster 2) 1.6 
49 ---  1.6 
50  NRN1   neuritin 1  1.6 
51  HSD17B2   hydroxysteroid (17-beta) dehydrogenase 2  1.6 
52  QRFP   pyroglutamylated RFamide peptide  1.6 
53  EVI2B   ecotropic viral integration site 2B  1.6 
54  CTSK   cathepsin K  1.6 
55  FGF2   fibroblast growth factor 2 (basic)  1.6 
56  PXN   paxillin  1.6 
57  PMS2CL   PMS2 C-terminal like pseudogene  1.6 
58  GOLGA8B   golgi autoantigen, golgin subfamily a, 8B  1.6 
59 ---  1.6 
60  CYR61   cysteine-rich, angiogenic inducer, 61  1.6 
61  OCLM   oculomedin  1.6 
62  LOX   lysyl oxidase  1.6 
63  AXL   AXL receptor tyrosine kinase  1.6 
64  PHLDB2   pleckstrin homology-like domain, family B, member 2  1.6 
65  TXNRD1   thioredoxin reductase 1  1.6 
66  SLIT2   slit homolog 2 (Drosophila)  1.6 
67  FGF5   fibroblast growth factor 5  1.5 
68  CMC1   COX assembly mitochondrial protein homolog (S. cerevisiae)  1.5 
69  RAB3B   RAB3B, member RAS oncogene family  1.5 
70  EID3   EP300 interacting inhibitor of differentiation 3  1.5 
71  MAP9   microtubule-associated protein 9  1.5 
72  CAPRIN2   caprin family member 2  1.5 
73  FAM101A   family with sequence similarity 101, member A  1.5 
74  SUZ12P   suppressor of zeste 12 homolog pseudogene  1.5 
75  IL1RL1   interleukin 1 receptor-like 1  1.5 
76  EFEMP1   EGF-containing fibulin-like extracellular matrix protein  1.5 
77  NAV3   neuron navigator 3  1.5 
78 ---  1.5 
79  TSPAN1   tetraspanin 1  1.5 
80  IL6   interleukin 6 (interferon, beta 2)  1.5 
81  C13orf15   chromosome 13 open reading frame 15  1.5 
82  SPP1   secreted phosphoprotein 1  1.5 
83  GLIS3   GLIS family zinc finger 3  1.5 
84  ZNF675   zinc finger protein 675  1.5 
85  RCN1   reticulocalbin 1, EF-hand calcium binding domain  1.5 
86  PPP1R12B   protein phosphatase 1, regulatory (inhibitor) subunit 1 1.5 
87  MME   membrane metallo-endopeptidase  1.5 
88  BMS1P5   BMS1 pseudogene 5  1.5 
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Table 2B. List of all 168 genes > 1.5x higher expressed in keratinocytes cultured on flat membranes 
than on papillary-structured collagen membranes. 
 
# Gene symbol Gene name Fold 
change 
1  SPINK1   serine peptidase inhibitor, Kazal type 1  -3.8 
2 ---  -2.8 
3  MPRSS11E   transmembrane protease, serine 11E  -2.5 
4  DCT   dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2) -2.3 
5  PSG6   pregnancy specific beta-1-glycoprotein 6  -2.3 
6  FAM70A   family with sequence similarity 70, member A  -2.3 
7  BPIL2   bactericidal/permeability-increasing protein-like 2 -2.3 
8  ELMOD1   ELMO/CED-12 domain containing 1 -2.2 
9  XKRX   XK, Kell blood group complex subunit-related, X-linked  -2.2 
10  CYP1A1   cytochrome P450, family 1, subfamily A, polypeptide 1  -2.2 
11  SERPINA3   serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 -2.2 
12  C12orf36   chromosome 12 open reading frame 36  -2.1 
13  ACPP   acid phosphatase, prostate  -2.1 
14  MLANA   melan-A  -2.1 
15  STEAP4   STEAP family member 4  -2.1 
16  IFIT1   interferon-induced protein with tetratricopeptide repeats 1 -2.1 
17  OR10A3   olfactory receptor, family 10, subfamily A, member 3  -2.1 
18  SEPT3   septin 3  -2.1 
19  TPPP3   tubulin polymerization-promoting protein family member 3  -2.1 
20  TYRP1   tyrosinase-related protein 1  -2.0 
21  NEBL   nebulette  -2.0 
22  ATP12A   ATPase, H+/K+ transporting, nongastric, alpha polypeptide -2.0 
23  SILV   silver homolog (mouse)  -2.0 
24  SPINK6   serine peptidase inhibitor, Kazal type 6  -2.0 
25  KRT4   keratin 4  -2.0 
26  MUC15   mucin 15, cell surface associated  -2.0 
27  LIPH   lipase, member H  -2.0 
28  ANKRD22   ankyrin repeat domain 22  -1.9 
29  HSPB8   heat shock 22kDa protein 8  -1.9 
30  LCE1D   late cornified envelope 1D  -1.9 
31  SERPINB4   serpin peptidase inhibitor, clade B (ovalbumin), member 4 -1.9 
32  PSG4   pregnancy specific beta-1-glycoprotein 4  -1.9 
33  LCE2B   late cornified envelope 2B  -1.9 
34  DEFB1   defensin, beta 1  -1.9 
35  CST6   cystatin E/M -1.9 
36  AZGP1   alpha-2-glycoprotein 1, zinc-binding  -1.9 
37  SMPD3   sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) -1.9 
38  CALB1   calbindin 1, 28kDa  -1.9 
39  ZNF750   zinc finger protein 750  -1.9 
40  AQP9   aquaporin 9  -1.9 
41  MX1   myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) -1.9 
42  IFI44L   interferon-induced protein 44-like  -1.9 
43  ALDH3B2   aldehyde dehydrogenase 3 family, member B2  -1.9 
44  TAS2R39   taste receptor, type 2, member 39  -1.9 
45  EPHX3   epoxide hydrolase 3  -1.8 
46  TYR   tyrosinase (oculocutaneous albinism IA)  -1.8 
47  FOXN1   forkhead box N1  -1.8 
48  CDRT1   CMT1A duplicated region transcript 1  -1.8 
49  PSG9   pregnancy specific beta-1-glycoprotein 9  -1.8 
50  SLC5A1   solute carrier family 5 (sodium/glucose cotransporter), member 1 -1.8 
51  DSG4   desmoglein 4  -1.8 
52  PDIA6   protein disulfide isomerase family A, member 6  -1.8 
53  TTC39A   tetratricopeptide repeat domain 39A  -1.8 
54  CLDN17   claudin 17  -1.8 
55  GDA   guanine deaminase  -1.8 
56  SCNN1B   sodium channel, nonvoltage-gated 1, beta  -1.8 
57  USP2   ubiquitin specific peptidase 2  -1.8 
58  KLK13   kallikrein-related peptidase 13  -1.8 
59  TMEM86A   transmembrane protein 86A  -1.8 
60  LCN2   lipocalin 2  -1.8 
61  SLC39A2   solute carrier family 39 (zinc transporter), member 2  -1.8 
62  PLA2G4E   phospholipase A2, group IVE  -1.7 
63  CPA4   carboxypeptidase A4  -1.7 
64  TMPRSS4   transmembrane protease, serine 4  -1.7 
65  RSAD2   radical S-adenosyl methionine domain containing 2  -1.7 
66  KLK14   kallikrein-related peptidase 14  -1.7 
67  FAM83C   family with sequence similarity 83, member C  -1.7 
68  MPRSS11F   transmembrane protease, serine 11F  -1.7 
69  LCE2D   late cornified envelope 2D  -1.7 
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70  RDH12   retinol dehydrogenase 12 (all-trans/9-cis/11-cis) -1.7 
71  PLA2G7   phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) -1.7 
72  SLC6A14   solute carrier family 6 (amino acid transporter), member 14 -1.7 
73  UQCRFS1  ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 -1.7 
74  TNFSF10   tumor necrosis factor (ligand) superfamily, member 10  -1.7 
75  LY6G6C   lymphocyte antigen 6 complex, locus G6C  -1.7 
76  TXNIP   thioredoxin interacting protein  -1.7 
77  RAET1L   retinoic acid early transcript 1L  -1.7 
78  SPINK7   serine peptidase inhibitor, Kazal type 7 (putative)  -1.7 
79  TRIM48   tripartite motif-containing 48  -1.7 
80  CXCL14   chemokine (C-X-C motif) ligand 14  -1.7 
81  BMP6   bone morphogenetic protein 6  -1.7 
82  RGS2   regulator of G-protein signaling 2, 24kDa  -1.7 
83  IFI27   interferon, alpha-inducible protein 27  -1.7 
84  MT1G   metallothionein 1G  -1.7 
85  KRT78   keratin 78  -1.7 
86  BBOX1   butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1 -1.7 
87  CYP4B1   cytochrome P450, family 4, subfamily B, polypeptide 1  -1.7 
88  NDUFA4L2   NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 -1.7 
89  PI15   peptidase inhibitor 15  -1.7 
90  HIST1H4H   histone cluster 1, H4h  -1.7 
91  GRHL1   grainyhead-like 1 (Drosophila)  -1.7 
92  CCL22   chemokine (C-C motif) ligand 22  -1.6 
93  EGR3   early growth response 3  -1.6 
94  OCA2   oculocutaneous albinism II  -1.6 
95  KRT80   keratin 80  -1.6 
96  OBP2B   odorant binding protein 2B  -1.6 
97  PDZK1IP1   PDZK1 interacting protein 1  -1.6 
98  TMPRSS13   transmembrane protease, serine 13  -1.6 
99  SCNN1A   sodium channel, nonvoltage-gated 1 alpha  -1.6 
100  GSTTP1   glutathione S-transferase theta pseudogene 1  -1.6 
101  CYP1B1   cytochrome P450, family 1, subfamily B, polypeptide 1  -1.6 
102  EDNRB   endothelin receptor type B  -1.6 
103  PVRL4   poliovirus receptor-related 4  -1.6 
104  RPL23AP32   ribosomal protein L23a pseudogene 32  -1.6 
105  IFIT3   interferon-induced protein with tetratricopeptide repeats 3 -1.6 
106  OPN4   opsin 4  -1.6 
107  NOV   nephroblastoma overexpressed gene  -1.6 
108  OAS1   2',5'-oligoadenylate synthetase 1, 40 /46kDa -1.6 
109  CLIC3   chloride intracellular channel 3  -1.6 
110  PGLYRP3   peptidoglycan recognition protein 3  -1.6 
111  ATG9B   ATG9 autophagy related 9 homolog B (S. cerevisiae)  -1.6 
112  OAS2   2'-5'-oligoadenylate synthetase 2, 69/71kDa -1.6 
113  CAMK1D   calcium/calmodulin-dependent protein kinase ID -1.6 
114  RAB27B   RAB27B, member RAS oncogene family  -1.6 
115  CCNA1   cyclin A1  -1.6 
116  MUCL1   mucin-like 1  -1.6 
117  FLVCR2   feline leukemia virus subgroup C cellular receptor family, member 2 -1.6 
118  CXCL11   chemokine (C-X-C motif) ligand 11  -1.6 
119  TMEM45B   transmembrane protein 45B  -1.6 
120  SPRR2C   small proline-rich protein 2C (pseudogene)  -1.6 
121  CLDN7   claudin 7  -1.6 
122  POF1B   premature ovarian failure, 1B  -1.6 
123  SCEL   sciellin  -1.6 
124  OVOL1   ovo-like 1(Drosophila)  -1.6 
125  TRIM16   tripartite motif-containing 16  -1.6 
126  SAMD9   sterile alpha motif domain containing 9  -1.6 
127  ABCG1   ATP-binding cassette, sub-family G (WHITE), member 1  -1.6 
128  MPZL3   myelin protein zero-like 3  -1.6 
129  HIST1H2BK   histone cluster 1, H2bk  -1.6 
130  SLC24A5   solute carrier family 24, member 5  -1.6 
131  KLK6   kallikrein-related peptidase 6  -1.6 
132  TRIM2   tripartite motif-containing 2  -1.6 
133  POTEE   POTE ankyrin domain family, member E  -1.6 
134  GGT6   gamma-glutamyltransferase 6  -1.6 
135  TCP11L2   t-complex 11 (mouse)-like 2  -1.6 
136  GPR110   G protein-coupled receptor 110  -1.6 
137  KRT23   keratin 23 (histone deacetylase inducible)  -1.6 
138  SULT2B1   sulfotransferase family, cytosolic, 2B, member 1  -1.6 
139  PSG8   pregnancy specific beta-1-glycoprotein 8  -1.6 
140  GRHL3   grainyhead-like 3 (Drosophila)  -1.6 
141  ERBB3   v-erb-b2 erythroblastic leukemia viral oncogene homolog 3  -1.6 
142  IGFBP5   insulin-like growth factor binding protein 5  -1.6 
143  CLIC5   chloride intracellular channel 5  -1.6 
144  FKBP9   FK506 binding protein 9, 63 kDa  -1.6 
145  PGLYRP4   peptidoglycan recognition protein 4  -1.6 
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146  C6orf35   chromosome 6 open reading frame 35  -1.5 
147  PLEKHA7   pleckstrin homology domain containing, family A member 7 -1.5 
148  CA9   carbonic anhydrase IX  -1.5 
149  BMP4   bone morphogenetic protein 4  -1.5 
150  ATP10B   ATPase, class V, type 10B  -1.5 
151  GALNT5   UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5) -1.5 
152  CRABP2   cellular retinoic acid binding protein 2  -1.5 
153  LCE2A   late cornified envelope 2A  -1.5 
154  DGAT2   diacylglycerol O-acyltransferase homolog 2 (mouse)  -1.5 
155  MAFB   v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) -1.5 
156  GMPR   guanosine monophosphate reductase  -1.5 
157  SBSN   suprabasin  -1.5 
158  CYP2F1   cytochrome P450, family 2, subfamily F, polypeptide 1  -1.5 
159  KRT13   keratin 13  -1.5 
160  TGM1   transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase) -1.5 
161  TIAM1   T-cell lymphoma invasion and metastasis 1  -1.5 
162  CCBP2   chemokine binding protein 2  -1.5 
163  CEBPA   CCAAT/enhancer binding protein (C/EBP), alpha -1.5 
164  FLJ13744   hypothetical FLJ13744  -1.5 
165  BNIPL   BCL2/adenovirus E1B 19kD interacting protein like -1.5 
166  AADACL2   arylacetamide deacetylase-like 2  -1.5 
167  RHCG   Rh family, C glycoprotein  -1.5 
168  RAB11FIP1   RAB11 family interacting protein 1 (class I)  -1.5 
 
Gross examination of the gene lists provided a first indication of the nature of the differ-
ences between the cells on the two membranes. For example, the list of genes with higher 
expression on the papillary-structured membranes (Table 2A) contained three transmem-
brane tetraspanins, three interleukin (IL) receptors and two interleukins, molecules generally 
associated with proliferation, which were all absent from the list of genes with higher expres-
sion on the flat membranes (Table 2B). The papillar list also contained development-related 
genes like fibroblast growth factor 2 (basic) (FGF2), wingless-type MMTV integration site 
family, member 7B (WNT7B), and dickkopf homolog 1 (Xenopus laevis) (DKK1). In addition, 
fibrillin 2 (FBN2) was present, which is known to be expressed by keratinocytes and is 
probably involved in the development and maintenance of the elastic dermal-epidermal 
network [29]. The list of genes with higher expression on the flat membranes (Table 2B), on 
the other hand, was more related to keratinocyte differentiation. It contained five keratins, 
four late cornified envelope (LCE) genes, beta 1 defensin (DEFB1) and cystatin E/M (CST6).  
RT-qPCR validation of microarray results 
To validate the microarray results, RT-qPCR was performed on seven >1.3-fold differen-
tially expressed genes selected for their reported association with skin biology [18,23-26] 
(Fig. 6), including four upregulated genes (#40: dickkopf homolog 1 (Xenopus laevis) 
(DKK1); #80: interleukin 6 (interferon, beta 2) (IL6); #97: vanin 1 (VNN1); and #306: lumican 
(LUM)), and three downregulated genes (#33: late cornified envelope 2B (LCE2B); #34: 
defensin, beta 1 (DEFB1); and #35: cystatin E/M (CST6)). All genes evaluated showed an 
up/downregulation as indicated by the microarray results. Upregulation of DKK1 and down-
regulation of LCE2B and CST6 were statistically significant using this approach. These re-
sults indicate that despite the heterogeneity of the cell populations, the microarray findings 
reflect real changes in gene expression. 
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Figure 6. RT-qPCR validation of differentially expressed genes in keratinocytes on papillary-structured membranes 
compared to flat membranes. Depicted are the fold-changes identified with the gene expression microarrays (open 
bars) and their validation using RT-qPCR (filled bars) ±S.E.M.. An asterisk (*) indicates statistically significant changes 
on papillary-structured versus flat membranes (p<0.05). 
 
 
 
Figure 7. Visualisation of proteins (bright green, arrowheads) from differentially expressed genes on papillary-
structured membranes with keratinocytes. Staining for fibrillin 2 (upregulated on papillary-structured membranes), and 
loricrin and cystatin E/M (both downregulated on papillary-structured membranes). The dotted line indicates a part of 
the border between the collagen membrane and cultured cell layer. Bars are 50 µm. 
 
Localisation of differentially expressed gene products on papillary-structured membranes 
To investigate whether the observed changes in gene expression are related to the loca-
tion of the cell on the collagenous membranes, the protein product of three >1.3-fold differ-
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entially expressed genes was visualised by immunohistochemical staining on cryosections 
of papillary-structured membranes (Fig. 7). 
Antibody staining for fibrillin 2 (upregulated #35) showed the presence of this protein on 
top of the papillar structures, while less staining was observed in the single cell layer on the 
flat part of the membrane between the papillar structures. In line with the microarray results, 
there was a link with the papillar structures, but apparently this was not related to the mor-
phologically distinct cells at the base of the structures, but at their top. Loricrin (downregu-
lated #236) and cystatin E/M (downregulated #35) staining was found in almost all cells, but 
at the base of the papillar-structures where multiple cell layers were present, staining was 
less intense for the more basal cells in the corner. This difference in staining intensity sup-
ports the microarray data. 
Pathway analysis of differentially expressed genes 
To obtain more insights in the biological meaning of the microarray data, the differentially 
expressed genes (Tables 2A and B) were analysed for known direct interactions between 
their protein products (Figs. 8A and B).  
Of the 88 genes upregulated in keratinocytes on papillary-structured membranes, 27 had 
a known direct interaction with each other (Fig. 8A). These proteins are mainly located at the 
plasma membrane or in the extracellular space. Key proteins in this network appear to be 
fibroblast growth factor 2 (FGF2), interleukin 6 (IL6), group IV A phospholipase A2 
(PLA2G4A), and prostaglandin-endoperoxide synthase 2 (PTGS2).  
Of the 168 genes upregulated in keratinocytes on flat membranes, 32 directly interacted 
with each other (Fig. 8B). Key player in this network is the transcription factor 
CCAAT/enhancer binding protein alpha (CEBPA) involved in differentiation and in mitotic 
growth arrest, whereas tyrosinase (oculocutaneous albinism IA) (TYR) acts as a central 
player in another part of the network.   
Discussion 
A collagen membrane matching the natural architecture of the human skin‟s basement 
membrane was constructed, by mimicking the topology of dermal papillae. Cultured kerati-
nocytes were able to establish a confluent layer. In contrast to the single layered keratino-
cytes on the flat part of the membrane, multiple layers were present at the base of the papil-
lary structures, containing morphologically distinct cells including young keratinocytes. This 
provided a first indication that the membrane architecture could result in a direct biological 
effect on the cultured cells. Microarray analysis was used as an unbiased and comprehen-
sive tool to obtain insight in the differences between keratinocytes on papillary-structured 
and flat membranes. The gene expression profiles obtained hinted to specific cell behaviour, 
and expression levels were validated by RT-qPCR, indicating that the observed differences 
in gene expression reflects real changes. This was confirmed by antibody staining for a 
number of proteins encoded by the differentially expressed genes. Thus, despite the initial 
concerns that differences could be diluted out, significant differences were found. 
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Figure 8. Pathway analysis of (A) the genes upregulated in keratinocytes on papillary-structured membranes and (B) 
upregulated in keratinocytes on flat membranes.  
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The list of upregulated genes on papillary-structured membranes contained genes 
known to be involved in cell signalling, development and proliferation. Pathway analysis 
provided more insight in the biological nature of the differences in gene expression. The 
protein products of genes upregulated on papillary-structured membranes were mainly situ-
ated on the plasma membrane and in the extracellular space. The key proteins in this net-
work have been reported to be involved in keratinocyte proliferation and migration. Fibro-
blast growth factor 2 (FGF2), for example, stimulates keratinocyte proliferation [30]. Inter-
leukin 6 (IL6) can indirectly induce keratinocyte migration [26]. In addition, group IV A phos-
pholipase A2 (PLA2G4A) and prostaglandin-endoperoxide synthase 2 (PTGS2, also known 
as cyclooxygenase 2 (COX-2)) are both required for the conversion of cell membrane phos-
pholipids into prostaglandins that are involved in keratinocyte migration and proliferation 
[31]. Fibrillins form microfibrils that act as a scaffold for elastin, and in skin fibrillin 2 is mainly 
found at the dermal-epidermal junction [32,33]. In our study, fibrillin 2 was found on top of 
the papillary structures resembling the top of dermal papillae. Since the protein was not 
found at the horizontal surfaces between the structures, it is possible that these cells on top 
experienced a distinct tension (stress) that stimulated fibrillin deposition. Very clearly, the 
cells sense their local microenvironment. The interplay of topological cues and intercellular 
communication will be subject of more detailed future studies. 
The list of genes upregulated on flat membranes contained a remarkable number of 
genes related to keratinocyte differentiation. Pathway analysis showed a more intracellular 
localisation of the gene products. The central transcription factor of one part of the network, 
C/EBPalpha is known for its role in keratinocyte terminal differentiation [34]. Proteins of the 
other part of the network, including tyrosinase (TYR), dopachrome tautomerase (DCP) and 
tyrosinase-related protein 1 (TYRP1), are known to be involved in the process of melano-
genesis [35].  
In this study, only type I collagen was used as a matrix for cell growth. To mimic the 
natural basement membrane, present between keratinocytes and the dermis, the papillary 
membrane may also be covered with basement membrane components such as type IV 
collagen and glycosaminoglycans. In addition, elastin may be included in the dermal struc-
ture, since it has been shown to stimulate keratinocyte proliferation [28]. Future research 
may also include the evaluation of keratinocytes cultured at the air-liquid interface, better 
representing the natural environmental conditions of keratinocytes. These additional experi-
ments will probably lead to a better understanding of the direct effect of membrane architec-
ture on keratinocyte behaviour.   
Conclusion 
A collagen membrane representing the natural architecture of the dermal papillae in hu-
man skin was constructed. Cellular morphology, gene expression signatures and protein 
expression of keratinocytes cultured on these membranes were different when compared to 
flat membranes. This indicates that cellular characteristics can be directed by physical modi-
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fication of biomaterials, which may form specific cellular niches. This knowledge may be 
used for the construction of improved tissue-engineered skin constructs. 
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Summary 
This thesis started with a general introduction in chapter 1, which described that the skin 
is the largest organ of the body and plays an important role in the defence against patho-
gens, regulation of body temperature, and the prevention from dehydration. When the skin is 
wounded, its original structure and functions have to be restored as quickly as possible. 
Tissue-engineered constructs are being developed to guide this skin regeneration process 
and reduce the formation of scar tissue.  
Chapter 2 provided an overview of methods that are used for the evaluation of tissue-
engineered skin constructs in animal models. The large variation in evaluation methods, 
animal models, and wound models is remarkable and hampers a systematic comparison 
between different studies. Therefore, the standard use of four evaluation methods is rec-
ommended: viz. an observer scar assessment scale, planimetry, H&E staining, and antibody 
staining for five key proteins in cutaneous wound healing.  
 
The following chapters described different aspects of the development of advanced tis-
sue-engineered constructs.  
Chapter 3 described how glycosaminoglycans like heparin can be incorporated in such a 
construct, and showed that scaffold pre-treatment and the type of analysis method may 
result in different estimations of the amount and activity of bound heparin. It is therefore 
important that assays are always adapted and validated for accurate measurements in the 
presence of a biomaterial. Additionally, this study underlined the importance to control 
crosslinking conditions on, in this case, the final amount and anticoagulant activity of bound 
heparin. Therefore, a detailed knowledge of the crosslinking process is essential to prepare 
a construct with desired properties.     
Chapter 4 described how this type of knowledge can be used for the preparation of an 
array of 48 different collagen membranes with defined characteristics. It was demonstrated 
that the array could be used to identify materials that specifically stimulated the proliferation 
of keratinocytes. The availability of robust in vitro arrays will allow a pre-selection of the most 
promising biomaterials for further evaluation in animal models and may thereby reduce the 
number of required laboratory animal.  
The formation of new blood vessels (angiogenesis) is often a time-consuming process in 
wounds treated with a tissue-engineered construct, and may thereby delay wound healing. 
Vascular endothelial growth factor (VEGF) stimulates angiogenesis and the cloning, large-
scale production, and purification of this protein was described in chapter 5. It was demon-
strated that this VEGF was biologically active, and this heparin-binding growth factor can be 
incorporated in tissue-engineered constructs that are designed to accelerate angiogenesis.  
The design, construction, and evaluation of a molecularly-defined acellular skin construct 
was described in chapter 6. This collagen-based double-layered construct was designed to 
mimic the skins architecture and contained effector molecules to modulate specific proc-
esses. Compared with a commercially available construct (Integra) and an untreated wound 
in a rat full-thickness wound model, the double-layered skin construct resulted at early time 
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points in the formation of more blood vessels, less contraction, and a higher cell influx. At a 
later time point, the presence of more elastic fibres was observed. Although the long-term 
differences were limited, these results indicated that the double-layered skin construct was 
able to guide the wound healing process.  
 
The next chapters described the development and use of a new method to evaluate the 
wound healing process, and the construction of an innovative biomaterial. 
Chapter 7 introduced gene expression microarrays as a novel read-out tool, and this 
was used to evaluate the construct of chapter 6. Using a freely-available online tool 
(DAVID), it was possible to identify biological processes that were up- or downregulated in 
construct-treated wounds. The presence or absence of these processes was validated by 
classical (immuno)histochemistry, confirming that this fast and unbiased approach can be 
used as an alternative read-out method. 
Finally, chapter 8 dealt with the production of a novel collagen membrane that mimics 
the 3D-architecture of the natural dermal papillae. The morphology and gene expression 
profile of keratinocytes cultured on these microstructured membranes was studied and 
demonstrated that cellular growth and differentiation can be guided by modulation of their 
3D-environment. 
In conclusion, this thesis described both the construction of innovative collagen-based 
biomaterials for skin tissue engineering applications and novel methods that can be used for 
the in vitro and in vivo evaluation of these materials.  
Future directions 
For future studies, the in vitro biomaterial array described in chapter 4 may be extended 
by the use of new combinations of modifications (e.g. the promising combination of type IV 
collagen and elastic fibres), the incorporation of new components (like growth factors, as 
produced in chapter 5), inclusion of other types of scaffold (e.g. porous scaffolds or the mi-
crostructured membranes of chapter 8), and evaluation of other cell types. Future experi-
ments with keratinocytes will also have to assess air-exposed culturing, since this better 
resembles the natural environment of these cells. In addition, it will be interesting to use 
alternative read-out methods like gene expression microarrays to characterise the cellular 
response to different biomaterials with defined modifications.  
An improved double-layered skin construct may be produced by using the papillar-
structured membranes of chapter 8 as a top layer. This epidermal layer may be supple-
mented with elastic fibres, since these stimulated keratinocyte growth in the biomaterial 
array (chapter 4). In vivo evaluation of these modified constructs will obviously include the 
recommended methods of chapter 2. In addition, methods for the objective quantification of 
e.g. histological observations will continuously be monitored and adopted when feasible. 
Combined with the standardisation of animal and wound models, this will allow a better 
comparison of different constructs and lead to an acceleration of the pre-clinical research 
and developmental phase. 
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Gene expression microarrays will probably soon be used as a fast and unbiased ap-
proach for the evaluation of other tissue-engineered constructs and/or organs. Interpretation 
of our study in chapter 7 was limited by a combination of the incompleteness of the underly-
ing gene ontology (GO) terms and relatively poor annotation of the rat genome. Therefore, 
future development of these terms and annotations, in combination with the availability of 
new analysis tools will improve the interpretation of microarray results. In addition, new 
techniques will allow faster, cheaper and more in-depth analysis. For example, next genera-
tion sequencing holds promises for even more reliable RNA expression level analysis, and 
may soon replace microarrays. 
A better understanding of the regenerative process may lead to the identification of novel 
important players in wound healing. Like VEGF in chapter 5, additional effector molecules 
that are interesting for tissue engineering applications can be cloned and produced for fur-
ther evaluation. In addition, the availability of the VEGF expression vector opens opportuni-
ties for molecular fusion of the protein to tracking molecules like green fluorescent protein 
(GFP) to investigate e.g. its in vitro and in vivo distribution.  
In the end, this research will hopefully result in a future where a patient with burns, acute 
wounds, or a non-healing ulcer enters the hospital, the surgeon takes an affordable con-
struct from the shelf, cuts it in the right dimensions, and places it on the wounded area 
where this construct will immediately fulfil the skin‟s protective function and guides the re-
generation process to a quick restoration of the original skin. 
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Nederlandse samenvatting 
De huid is het grootste orgaan van het menselijk lichaam en speelt een belangrijke rol in 
de afweer tegen ziekteverwekkers, de regulatie van de lichaamstemperatuur en het voor-
komen van uitdroging. Indien de huid beschadigd raakt is het zaak deze functies zo snel 
mogelijk te herstellen. In het geval van grote (brand)wonden gaat dit meestal gepaard met 
contractie en littekenvorming. Dit is ongewenst, aangezien littekens vaak afwijken van de 
omringende gezonde huid wat betreft kleur en functie en ze rondom gewrichten de mobiliteit 
kunnen beperken. Een mogelijke oplossing van dit probleem is het gebruik van tissue engi-
neering/regeneratieve geneeskunde. 
Tissue engineering is een interdisciplinair vakgebied dat de principes van levensweten-
schappen en technologie aanwendt om biologische substituten te ontwikkelen die de functie 
van weefsels repareert, behoudt of verbetert. Kort samengevat is tissue engineering dus het 
“bouwen van weefsels”. Onze aanpak om beschadigde huid te genezen is door middel van 
het implanteren van een construct (zonder cellen) dat de natuurlijke huid zo veel mogelijk 
nabootst. Als basismateriaal hiervoor wordt het belangrijkste structurele eiwit van de huid 
gebruikt, collageen type I. Dit kan worden gecombineerd met bijvoorbeeld elastine en biolo-
gisch actieve suikers (glycosaminoglycanen) en groeifactoren, die elk hun specifieke rol 
spelen in de biologie van de huid. Het construct wordt vaak verstevigd door middel van een 
crosslink methode die tegelijkertijd het koppelen van glycosaminoglycanen mogelijk maakt. 
Na een algemene introductie (hoofdstuk 1) begint dit proefschrift in hoofdstuk 2 met 
een overzicht van methoden die momenteel in de kliniek gebruikt worden om littekenweefsel 
te evalueren. Dit wordt gevolgd door een uitgebreid overzicht van methoden die in de litera-
tuur beschreven zijn om tissue-engineered huidconstructen in diermodellen te evalueren. 
Opvallend is dat hiervoor een groot aantal verschillende evaluatiemethoden, dier- en wond-
modellen gebruikt worden. Standaardisatie is noodzakelijk om een goede vergelijking tussen 
verschillende studies mogelijk te maken. 
 
Hierna volgt een aantal hoofdstukken waarin verschillende aspecten worden belicht die 
nodig zijn om tot de ontwikkeling van een huidconstruct te komen.  
Het glycosaminoglycaan heparine wordt vaak in tissue-engineered constructen inge-
bouwd. Hoofdstuk 3 beschrijft zeven verschillende methoden die gebruikt kunnen worden 
om de hoeveelheid en activiteit van dit ingebouwde heparine te analyseren. De resultaten 
maken duidelijk dat de gekozen methode en de voorbehandeling van het biomateriaal van 
groot belang zijn voor een goede analyse. Ook wordt bevestigd dat het belangrijk is om de 
crosslinkcondities te controleren, aangezien dit een groot effect kan hebben op de hoeveel-
heid gebonden heparine en de activiteit hiervan.  
In hoofdstuk 4 wordt de ontwikkeling beschreven van een celkweekopzet om in één 
keer een groot aantal variaties van een biomateriaal te kunnen testen. Als voorbeeld wordt 
de groei geëvalueerd van opperhuidcellen (keratinocyten) op 48 verschillende moleculair 
gedefinieerde collageenmembranen. Deze modificaties laten een duidelijk effect op de cel-
groei zien en bijvoorbeeld de toevoeging van elastine vezels blijkt de groei van keratinocy-
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ten te stimuleren. Door nieuw ontwikkelde materialen eerst in een dergelijk celkweeksys-
teem te screenen kunnen vervolgens enkel de meest veelbelovende in diermodellen worden 
geëvalueerd. Deze aanpak kan het aantal gebruikte proefdieren verminderen.  
Het wondgenezingsproces kan vertraagd worden door de langzame vorming van nieuwe 
bloedvaten waardoor het weefsel te weinig zuurstof en voeding krijgt. Vasculair endotheel 
groeifactor (VEGF) is een eiwit dat kan worden gebruikt om deze bloedvatvorming te stimu-
leren. In hoofdstuk 5 wordt het kloneren, de productie en zuivering van actief rat VEGF 
beschreven. Dit gezuiverde eiwit kan vervolgens in huidconstructen worden geïncorporeerd. 
In hoofdstuk 6 wordt de ontwikkeling van een geavanceerd dubbellaags huidconstruct 
beschreven, bestaande uit moleculair gedefinieerde componenten als collageen type I, 
elastine, glycosaminoglycanen en groeifactoren. Tevens wordt beschreven hoe dit construct 
in een rat wondmodel is geïmplanteerd en wordt het vergeleken met een commercieel ver-
krijgbaar huidconstruct (Integra) en onbehandelde wond. Op vroege tijdstippen leidt de toe-
passing van dit dubbellaags construct tot minder wondcontractie, de vorming van meer 
bloedvaten en een hogere infiltratie van cellen. Op de lange termijn blijkt er meer vorming 
van elastinevezels plaats te vinden. Toepassing van dit construct leidt dus tot (tijdelijke) 
verbetering van verschillende aspecten van het wondgenezingsproces. 
 
In de daarop volgende hoofdstukken ligt de focus op de ontwikkeling van een nieuwe 
methode om wondgenezing te evalueren en op de constructie van een innovatief biomateri-
aal. 
In hoofdstuk 7 wordt de wondgenezing na toepassing van het dubbellaags construct uit 
hoofdstuk 6 geëvalueerd met behulp van genexpressie microarrays. Het achterliggende idee 
is dat ieder gen codeert voor een eiwit met een specifieke biologische functie en dat het 
expressieniveau van ieder gen correleert met de hoeveelheid geproduceerd eiwit. Door 
gelijktijdig de expressieniveaus voor alle bekende genen (tijdens deze studie ~8.000 voor de 
rat) te analyseren wordt getracht inzicht te verkrijgen in de rol van verschillende biologische 
processen tijdens wondgenezing. Lijsten van genen met veranderde expressie worden ge-
analyseerd en biologische processen worden geïdentificeerd die verhoogd of juist vermin-
derd plaats vinden in de regenererende huid. Bevestiging van deze observaties met (immu-
no)histologische technieken toont aan dat deze snelle en objectieve aanpak geschikt is als 
alternatieve evaluatiemethode.  
Tot slot wordt in hoofdstuk 8 de productie beschreven van een membraan dat de drie-
dimensionale structuur van de papillaire dermis in de huid nabootst. Het is mogelijk kerati-
nocyten te kweken op deze membranen. Rondom de basis van de microstructuren op deze 
membranen zijn cellen met een afwijkende morfologie te zien. Het gaat hier waarschijnlijk 
om jonge, minder gedifferentieerde keratinocyten. Genexpressieanalyse met behulp van 
microarrays wijst op de gestructureerde membranen in de richting van processen als migra-
tie en proliferatie, terwijl op vlakke membranen meer differentiatie optreedt. Door de driedi-
mensionale omgeving aan te passen is het dus mogelijk om cellen in een bepaalde richting 
te sturen. 
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Concluderend beschrijft dit proefschrift zowel de constructie van vernieuwende collagene 
biomaterialen voor toepassing in huid tissue engineering alsmede nieuwe methoden om de 
in vitro en in vivo respons op deze materialen te evalueren. 
Toekomstvisie 
Voor toekomstige studies kan de in vitro celkweektest uit hoofdstuk 4 worden uitgebreid 
door toevoegingen te combineren (zoals de veelbelovende combinatie van collageen type IV 
en elastine vezels), nieuwe componenten toe te voegen (bijvoorbeeld groeifactoren, zoals 
geproduceerd in hoofdstuk 5), andere typen scaffold te gebruiken (bijvoorbeeld poreuze 
scaffolds of het gestructureerde membraan uit hoofdstuk 8) en andere celtypen te evalue-
ren. Keratinocyten zullen tijdens de kweek ook aan de lucht blootgesteld worden, aangezien 
dit de natuurlijke situatie beter benadert. Ook is het interessant om alternatieve uitleesme-
thoden zoals genexpressie microarrays te gebruiken om de cellulaire reactie op verschillen-
de moleculair gedefinieerde biomaterialen te analyseren.    
Door de gestructureerde membraan van hoofdstuk 8 als toplaag voor een construct te 
gebruiken kan deze mogelijk worden verbeterd. Aan deze epidermale laag kunnen elastine-
vezels worden toegevoegd, aangezien in hoofdstuk 4 werd aangetoond dat deze keratino-
cytgroei stimuleren. Uiteraard zullen bij in vivo evaluatie van deze vernieuwde constructen 
de aanbevelingen van hoofdstuk 2 in acht worden genomen. Daarnaast zullen de ontwikke-
lingen op het gebied van histologische quantificatie nauwlettend worden gevolgd en, indien 
geschikt, worden geïmplementeerd. In combinatie met de standaardisatie van dier- en 
wondmodellen zal dit een betere vergelijking tussen constructen mogelijk maken en leiden 
tot een kortere preklinische onderzoeks- en ontwikkelingsfase.  
Genexpressie microarrays zullen spoedig gebruikt worden als snelle en onbevooroor-
deelde methode om andere tissue-engineered huidconstructen en/of organen te analyseren. 
De interpretatie van onze resultaten in hoofdstuk 7 werd belemmerd door een combinatie 
van de onvolledigheid van de onderliggende genontologie (GO) termen en relatief beperkte 
annotatie van het rattengenoom. Verdere ontwikkeling van deze termen en annotaties zullen 
daarom, in combinatie met de beschikbaarheid van nieuwe analysemethoden, de interpreta-
tie van microarrayresultaten verbeteren. Daarnaast zullen nieuwe technieken een snellere, 
goedkopere en meer grondige analyse mogelijk maken. Next generation sequencing is 
bijvoorbeeld veelbelovend om RNA expressieniveaus nog betrouwbaarder te detecteren. 
Een beter begrip van het herstelproces zal leiden tot de identificatie van nieuwe belang-
rijke spelers in wondgenezing. Net zoals VEGF in hoofdstuk 5 kunnen andere interessante 
biologisch actieve moleculen worden gekloond en geproduceerd voor verdere evaluatie. 
Daarnaast maakt de beschikbaarheid van de VEGF expressievector het mogelijk om dit 
eiwit moleculair te verbinden aan signaalmoleculen zoals green fluorescent protein (GFP) 
om op deze manier bijvoorbeeld de in vitro en in vivo distributie van het eiwit te onderzoe-
ken. 
Uiteindelijk zal deze aanpak hopelijk resulteren in een toekomst waarin een patiënt met 
brandwonden, acute wonden of een moeilijk helende zweer het ziekenhuis binnen komt, de 
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chirurg een betaalbaar construct van de plank pakt, het in de juiste vorm knipt en op het 
wondgebied legt, waarna het construct direct de beschermende rol van de huid vervult en 
het regeneratieproces dirigeert naar een spoedig herstel van de originele huid. 
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denken. Meteen nóg een leuke familie erbij met Mat, Hetty, Fieke, Olaf, Lisa en Floor. Hoe 
kun je een wetenschappelijke dissertatie nu beter eindigen dan met een hoogstaand citaat 
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